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1   Summary 
This thesis addresses a set of diverse topics that are ultimately directed toward a better 
understanding of how signal transduction influences transcriptional control in different tissue 
environments. To this end, regulation of the chemokine CCL5 represents an excellent 
example of the flexibility and selectivity that underlies the tissue/signal specific regulation of 
gene expression. This regulation of CCL5 was explored in two different tissue settings; 
natural killer and renal mesangial cells. The signal transduction events that control 
expression of this gene in each cell context was further studied from the stand point of a set 
of central regulatory pathways, namely, the MAP kinases. The MAP kinase pathways are 
known underlie the regulation of both NK and mesangial cells expressed genes.  
CCL5 regulation in natural killer cells is constitutive, whereas it is inducible in mesangial cells 
by proinflammatory signals (TNF-α and INF-γ). Interestingly, in both settings, control is 
achieved in large part through signaling by the JNK MAP kinase, yet the transcriptional 
elements moderating this control, differ significantly between the two cell types. Constitutive 
activation of the JNK MAP kinase controls the expression of CCL5 in natural killer cells 
through SP1, a constitutive transcription factor. In glomerular mesangial cells constitutive 
transcription factors (SP1 and AP1) as well as transcription factors induced by stimulation 
with TNF-α and INF-γ (IRF1, p50, p65 and AP1) are required for expression of the same 
gene. Again the JNK MAP kinase pathway was found to play a central role in the expression 
of CCL5 by mesangial cells, but here it was found to act primarily through activation of 
transcription factor AP1 (Jun D). Thus, the same promoter is controlled by different 
mechanisms in the two cell types examined, and yet the JNK MAP kinase pathway, while 
important to the control of CCL5 expression in both cell types, acts via different transcription 
factors.  
These results provide an excellent example of the flexibility of promoter regulation and at the 
same time shows how the same signalling cascades are used in different tissue settings. To 
explore in more detail how these regulatory events come together to control broader 
networks in specific tissue environments, a final set of experiments were performed. These 
experiments were based on the hypothesis of functional context which states that 
higherarchical promoter features can link the transcription of genes in specific biological 
settings. The promoter features and associated regulatory pathways identified for the CCL5 
promoter in mesangial cells, were modelled and then used to search for other human 
promoters with similar features using bioinformatics tools. The genes identified were 
compared to transcriptomic profile data derived from a series of patient samples that were 
characterized by activated mesangial cells (e.g. IgA nephropathy). The modelling, 
bioinformatics and subsequent verification study allowed characterization of a larger 
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regulatory network, also controlled in part through JNK MAP kinase that appears to underlie 
control of CCL5-related genes in this tissue setting.  
This general study shows that it is feasible to use experimentally generated data on the 
analysis of a single promoter (CCL5) to identify co-regulated genes using bioinformatics 
approaches independent of a priori knowledge about their biological connection. In addition, 
the analysis provides information about common pathways that represent potential targets 
for therapeutic intervention. These results further demonstrate that in addition its role in 
regulating macrophage derived cytokines and chemokines, JNK/Jun D pathways also plays a 
crucial role in the control of resident tissue mesangial cell derived cytokines and chemokines. 
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2   Introduction 
CCL5/RANTES is a member of the chemotactic cytokines family also known as chemokines. 
The name RANTES stands for regulated upon activation normal T cell expressed and 
secreted. According to the new nomenclature for chemokines and chemokine receptors, it is 
referred to as CCL5 (CC chemokine ligand 5) [1, 2]. 
2.1   Chemokines 
Chemokines can be produced by diverse tissues as a reaction to pro-inflammatory signals. 
They are also constitutively expressed by some tissue environment [3-5]. Chemokines are 
selectively chemotactic for leukocyte sub-populations and induce their immigration from the 
blood stream into the tissues in physiological and pathological processes [6]. Chemokines 
and their receptors have been shown to be involved in the control of haematopoiesis and to 
induce the homing of leukocytes in lymphatic organs [7]. Chemokines also play role in 
angiogenesis and embryogenesis [8]. The common structural characteristics of chemokines 
involve four conserved cystein- residues the position of which are used to sub-classify the 
family into CC, CXC, C and CX3C sub-classes. X stands for any amino acid between the first 
two cystein in the primary structure of the protein.  
2.2   Chemokine receptors 
Chemokine receptors belong to a family of G-protein coupled receptors with seven 
transmembrane domains. They are classified as CC, CXC, C and CX3C chemokine 
receptors based on their ligand binding profile [1]. Different chemokines can bind the same 
receptor and vice-versa, demonstrating a complex, partially redundant network (Table 
2.1)[9]. 
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Table 2.1   Chemokine receptors and their ligands 
(Adapted from Taub et. al. 2004 Curr. Protoc. Immunol) 
Receptor Ligands 
CCR1  CCL3, CCL5, CCL7, CCL13, CCL14, CCL15, CCL16, CCL23 
CCR2  CCL2, CCL7, CCL8, CCL13, CCL16 
CCR3  CCL5, CCL7, CCL8, CCL11, CCL13, CCL15, CCL16, CCL24, CCL26, 
CCL28 
CCR4  CCL17, CCL22 
CCR5  CCL3, CCL4, CCL5, CCL8, CCL11, CCL14, CCL16 
CCR6  CCL20 
CCR7  CCL19, CCL21 
CCR8  CCL1 
CCR9  CCL25 
CCR10  CCL27, CCL28 
CXCR1  CXCL6, CXCL7, CXCL8 
CXCR2 L8 CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXC 
CXCR3-A  CXCL9, CXCL10, CXCL11 
CXCR3-B  CXCL4, CXCL9, CXCL10, CXCL11 
CXCR4  CXCL12 
CXCR5  CXCL13 
CXCR6  CXCL16 
CXCR7  CXCL12 
XCR1  XCL1, XCL2 
CX3CR1  CX3CL1 
CCX-CKR  CCL19, CCL21, CCL25 
D6 CCL2, CCL3L1, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, 
CCL17, CCL22 
DARC/Duffy  
 
CCL2, CCL7, CCL8, CCL11, CCL13, CCL14, CCL16, CCL17, CXCL1, 
CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL11, CXCL13 
2.3   Inflammation 
 4 
Inflammation is the response of tissue to injury. Different kinds of stimuli can produce injury. 
It is characterised in the acute phase by increased blood flow and vascular permeability 
along with the accumulation of fluid, leukocytes and chemokines [3, 10, 11]. Cytokines and 
chemokines are key molecules for the initiation, progression and resolution of the 
inflammatory response. Injury of all type of tissues lead to the secretion of cytokines and 
chemokines that are locally retained on matrix and cell-surface heparan sulfate 
proteoglycans, establishing a chemokine concentration gradient surrounding the 
inflammatory stimulus, as well as on the surface of the overlying endothelium. Leukocytes 
rolling on the endothelium in a selectin-mediated process are brought into contact with 
chemokines bound on cell-surface via heparan sulfate proteoglycans. Chemokine signaling 
activates leukocyte integrins, leading to firm adherence and extravasation. The newly 
recruited leukocytes are activated by local proinflammatory cytokines that further enhance 
the local production of cytokines and chemokines (Figure 2.1) [12-20]. Cytokines and 
chemokines are involved in regulation of the activation of resident cells such as fibroblast, 
endothelial cells, mesangial cells, tissue macrophages, neutrophils, mast cells and NK cells, 
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as well as the newly recruited inflammatory cells such as monocytes, lymphocytes, 
neutrophils, eosinophils, T cells and NK cells  [12-18, 21-26]. Inflammatory responses 
generally take place within defined tissue microenvironments. The interaction between 
resident cells and the infiltrated cells is mediated in part though the secretion of cytokines 
and chemokines which helps lead to the resolution of the inflammatory process [3, 11, 27-
30].  
The inflammatory chemokines appear to be kept under tight regulatory control and 
expressed only in response to specific stimuli [31-33].                        
        
Figure 2.1 Mechanisms of chemokine-mediated chemotaxis in vivo  
(Biochemical society of transactions (2004)[20] 
2.4   The CCL5 chemokine 
CCL5 is a member of the C-C chemokine family and was originally identified during a screen 
for cDNAs selectively expressed by “functionally mature” cytotoxic T lymphocytes and not by 
B cells. The substractive hybridization approach used in this study yielded several novel 
cDNA clones one of which was found to encode for a new member of the family of 
chemotactic cytokines, now known as the chemokines [2]. CCL5 protein is expressed in vivo 
in diseases that are characterized by a mononuclear cell infiltration such as renal allograft 
rejection, delayed-type hypersensitivity, kidney glomerular disease and autoimmune 
diseases [29, 34-38]. The in vitro expression of CCL5 can be induced in a variety of cell 
   5
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types including T cells, monocytes, basophils, mesangial cells, fibroblasts, astrocytes, 
epithelial cells and endothelial cells [4, 39-47].  
2.5   Biochemical features of CCL5 
CCL5 is synthesized as a 91 amino-acid protein with a leader sequence of 23 amino-acids 
cleaved in the endoplasmic reticulum. The mature protein is strongly alkaline with an 
isoelectric point at pH 9.5 and a molecular weight of 7.847 Daltons. Two disulfide bonds 
between four conserved cysteins give the protein the secondary structure typical for 
chemokines which is shown in (Figure 2.2) [2, 48]. 
                 
Figure 2.2   Amino acid sequence and secondary structure of the CCL5 protein. The secondary 
structure originates from disulfide bonds between the four conserved cysteins of the CC chemokines. 
Cys 10 is linked with Cys 34 and Cys 11 is linked with Cys 50. [49] 
2.6   Functions of CCL5  
CCL5 is a chemotactic cytokine and contributes to inflammatory process through directed 
chemotaxis of select leukocyte subpopulations to sites of inflammation [34]. But the activity of 
CCL5 is not restricted to chemotaxis. It is also a powerful leukocyte activator, a feature 
potentially relevant in a range of inflammatory disorders [24, 34, 36, 47, 50-52]. For example, 
CCL5 can stimulate T cell proliferation, enhance target killing and induce respiratory burst in 
basophiles [50, 53-56]. CCL5 has also attracted attention because it can also suppress, and 
in some circumstances enhance, HIV infection and replication [57, 58]. 
2.6.1   CCL5: a pro-inflammatory chemokine 
CCL5 induces leukocyte migration or activation by binding to specific receptors in the seven-
transmembrane G protein-coupled receptor (GCPR) family, namely CCR1, CCR3 and CCR5. 
 6 
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CCL5 mediates the trafficking and homing of classical lymphoid cells such as T cells and 
monocytes, but also acts on a range of other cells, including basophils, eosinophils, natural 
killer cells, dendritic cells and mast cells. These leukocytes have been shown to express the 
CCL5 receptors CCR1, CCR3 and CCR5.[32]. CCL5 production, which is generated for 
example by CD8+ T cells, macrophages, epithelial cells, fibroblasts and natural killer cells or 
released by platelets, is a particular feature of inflammation. Increased CCL5 expression has 
been associated with a wide range of inflammatory disorders and pathologies, including 
allogeneic transplant rejection, atherosclerosis, arthritis, atopic dermatitis, inflammatory 
airway disorders such as asthma, delayed-type hypersensivity reactions, glomerulonephritis, 
endometriosis, some neurological disorders (such as Alzheimer’s disease) and certain 
malignancies. In all of these pathologies, CCL5 is thought to promote leukocyte infiltration to 
sites of inflammation [32, 38, 52, 57, 59-61]. 
2.7   Genomic organisation of the CCL5 gene 
The CCL5 gene displays the three exon/two intron organisation common to the C-C 
chemokine family. The CCL5 gene spans approximately 9.01 kb and is composed of three 
exons of 0.266, 0.112 and 0.974 kb and two introns of approximately 1.59 and 6.06 kb 
Human CCL5 is encoded by a single mRNA transcript approximately 1.352 kb in length. The 
mRNA is composed of a short 5’ untranslated region, a coding region of 276 bases and a 
long 3’ untranslated region which contains a series of Alu repeats. 
2.8  Signal and tissue specific transcriptional regulation of the 
CCL5 gene 
While CCL5 is expressed by many cell types, the mechanisms underlying transcriptional 
regulation of the gene can vary significantly from cell type to cell type. Importantly, while only 
one CCL5 promoter is found in the human genome, the same sequence allows great 
flexibility in transcriptional regulation. In this regard, the promoter has been used as a 
molecular probe to learn about signal and tissue specific regulation of transcription. 
Approximately 1 kb of immediate upstream region of the human CCL5 promoter has been 
analyzed for functional regulatory regions in a series of cells. The results show the general 
requirement of different combinations of five important regulatory regions, Ets/AP1/CREB (-
203 to -186), IRF/Ets/HMGY (-137 to -119), CEBP/NF-IL6 (-125 to - 92), NF-kB/KLF13/SP1 
(-75 to -56) and NF-kB/SP1 (-55 to -39) for the control of transcriptional regulation in different 
cell types, and under different stimulatory conditions (Figure 2.3) [4, 62, 63].  
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Figure 2.3   Schematic representation of the different regions of CCL5 promoter involved in the 
transcriptional regulation of CCL5. Inside the boxes appear the names of the different transcription 
factors contained in the region 
2.8.1   Transcriptional regulation in monocytes 
Human monocytes and macrophages effectively induce CCL5 mRNA expression within an 
hour after activation with lipopolysaccharide. Stimulation with TNF-α, IFN-γ or IL-1β does not 
significantly influence CCL5 mRNA levels in normal or transformed monocytes. The minimal 
functional CCL5 promoter in monocytes was determined using a series of 5’ to 3’ CCL5 
promoter-reporter deletion constructs. These reporter constructs tested in the monocyte cell 
line MonoMac 6 demonstrate that the immediate -230 upstream sequences and the 
elements, AP1/CREB (-203 to -186), IRF1/Ets (-137 to -119), CEBP (-125 to -97), NF-
kB/SP1 (-75 to -56) and NF-kB (-55 to -39) are important for optimal constitutive and induced 
promoter-reporter gene activity [39, 40]. 
2.8.2   Transcriptional regulation in astrocytes 
Miyamoto et al. showed that CCL5 is transcriptionally regulated in the astrocyte cell line 
CH235. Stimulation with IL-1β but not with TNF-α, resulted in upregulation of CCL5 gene 
expression. Transient transfection assays in the CH235 cell revealed a different optimal 
promoter relative to monocytes for basal as well as induced transcription. Results show that 
the promoter sequences between -278 and +58 were sufficient for IL-1β-inducibility. In vitro 
DNA binding assays demonstrated constitutive binding of Sp1, HMG, Ets domain (GABP 
α/β), and bZIP family members (Fra 1, Fra 2 and Jun D) to their cognate sites in the CCL5 
promoter, whereas NF-kB and IRF-1 bind in an IL-1β-inducible manner. Miyamoto 
spectulated that the formation of a higher order nucleoprotein complex (enhanceosome) may 
be critical for IL-1β induction of the CCL5 promoter in astrocytes [46]. 
2.8.3   Transcriptional regulation in fibroblast cells 
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In synovial and renal fibroblast cells, CCL5 transcription regulation has been studied in the 
context of TNF-α and IFN-γ stimulation. [64], Ballen et al. (Unpublished data), Blaber et.al. 
and Cho et.al. have all shown that similar to other cell types, the immediate -230 bases retain 
wild-type levels of inducible promoter activity. However in this instance the optimal promoter 
in these cells includes the transcription factor binding elements; AP1/CREB (-203 to -186), 
IRF1/Ets (-137 to -119), NF-kB/SP1 (-75 to -56) and NF-kB (-55 to -39) to mediate inducible 
CCL5 transcription in response to TNF-α and IFN-γ stimulation [64-66]. 
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2.8.4   Transcriptional regulation in epithelial cells 
Casola et. al. has shown that CCL5 is transcriptionally regulated in alveolar epithelial cells 
and stimulation with TNF-α results in upregulation of the gene expression. Transient 
transfection assays show that the optimal promoter includes the binding elements; 
AP1/CREB (-203 to -186), NF-IL6 (-102 to - 92) IRF1/Ets (-137 to -119), CEBPβ (-125 to -
97), NF-kB/SP1 (-75 to -56) and NF-kB (-55 to -39) and are required for the inducible CCL5 
transcription [67]. 
2.8.5   Transcriptional regulation in T lymphocytes 
The expression of CCL5 by T lymphocytes may be in part, a developmentally controlled 
event. Early CCL5 expression is seen following the activation of resting peripheral blood T 
cells. This is followed by a strong upregulation occurring three to five days later as the T cells 
become functionally mature. A high level of CCL5 expression is maintained indefinitely in 
vitro by activated T cells, such as cytotoxic and helper T lymphocytes. Four transcriptional 
control elements; NF-IL6 (-102 to - 92), CEBPε (-125 to -97), NF-kB/SP1 (-75 to -56) and NF-
kB (-55 to -39) contribute to early as well as late CCL5 expression in T cells [68, 69]. 
Recently, it has been shown that RFLAT-A (KLF13) a member of KLF family of transcription 
factor binds to the NF-kB/SP1 (-75 to -56) region and recruits a complex of nuclear proteins 
(brg1, NLK, and p300/CBP) to the CCL5 promoter which controls the transcription of CCL5 in 
CTL [70]. 
Experimental analysis of CCL5 promoter in different cells/tissues type shows that the signal 
and cell specific regulation of CCL5 transcription can differ widely. The diversity in the CCL5 
promoter regulation depends upon the different combinations of five promoter regions which 
mediate signal and tissue specific regulation.  
As we have seen, the CCL5 promoter has been extensively studied in different cell types. In 
this regard, the promoter can be used as a molecular probe to help study aspects of signal 
and tissue specific gene regulation. Characterization of the molecular mechanisms 
underlying CCL5 promoter regulation in natural killer cells and in renal mesangial cells is a 
central goal of this doctoral thesis. 
2.9   Regulatory pathways linked to CCL5 transcription 
An important component of the inflammatory response is the production and release of 
immuno-regulatory cytokines and chemokines. Pro-inflammatory cytokines and tissues 
stress (pathogens) induce chemokines such as CCL5 that are involved in the recruitment of 
leukocytes to the site of injury or stress. In this process, CCL5 is generally regulated 
transcriptionally, although post-transcriptional and translational mechanisms may also be 
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important. Several pathways transmit the signals that trigger CCL5 production. Among them, 
the nuclear factor kappa B (NF-kB) pathway has been shown to play an essential role in 
activating CCL5 in most settings. In addition, other signaling pathways, such as mitogen-
activated protein kinases (MAPK), signal transducer and activator of transcription (STAT) 
have been also shown as important regulators of CCL5 expression in some cell types [4, 34, 
62, 63, 71-73]. 
Mitogen-activated protein kinase (MAPK) pathways regulate diverse biologic processes 
including aspects of inflammation. MAPK pathways can be activated by an enormous array 
of stimuli, they phosphorylate numerous proteins including transcription factors and thus 
influence gene expression. Five families of MAPKs have been defined in mammalian cells: 
extracellular signal-regulated kinases (ERK1 and ERK2), Jun N-terminal kinases (JNK1, 
JNK2 and JNK3); p38 kinase isozymes (p38 , p38ß, p38  and p38 ); ERK3/ERK4; and 
ERK5 [74-76].  
The first three MAPKs, and their activators, are implicated in human diseases and are targets 
for drug development (Figure 2.4). MAPK cascades in mammalian cells are preferentially 
activated by proinflammatory cytokines such as tumour necrosis factor-α (TNF-α), 
interleukins and oxidative stress. MAPK pathways are shown to regulate transcription factors 
such as CREB, ELK1 (Ets-like gene 1), Ets1, HSF1 (Heat shock factor), MEF2 (Myocyte 
enhancing factor 2), cMyc (avian myelocytomatosis viral oncogene homolog), STAT1/3/6 
(Signal transducer and activator of transcription), CHOP, NFAT (nuclear factor of activated T-
cells) and p53 and consequently regulate a diverse set of cellular/tissue functions [77-96]. 
The most common downstream target of MAPK pathways are the AP1 (Activator protein 1) 
family of transcription factors (Jun B, c Jun, ATF and Jun D). MAP kinase activation has 
been shown to induce the phosphorylation of; c-Jun, Jun D and ATF-2 (activating 
transcription factor 2) in the nucleus, leading to AP-1 dependent gene expression. AP-1 
plays a regulatory role in the transcriptional activation of the genes involved in inflammation, 
cell proliferation, apoptosis and extra-cellular matrix accumulation. AP-1 has been proposed 
to play a role in the pathogenesis of inflammation and fibrotic diseases such as 
glomerulonephritis [74, 97-99]. 
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Figure 2.4   Activators and effectors of the principal mitogen-activated protein kinase (MAPK) 
families. Only representative MAPK effectors (transcription factor substrates) are shown. (Symbols 
are used as defined in 2.9) This schem is a simplified modification from the KEGG database pathway 
view 
2.9.1   MAP kinase pathways in human NK cell biology 
Natural killer (NK) cells have features similar to CD8+ T cells in that they recognize and lyse 
virally infected and neoplastic cells, express receptors such as CD28, CD43, 2B4 and 
contain cytolytic granules. In T lymphocytes, ERK, JNK and p38 kinase activities are 
necessary for proper T cell development and for IL-2 gene transcription in response to TCR 
stimulation. In addition, MAP kinases are also required for proper T differentiation and 
effector function [76, 100]. 
NK cells lack a T cell-like predominant receptor. The function of NK cells is controlled by a 
co-ordinated signal generated from the ligation of inhibitory and activating receptors (Table 
2.2 and Table 2.3) [101].  
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                        Table 2.2. Inhibitory receptors and their ligands [101] 
                        
                    Table 2.3. Activating receptors and their ligands [101] 
                  
The NK inhibitory receptors regulate NK cells actions by interrupting intracellular activation 
signals when MHC class I molecules are correctly expressed [102, 103]. Activating receptors 
bind MHC class I molecules and trigger NK responses to cells with viral, bacterial, or 
parasitic infections or to some tumor cells with downregulated MHC class I molecules [104].  
 12 
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The effector function of each receptor molecule is determined by the sequence of its 
transmembrane region and cytoplasmic tail [105]. Generally, inhibitory receptors possess an 
immunoreceptor tyrosine-based inhibitory motif (ITIM) in their cytoplasmic tails [102], which 
decreases activation [106]. Upon stimulation, the ITIM becomes tyrosine phosphorylated and 
associates with intracellular phosphatases such as Src homology 2 (SH2) domain–containing 
protein tyrosine phosphatase 1 (SHP1) or SHP2. SHP1 then dephosphorylates the actin 
cytoskeleton regulator, Vav, which blocks actin-dependent activation signals [106]. In 
contrast, activating receptors lack ITIMs in their cytoplasmic tails and often contain charged 
residues that facilitate association with adaptor molecules containing immunoreceptor 
tyrosine-based activation motifs (ITAMs or YINM) such as DAP12/KARAP (DNAX-activating 
protein of 12 kD), FcRγ, CD3ζ and DAP10 [107, 108]. When activating receptors are 
associated with ITAM-containing adaptor molecules, the adaptor molecules become tyrosine 
phosphorylated and the subsequent molecular cascade leads to activation of a series of 
intracellular downstream signaling molecules, ultimately resulting in polarization and 
exocytosis of cytokines, chemokines and granules to lyse the target cells [101, 109-112] . 
Several NK cell receptors such as CD94-NKG2C/E, CD16, NCR (NKp30,NKp44, NKp46 ), KIR-
S, 2B4 (CD244), and NKG2D have been shown to activate MAP kinases, PI-3K and protein 
kinase C pathways (Figure 2.5) [108, 113, 114]. These NK cell receptors coupled to the 
activation of Src family PTKs (protein tyrosine kinases) such as Lck. Lck activation leads to 
the tyrosine phosphorylation of IBPs, which can then recruit and activate PTKs of the Syk 
(spleen tyrosine kinase) family [113]. Signaling adaptors that act downstream of Syk family 
members include at least the Vav guanine nucleotide exchange factors (Vav1 and Vav2) 
[115], SLP-76 (SH2 domain-containing leukocyte protein of 76 kD), Shc, LAT (linker for 
activation of T cells) and NTAL (non-T cell activation linker) [116]. Vav activates the Rho 
family GTPase (small guanosine triphosphatase) Rac1, which initiates the activation of the 
MAPK ERK (extracellular signal-regulated kinase) through the cytoplasmic kinases PAK1 
(p21-activated kinase 1) and MEK (mitogen-activated or extracellular signal-regulated protein 
kinase kinase) [117]. LAT and SLP-76 couple ITAM-dependent signals to Ras activation 
through Grb2. LAT also mediates the 2B4-SAP-ERK/p38 MAP kinase activation pathway 
[118] 
DAP10-dependent signaling pathways include Vav (the Vav1 isoform) [115, 119]; SLP-76; 
PLC-γ (phospholipases C-γ); phosphatidylinositol 3-kinase (PI3K); and Grb2 [114, 119, 120]. 
Therefore, both ITAM- and DAP10-dependent pathways can activate the Vav-Rac-PAK1-
MEK-ERK signaling cascade that appears critical to NK cell cytotoxicity. NK cell cytokine 
secretion requires additional or distinct signals, which are dependent upon the p38 and the 
JNK (c-Jun N-terminal kinase) MAPK [121].  
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Figure 2.5   Schematic representation showing that many NK activating receptors employ the 
MAP kinase pathway to regulate the cytokines and cytolytic granules during NK cell activation  
(This schematic representation is based on Vivier et. al, 2004 and references described in 2.9.1) 
Symbols are used as defined in 2.9.1 [107, 108, 114, 115, 117, 118, 120] 
 
The MAPK (ERK, JNK, and p38), PKCs and PI3K pathways are involved in triggering the 
polarization and secretion of cytolytic granules in NK cells (Figure 2.5). However, the role of 
these pathways in the control of chemokines such as CCL5 expression in NK cells has not 
been investigated. 
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2.9.2   MAP kinase pathways in glomerulonephritis 
The kidneys filter the body's blood supply with structures known as nephrons (Figure 2.6). 
Each nephron is composed of a glomerulus and a tubule. The glomerulus filters wastes and 
excess fluids, while the tubules modify the waste to form urine. 
                       
Figure 2 6   Shows the structure of the nephron, which filters waste from the body's blood 
supply. Each nephron is composed of a glomerulus and a tubule. The glomerulus filters wastes and 
excess fluids, while the tubules modify the waste to form urine. (Adapted from BCU, UK, 
http://www.health.bcu.ac.uk/physiology/renalsystem) 
 
There are many causes of glomerular disease. These include inflammation of the glomeruli, 
which is called glomerulonephritis. Glomerular disease reduces the ability of the kidneys to 
both filter and retain substances in bloodstream. Glomerulonephritis may be a temporary and 
reversible condition, or it may get worse. Progression may result in chronic kidney failure and 
end stage kidney disease. Glomerulonephritis is a type of kidney disease caused by 
inflammation of the internal kidney structures (glomeruli). Glomerulonephritis is seen as an 
ongoing process with inflammation and matrix deposition [122-124]. 
Glomerular inflammation activates intrinsic glomerular cells to secrete pro-inflammatory 
mediators. Among these chemokines facilitate glomerular leukocyte recruitment during the 
initiation, amplification and progression phases of glomerulonephritis [125, 126]. In turn, the 
infiltrating leukocytes contribute to the glomerular damage by releasing inflammatory and 
profibrotic factors.  
Chemokine-mediated leukocyte recruitment and activation forms an integral part in this 
process [125]. The functional roles of chemokines in the pathogenesis of glomerulonephritis 
have been demonstrated in animal models by blocking chemokine activity with neutralizing 
antibodies, chemokine receptor antagonists, and targeted disruption of chemokine and 
chemokine receptor genes [126, 127]. In the rat, neutralizing antibodies to CXC chemokines, 
   15
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including CXC chemokine ligand (CXCL) 1/macrophage inflammatory protein (MIP)-2 and 
cytokine-induced neutrophil chemoattractant (CINC), reduced glomerular neutrophil 
infiltration and proteinuria during the acute phase of nephrotoxic serum nephritis [126, 127]. 
Blockade of the CXC chemokine receptor CXCR2, which binds multiple CXC chemokines 
with the peptide analog growth regulated oncogene (GRO)-a8–73 demonstrated a role of 
CXCR2 in mediating glomerular monocyte recruitment in the same model [128]. Neutralizing 
antibodies to the CC chemokine CCL2/MCP-1, a major monocyte/macrophage 
chemoattractant, reduced glomerular macrophage influx and proteinuria in rat nephrotoxic 
serum nephritis and abrogated glomerular leukocyte infiltration and proteinuria in murine 
nephrotoxic nephritis [126, 129]. Beneficial effects of two CCL5/RANTES analogs, amino-
oxypentane (AOP)–RANTES and Met–RANTES, which block binding of human receptors 
CCR1, CCR3 and CCR5, have been demonstrated in rodent studies. AOP–RANTES 
inhibited glomerular macrophage infiltration in anti-Thy 1.1 nephritis, a model of 
mesangioproliferative glomerulonephritis [126], and Met– RANTES reduced glomerular 
leukocyte infiltration and proteinuria in murine nephrotoxic serum nephritis [129]. 
 
The activation of MAPK/AP1 signalling pathways have been identified in a number of 
experimental models of immune-mediated kidney disease including rat anti-glomerular 
basement membrane (GBM) glomerulonephritis and passive Heymann’s nephritis, as well as 
in models of renal injury induced by nonimmune insults. Blockade of the JNK MAP kinase 
can reduce proteinuria and glomerular lesions in the rat anti-glomerular basement membrane 
(GBM) disease model [130-133]. The protective effect of JNK inhibition was found to be due 
in part to the modulation of macrophage activation. Jun D which is a component of the 
MAPK/AP1 pathway was shown by Behmoaras et. al. to be a susceptibility marker for 
glomerulonephritis [134].  
The role of local tissues in glomerulonephritis is well established [135-140], however the role 
of MAPK/AP1 pathways as a pathogenic or susceptible marker for glomerulonephritis has 
been mostly studied in the context of macrophage derived cytokines, chemokines and 
activation state of macrophage [130, 131, 134]. The potential role of MAPK/AP1 in controlling 
mesangial cell derived cytokine and chemokine production was largely unknown. 
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General goals of this doctoral thesis: 
There are a set of goals that lie at the centre of this thesis. First, to compare and contrast the 
general transcriptional regulation of CCL5 in two different tissue settings:- NK cells vs. 
mesangial cells. Second, to explore the potential biologic roles of the MAP kinases in both 
tissue settings in the context of CCL5 regulation. To determine which MAP kinase pathways 
may be used in control of CCL5 by these cell types, and to determine how subsequent 
downstream signaling events compare between the two cell types. Finally, it has been 
hypothesized that signal and transcriptional regulatory features can uniquely identify the 
tissue specific context of gene expression. To explore this hypothesis in more detail, a 
bioinformatics based approach was used to study and define a potential tissue specific 
CCL5-linked regulatory network. 
 
NK cells 
CCL5 is expressed by NK cells. However, how this expression was controlled in these cells 
was unknown at the onset of this thesis. MAP kinase pathways are central mediators of 
signal transduction and have been shown to control biologic processes in NK cells that could 
be linked to CCL5 biology. For example, NK cell receptors have been shown to activate MAP 
kinase pathways that were subsequently found to be involved in the triggering, polarization 
and secretion of cytolytic granules in NK cells (Chen et.al. 2006; Chen et.al. 2007; Liang 
et.al. 2005; Li et.al. 2008). The potential role of the MAP kinase pathways in the control of 
expression of the chemokine CCL5 in NK cells was investigated. To this end: 
• The expression profile of CCL5 and cytotoxins (perforin and granzymes) were 
analyzed and compared. 
• Regulatory control of the CCL5 promoter in NK cells was characterized and the 
upstream signaling pathways determined. 
• The regulatory pathways for CCL5 expression in the context of NK cell stimulation 
were examined. 
 
Mesangial cells 
Human mesangial cells induce expression of CCL5 in response to the proinflammatory 
stimuli provided by TNF-α and IFN-γ. Both stimuli are required for optimal activation. The 
molecular mechanisms underlying this activation were unknown. Activation of the MAPK/AP1 
pathway has also been observed in glomerular inflammation and thus could also play a role 
in the induction of CCL5 [130-132]. The potential role of MAPK/AP1 pathways in driving 
CCL5 expression in mesangial cells was investigated. To this end: 
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• The expression of CCL5 in response to TNF-α and IFN-γ stimulation were 
analyzed and the role of MAP kinase in the induced CCL5 expression was 
characterized. 
• Regulatory control of the CCL5 promoter in mesangial cells was characterized in 
detail and the relevant signaling pathways determined. 
 
Promoter modelling and network analysis  
As a final extension of this project, inflammatory gene regulatory pathways linked to CCL5 
expression were explored in the context of an exemplary glomerular disease (IgA 
nephropathy). IgA nephropathy (also known as IgA nephritis, IgAN, Berger's disease and 
synpharyngitic glomerulonephritis) is a form of glomerulonephritis (inflammation of the 
glomeruli of the kidney). IgA nephropathy the most common glomerulonephritis is 
characterized by deposition of IgA antibody in the glomerulus leading to the hyperactivation 
of mesangial cells [138, 141]. CCL5 expression and its role in the initiation, amplification and 
progression of glomerulonephritis, including IgA nephropathy, has been shown [34, 122, 142, 
143]. In an attempt to identify potential gene networks linked to CCL5 activation in IgA 
nephropathy, a bioinformatics-based promoter modelling approach of the functional CCL5 
promoter in activated mesangial cells was used to identify other human promoter with similar 
features. The results were then compared to trancriptomic data from a cohort of control and 
patient samples, co-expression was verified and the novel description of two new CCL5-
associated proinflammatory genes were linked to the biology of IgA nephropathy.   
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3   Materials and methods 
3.1   Materials 
3.1.1   Medium and supplements 
IMDM      Invitrogen, Carlsbad (Cat. Nr. 21980-032) 
RPMI1640     Invitrogen, Carlsbad (Cat. Nr. 61870-010) 
DMEM      Invitrogen, Carlsbad (Cat. Nr. 21885-025) 
FCS      Biochrom AG, Berlin (Cat. Nr. S0615) 
PBS (1X)     PAA Lab, Pasching (Cat. Nr. H15-002) 
Trypsin (0.5mg/ml and EDTA  PAA Lab, Pasching (Cat. Nr. L11-004) 
Sodium pyruvate    GIBCO/Invitroge, Carlsbad,(Cat. Nr 11360) 
Nonessential amino acids   GIBCO/Invitroge, Carlsbad (Cat. Nr 11140) 
Penicillin/Streptomycin (100x)  PAA Lab, Pasching (Cat. Nr. P11-010) 
Dimethylsulfoxide (DMSO)   Merck, Darmstadt (Cat. Nr. 1167431000) 
Trypanblue (0.4% solution)   Sigma-Aldrich, Taufkirchen (Cta. Nr. T8154) 
3.1.2   Cell lines and primary cells 
YT   > The YT cell line is an interleukin-2 (IL-2) independent human natural 
killer-like leukemic cell line established from a patient with acute 
lymphoblastic lymphoma and thymoma [YT cell line was generously 
provided by C. Clayberger (Stanford University, Stanford, CA)] 
NK92   > The NK-92 cell line is an interleukin-2 (IL-2) dependent natural killer 
cell line derived from the peripheral blood mononuclear cells taken 
from a 50 year old Caucasian male with rapidly progressive non-
Hodgkin's lymphoma (NK92 cell line was purchased from German 
Collection of Microorganisms and Cell Cultures; DSMZ Nr. ACC 488) 
NKL      > The NKL cell line was established from the the peripheral blood of a 
patient with large granular lymphocyte (LGL) leukemia [NKL cell line 
was generously provided by Peter Cresswell (Yale University)]. 
Primary NK cell > Freshly isolated from human peripheral blood 
HIMC   > Human immortalized mesangial cell [45] 
Materials and Methods 
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3.1.3   Culture media 
YT  IMDM with L-glutamine supplemented with 20% FCS and 1% sodium 
pyruvate 
NK92 RPMI with L-glutamine supplemented with 15% FCS, 10% horse 
serum, 1% sodium pyruvate, 1% Non essential amino acids and 200 
Units IL2 
NKL   RPMI with L-Glutamine supplemented with 10% FCS and 200  
Units/ml IL2 
Primary NK cell RPMI with L-glutamine supplemented with 10% FCS, 10% human 
serum, 1% sodium pyruvate, 1% non-essential amino acids (NEAA) 
and 200 Units/ml IL2.  
HIMC  DMEM with L-glutamine supplemented with 10% FCS and 1% penicillin 
and streptomycin. 
3.1.4   Cell culture 
Primary NK cells: 
Human primary NK cells were isolated from healthy donors using a Human NK negative 
isolation Kit (Dynal, cat. No.113.15) used according to manufacturer's protocol. Purity, 
assessed by α-CD3 and α-CD56 flow cytometry analysis was >97%. Freshly purified cells 
were cultured in RPMI 1640 supplemented with 10% human serum and 1% L–glutamine, 1% 
NEAA, 1% sodium pyruvate and 200 U/ml recombinant IL-2 for a maximum of 24 h  
(All experiments with primary NK cells were performed within 24 h of isolation). 
Natural killer cell lines: 
All NK cell lines used were grown in suspension culture. With the exception of the YT cell 
line, all cell lines were grown in the presence of IL2. To carry the cell lines, cell suspensions 
were centrifuged at 1200 rpm for 5 min. The growth media was removed and the cells were 
washed once with 1x PBS and resuspended in fresh medium and plated on new plates. The 
NK cell lines generally grew to a density of approximately 0.5 x106/ml and after that reduced 
or stopped growth. 
 
Human immortalized mesangial cells: Cell seeding for stimulation: 
The HIMC line was previously described [45]. The cells were generally grown to 80% 
confluency and detached from the plates using 1x Trypsin-EDTA. The enzymatic reaction 
was stopped by addition of culture medium. The cell suspension was centrifuged at 1200 
rpm for 5 min. Afterwards the growth media was removed and the cells were washed once 
with 1x PBS, resuspended in fresh complete medium, and plated on new plates one day in 
advance. 
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The following numbers of cells were seeded in different plate formats one day prior to 
stimulation: 
 
Flasks type      Cells seeded 
150 mm      6.5 x106
100 mm      3 x106
6 well plates      0.4 x106
12 well plates      0.17 x106
24 well plates      0.1 x106
 
24 h following cell seeding, cell confluency was found to be approximately 80%. This 
procedure was always used for the various simulation studied described in the course of the 
thesis. 
3.1.5   Microbiology 
Medium preparation for DH5 α and XL1 blue culture: 
1x LB medium (1 Litre)   10 g Tryptone (BD Bio, San Jose - 2117050) 
     5 g Yeast Extract (BD Bio, San Jose - 212750) 
     10 g NaCl  
3.1.6   Nucleic acid isolation, purification and quantification kits 
Quick-change site-directed 
mutagenesis kit    Stratagene, La Jolla (Cat. Nr. 200518) 
Endofree plasmid maxi kit   Qiagen, Hilden (Cat. Nr. 12362) 
QiaPrep plasmid midi kit   Qiagen, Hilden (Cat. Nr. 12143) 
QiaPrep spin miniprep kit   Qiagen, Hilden (Cat. Nr. 27106) 
QiaPrep gel extraction kit   Qiagen, Hilden (Cat. Nr. 28704) 
RNeasy mini kit    Qiagen, Hilden (Cat. Nr. 74106) 
RNase free DNase set   Qiagen, Hilden (Cat. Nr. 79254) 
Quant-It dsDNA BR assay kit  Invitrogen, Carlsbad (Cat. Nr. Q32853) 
Quant-It dsRNA BR assay kit  Invitrogen, Carlsbad (Cat. Nr. Q10211) 
Quant-It protein assay kit   Invitrogen, Carlsbad (Cat. Nr. Q33212) 
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3.1.7   Reagents for molecular biology assays 
3.1.7.1   Reagents for reverse transcription and quantitative real-time-PCR (qRT-PCR) 
Superscript II reverse transcriptase  Invitrogen, Carlsbad (Cat. Nr. 18064-014) 
0.1 M DTT     Invitrogen, Carlsbad (Cat. Nr. Y00147) 
Acrylamid     Ambion (Cat. Nr. 9520) 
Hexamer primer    Roche Diagnostics, (Cat. Nr. 14173921) 
RNase inhibitor    Promega, Mannheim (Cat. Nr. N2511) 
dNTPs:     Amarsham Pharmesia, Uppsala 
TaqMan universal PCR master mix  Roche Diagnostics, (Cat. Nr. 4304437) 
3.1.7.2   Reagents for SYBRgreen quantitative real-time-PCR (qRT-PCR) 
10x Taq Buffer without detergent  Fermentas, St. Leon-Rot (Cat. Nr. B55) 
dNTPs (25 mM)     Amersham pharmesia, Uppsala 
Rox reference dye     Invitrogen, Carlsbad (Cat Nr 12223-012) 
PCR optimizer     Bitop, Witten (LC120-0001) 
BSA PCR grade     Fermentas, St. Leon-Rot (Cat. Nr. B14) 
SYBRgreen 1     Fluka, Taufkirchen (86205) 
MgCl2 25 mM      Ferments, St. Leon-Rot (Cat. Nr. R0971) 
3.1.7.3   Reagents for western blotting 
MagicMarc XP (western blotting)  Invitrogen, Carlsbad (Cat. Nr. LC5602) 
Molecular weight marker   PeQLab, Erlangen (Cat. Nr. 27-2111) 
ECL plus detection reagents   GE Healthcare (Cat. Nr. RPN2132) 
30% Bisacrylamide    Carl Roth (Cat. Nr. 3029) 
SDS      Carl Roth (Cat. Nr. 5136) 
APS      Bio-Rad (Cat. Nr. 161-0700) 
TEMED     Bio-Rad (Cat. Nr. 161-0801) 
PVDF      Millipore (Cat. Nr. IPVH09120) 
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3.1.7.4   Antibodies 
Table 3.1   Antibodies for western blotting and supershift/blocking 
Antibody Company Cat.Nr. WB Dilution 
Anti SP1 Upstate 07-645 1:1000 
Anti SP3 Upstate 07-107 1:1000 
Anti p50 (NLS) Santa Cruz SC-114 1:1000 
Anti p52 (K-27) Santa Cruz SC-298X 1:1000 
Anti p65 Upstate 06-418 1:1000 
Jun-B (N17) Santa Cruz SC-46X 1:1000 
Jun-C (H-79) Santa Cruz SC-1694X 1:1000 
Jun-D (329) Santa Cruz SC-74X 1:1000 
Fra-1 (H-50) Santa Cruz SC-22794X 1:1000 
Fos-B (102) Santa Cruz SC- 48X 1:1000 
Fos-C (4) Santa Cruz SC-52X 1:1000 
Ets1 (C-20) Santa Cruz SC-350X 1:1000 
Ets2 (C-20) Santa Cruz SC- 351X 1:1000 
IRF1 (C-20) Santa Cruz SC-497X 1:1000 
IRF2 (C-19) Santa Cruz SC-498X 1:1000 
IRF3 (FL-425) Santa Cruz SC-9082X 1:1000 
IRF7 Santa Cruz SC-X 1:1000 
anti -ERK1/2 Cell Sinaling 9102 1:1000 
anti -JNK1/2/3 Cell Sinaling 9252 1:1000 
anti -p38 Cell Sinaling 9212 1:1000 
anti phospho-ERK1/2 (Thr202/Tyr204)  Cell Sinaling 9101 1:1000 
anti phospho-JNK1/2/3 (Thr183/Tyr185) Cell Sinaling 9251 1:1000 
anti phospho-p38 (Thr180/Tyr182)  Cell Sinaling 9211 1:1000 
IKK α Antibody Cell Sinaling 2682 1:1000 
IKK β (L570) Antibody Cell Sinaling 2678 1:1000 
Phospho-IKKα/β (Ser176/180) Cell Sinaling 2697 1:1000 
NF-kB p65 (C22B4)  Cell Sinaling 4764 1:1000 
phospho-NF-kB p65 (Ser536) Cell Sinaling 3033 1:1000 
IkBα (L35A5)  Cell Sinaling 4814 1:1000 
phospho-IkBα (Ser32)  Cell Sinaling 2859 1:1000 
phospho-c-Jun (Ser73) Cell Sinaling 9164 1:1000 
KLF13 Abcam ab1127 1:500 
β actin  Abcam ab8227 1:3000-5000 
 
Table 3.2   Secondary antibodies for western blotting 
Antibody Company Cat.Nr. WB Dilution 
anti-Rabbit IgG, HRP-
linked Antibody 
Cell Signaling 7074 1:5000 
anti- mouse IgG, HRP-
linked Antibody 
Cell Signaling 7076 1:5000 
anti-Rabbit IgG, AP-linked 
Antibody 
Jackson 
ImmunoResearch 
111-055-003 1:1000 
anti-mouse IgG, AP-linked 
Antibody 
Jackson 
ImmunoResearch 
115-055-003 1:1000 
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Table 3.3   Antibodies for FACS and confocal microscopy 
Antibody Company Cat.Nr. Dilution 
mouse IgG2b-α-human 
CCL5 VL1 or VL2hy 
bridoma 
P. J. Nelson. 1997. Methods Enzymol. 
287:162-174 
1:2 in PBS/10% 
human serum 
mouse IgG1-α-human 
granzyme B  
Serotec MCA2120PE 1:100 
mouse-α-human perforin BD Biosciences 556434 1:10 
goat-α-mouse IgG1 CD3 
Pacific Blue  
DAKO PB982 According to 
manual 
goat-α-mouse IgG1 CD56 
APC  
BD Biosciences IM2474 According to 
manual 
rabbit-α-human CD8  Neomarkers RM-9116-R7 150 
Unconjugated mouse 
IgG2b isotype hybridoma 
clone TIB 173, kind donation from E. 
Kremmer, Munich 
According to 
experiment 
unconjugated mouse 
IgG2b monoclonal isotype  
BD Biosiences, clone MPC-
11, 559530 
According to 
experiment 
PE conjugated mouse 
IgG1, κ monoclonal 
isotype 
Serotec clone 
W3125, 
MCA928PE 
According to 
experiment 
goat-anti-mouse IgG1 
AlexaFluor A568 
Invitrogen Molecular 
Probes 
A-21144 1:500 
goat-anti-mouse IgG2b 
AlexaFluor 488 
Invitrogen Molecular 
Probes 
A-21141 1:500 
goat-anti-rabbit Cy5  Dianova, Jackson 
laboratories 
 1:100 
3.1.7.5   Reagents for EMSA 
γp32-ATP     PerkinElmer, Boston (Cat. Nr. NEG5)  
Probe purification kit    Stratagene, La Jolla (Cat. Nr. 400702) 
Poly(dI-dC)     Sigma Aldrich, Taufkirchen (Cat. Nr. P4929) 
Consensus/Mutant oligos   Santa-Cruz, Heidelberg 
3.1.7.6   Reagents for transient transfection  
Superfect     Qiagen, Hilden (Cat. Nr. 301305) 
Lipofectamin 2000    Invitrogen, Carlsbad (Cat. Nr. 11668-019) 
SiPort - NeoFX    Ambion (Cat. Nr. 4511) 
Electroporation cuvettes   PeqLab, Erlangen (Cat. Nr. 71-2030) 
3.1.7.7   Reagents for Chip 
Pansorbin cells    Calbiochem, San Dieago (Cat. Nr. 507862) 
Herring sperm DNA    Roche Diagnostics (Cat. Nr. 11467140001)
Proteinase K     Roche Diagnostics (Cat. Nr. 03115828001) 
tRNA      Ambion (Cat. Nr 7119)  
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 3.1.8   Other reagents 
TMB substrate reagent A and B  BD Bioscience (Cat. Nr. 555214) 
Formaldehyd (37%)    Sigma Aldrich (Cat. Nr. F8775) 
PMA      Sigma Aldrich (Cat. Nr. P1585) 
Ionomycin     Sigma Aldrich (Cat. Nr. I3909) 
Protease inhibitors cocktail   Roche Diagnostics (Cat. No.04693116001) 
Phosphatase inhibitors cocktail  Sigma Aldrich (Cat. Nr. P2850)
DTT      Bio-Rad (Cat. Nr 161-0611) 
Tween 20     Sigma Aldrich (Cat. Nr 93773) 
Triton (X100)     Sigma Aldrich (Cat. Nr 93426) 
Agarose     Invitrogen, Carlsbad (Cat. Nr. 155-10-027) 
1kb Ladder (DNA-agarose gel)  Roche, Basel (Cat. Nr. 13365345) 
3.1.8.1   Enzymes 
Taq-DNA- polymerase   NEB, Beverly (Cat. Nr. M0267) 
T4-DNA- ligase    NEB, Beverly (Cat. Nr. M0201) 
Phusion-Taq-polymerase   NEB, Beverly (Cat. Nr. F-553)   
Restriction digesion enzymes  NEB, Beverly/Roche, Basel 
RNase      Roche, Basel (Cat. Nr. 10109134001) 
Alkaline phosphatase    Roche, Basel (Cat. Nr. 11758250001) 
3.1.8.2   Recombinant proteins 
Recombinant human IL2 (rhIL2)  Peprotech, Rocky Hill (Cat. Nr. 200-02) 
Recombinant human TNF-α (rhTNF-α) Peprotech, Rocky Hill (Cat. Nr. 300-01A) 
Recombinant human IFN-γ (rhIFN-γ) Peprotech, Rocky Hill (Cat. Nr. 300-02) 
3.1.8.3   Consumables 
Cell culture plates      TPP AG, Trasadingen, Switzerland 
Cell culture flasks     TPP AG, Trasadingen, Switzerland 
Cell scraper      TPP AG, Trasadingen, Switzerland 
Falcon tubes 15 ml/50 ml    BD Bioscience, Heidelberg 
Taqman plates     Sarstedt, Nümbrecht 
Taqman cover     Sarstedt, Nümbrecht 
ELISA plate maxisorb    Nunc, Roskilde, Denmark 
Luminometer tubes     Sarstedt, Nümbrecht 
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3.1.9   Instruments 
ABI Prism 7000 sequence detection system Applied Biosystems, Darmstadt 
Plate reader       GENiosPlus Tecan, Crailsheim 
Gel electrophoresis apparatus   MBT Brand, Gießen 
Geneamp PCR system 9700 PE   Applied Biosystems, Darmstadt 
Incubator modell 400     Brutmaschinen, Hammelburg 
Liquid blocker, super pap pen   Daido Sangyo, Tokyo, Japan 
Leica microscope Q600 Qwin   Leica, Cambridge, UK 
MinifugeT      Heraeus, Hanau 
Megafuge 1.0R     Heraeus, Hanau 
Micro centrifuge 5415 D    Eppendorf, Hamburg 
Neubauer counting chamber    Braun, Melsungen 
Power supply powerPac 300    Biorad, München 
QubitTM fluorometer     Invitrogen, Karlsruhe 
Thermomixer comfort     Eppendorf, Hamburg 
Sonifier 250      Branson Ultrasonics Corporation, USA 
Steamer multiGourmet    Braun, Kronberg 
UV transilluminator      Bachofer, Reutlingen 
Water bath haake SWB20    Thermo Haake, Karlsruhe 
Molecular dynamics storm 840 
phosphor imager     Sigma Aldrich, USA 
Luminometer      Berthold Detection Systems, USA 
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3.1.10   Reagents for signaling pathways studies 
Signalling pathways inhibitors  
Name of 
inhibitor 
Pathway 
specificity 
Cat. Nr. Company Concentration used 
Gö6976 PKC 365250 Calbiochem 0.5 – 1 µM 
Gö6983 PKC 365251 Calbiochem 0.5 – 1 µM 
LY294002 PI-3K 440202 Calbiochem 05 – 10 µM 
MNK1 ERK-MNK-eIF4E 454861 Calbiochem 02 – 06 µM  
PD98059 ERK MAPK P215 Sigma Aldrich 50 – 100 µM 
SP600125 JNK MAPK S5567 Sigma Aldrich 50 – 100 µM 
SB203580 P38 MAPK S8307 Sigma Aldrich 10 – 20 µM 
 
The maximum concentrations of inhibitors used for Primary NK cells:  
MAPK inhibitors, ERK- 50 µM, JNK- 50 µM and p38- 20 µM.  
PKC inhibitors, Gö6976- 1 µM, Gö6983-1 µM, PI-3K-10 µM and MNK1- 6 µM 
The maximum concentrations of inhibitors used for the NK cell line YT: 
MAPK inhibitors, ERK-100 µM, JNK- 100 µM and p38-20 µM.  
PKC inhibitors, Gö6976-2 µM, Gö6983-2 µM, PI-3K-10 µM and MNK1-6 µM 
The maximum concentrations of inhibitors used for the Mesangial cell line: 
MAPK inhibitors, ERK- 50 µM, JNK- 50 µM and p38- 20 µM.  
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3.2   Methods 
3.2.1   Analysis of gene expression 
3.2.1.1   Total RNA isolation 
To analyze mRNA expression, total RNA was isolated from the control and stimulated cells 
using the RNeasy mini kit (Qiagen, Hilden) as described in the manufacture’s manual. 
3.2.1.2   Glomerular gene expression data 
Human renal biopsy specimens were procured from an international multicenter study, the 
European Renal cDNA Bank – Kroener-Fresenius Biopsy Bank (ERCB-KFB). The human 
biopsy analyses were performed in co-operation with PD Dr. Clemens Cohen (Medizinishche 
Poliklinik der LMU) and Prof Dr. Hermann-Josef Gröne (DKFZ, Heidelberg). The DNA array 
studies are part of a large scale study of human renal disease organized through the ERCB.  
Biopsies were obtained from patients when clinically indicated, and were molecularly 
analyzed after informed consent and with approval of the local ethics committees. For array 
analysis of glomeruli from patients with IgA-nephropathy and controls (pre-transplant allograft 
biopsies), total RNA was isolated from manually microdissected glomeruli. RNA quality and 
quantity was controlled by microfluid electrophoresis using the RNA 6000 LabChip on a 2100 
Bioanalyzer (Agilent Technologies, Waldbronn, Germany). The poly-A RNA was amplified as 
previously described [144].  
In short, total RNA was reverse-transcribed with a T7-(dT)24 primer (Applied Biosystems, Cat. 
Nr. AM5712). After the second-strand synthesis the double-stranded cDNA was blunt-
ended, purified and transcribed using the MEGAscript T7 kit (Ambion, Austin, TX, USA). The 
unlabeled cRNA was purified followed by a quality check using the Bioanalyzer mRNA pico 
assay. For the second round of cDNA synthesis cRNA was reverse-transcribed using a 
pd(N6) random hexamer primer. After RNAse H treatment the second-strand synthesis was 
performed in the presence of a T7-(dT)24 primer. Double-strand cDNA was blunt ended, 
purified and subjected to in-vitro transcription using the BioArray HighYield RNA transcript 
labelling kit (Enzo Laboratories, Farmingdale, NY). The biotin-labelled cRNA was finally 
purified followed by a quality check using the Bioanalyzer mRNA nano assay.  
The fragmentation, hybridization, staining and imaging was performed according the 
Affymetrix Expression Analysis Technical Manual (HG-U133A). Expression data were 
normalized using Robust Multichip Average expression summary [145]. We analyzed the 
expression arrays with Significance Analysis of Microarray [146]. Finally, we used the dChip-
software for the hierarchical clustering [147]. 
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3.2.1.3   Reverse transcription (RT) 
RT was performed in 45 µl volume, containing 9 µl 5x RT buffer, 2 µl dithiothreitol (0.1 M 
DTT), 0.9 µl dNTP (25 mmol), 1 µl RNase inhibitor and 0.5 µl Microcarrier acrylamide (15 
µg/ml), 0.5 µl random hexamers (20x) and 200 U reverse transcriptase and 30 µl of the RNA 
solution for one hour at 42°C. In papallel, 1:10 diluted RNA was used for RT-. For RT- 
reverse transcription reaction controls, reverse transcriptase was excluded. 
3.2.1.4   Quantitative real-time-PCR (qRT-PCR) 
qRT-PCR was performed on a TaqMan ABI 7700 Sequence Detection System (PE 
Biosystems, Weiterstadt, Germany) using heat-activated TaqDNA polymerase (Amplitaq 
Gold; PE Biosystems). After an initial hold of two min at 50°C and ten min at 95°C, the 
samples were cycled 40 times at 95°C for 15 seconds and 60°C for 60 seconds. For all 
quantitative analyzes the cDNA content of each sample was compared with another sample 
following the ΔΔCt technique. 
This procedure uses the formula A0/B0 = (1+E)(Ct,B-Ct,A) where A0 is the initial copy number of 
sample A; B0 is the initial copy number of sample B; E, efficiency of amplification; Ct, A,  
threshold cycle of sample A; and Ct, B threshold cycle of sample B. The amplification 
efficiency was defined as 1 as all analyzes were performed during the same runs including 
control dilution series. Similar amplification efficiencies for targets and housekeeping genes 
were demonstrated by analyzing serial dilutions showing an absolute value of the slope of 
log input cDNA amount versus ΔCT (Ct housekeeping gene - Ct target) of < 0.1. Sequences 
with following gene bank accession numbers served for the design of a pre-developed 
TaqMan assay reagents (PDAR) or primers, probe and 2x Master mix for PCR was 
purchased from Applied Biosystems: AF043341 (human CCL5) and M33197 (human 
GAPDH) as housekeeping gene. 
These assay reagents were specifically designed not to amplify genomic DNA samples (e.g. 
to span sequences with intervening introns). Controls consisting of H2O were negative in all 
runs. 
3.2.1.5   SYBRgreen method of quantitative real-time-PCR (qRT-PCR) 
The pre-developed TaqMan assay reagents (PDAR), primers and probes were purchased 
from Applied Biosystems. In addition to TaqMan analysis, the SYBRgreen method was also 
used to analyze the gene expression of interest. 
SYBRgreen-based detection for qRT-PCR works if one gene-specific amplicon is generated 
during the reaction. Unlike TaqMan-based assays, SYBRgreen detection allows one to check 
the specificity of the PCR reaction by assessing the melting curve of the DNA duplex. At low 
temperature, the PCR DNA product is double stranded, and intercolates SYBRgreen which is 
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detected using florescence. With increasing temperature, the DNA product melts or 
dissociates becoming single stranded, releasing SYBRgreen and decreasing the fluorescent 
signal. Most qRT-PCR instruments generally plot melting curves as a first derivative. In 
SYBRgreen, specificity of the primers can be analyzed by dissociation curve analysis. 
3.2.1.5.1   Preparation of SYBRgreen master mix 
Table 3.4   SYBRgreen master mix 
2x SYBRgreen master mix  (500 µl Volume) 
10x Taq Buffer without detergent (Fermentas - B55) 100 µl 
dNTPs(25 mM) Amersham pharmesia 7.5 µl 
Rox (Invitrogen Cat Nr 12223-012, 500 µl) 20 µl 
PCR Optimizer (Bitop LC120-0001 1 ml ) 200 µl 
BSA PCR Grade (Fermentas – B14) 10 µl 
SYBRgreen 1 (Fluka – 86205,stock 1:100 in 20% DMSO) 2 µl 
MgCl2 25 mM (Fermentas – R0971) 120 µl 
H2O 40.5 µl   
3.2.1.5.2   Preparation of reaction mix for each 20 µl reaction 
10 µl    2x SYBRgreen master mix 
0.6 µl    Forward primer (10 pmol) 
0.6 µl    Reverse primer (10 pmol) 
0.16 µl    Taq polymerase (NEB M0267) 
6.64 µl    H2O and 2 µl cDNA (1:10 diluted) 
3.2.1.5.3   The polymerase chain reaction for SYBRgreen quantitative-PCR (qRT-PCR) 
10 min 95°C followed by 40 cycles of 15 sec 95°C and 1 min 60°C in 20 µl reaction. 
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3.2.1.5.4   SYBRgreen primers  
Table 3.5   Primers  
Target gene Primers sequence  (5’ → 3’) 
SP1 FW CAGTAGCAGCAGCACTGGAG 
RV TTGCTGTTCTCATTGGGTGA 
IRF1 FW ACCCTGGCTAGAGATGCAGA 
RV CTTCCATGGGATCTGGAAGA 
P65(RELA) FW CCACGAGCTTGTAGGAAAGG 
RV GTCCCGCTTCTTCACACACT 
WISP1 FW CTTCTCCCTTGTCCTGCTTG 
RV TGGGTCTCTCAAGGCTCTGT 
FW GCGATGTGGACATCCATACA 
RV GGTTGATAGGAGCGTGTGCT 
CALCRL FW CAAAGAATTTCCTTAAGAGCTGGA 
RV AGACGATATGCACAATTGTCTCC 
RARRES3 FW TGTGAGCAGGAACTGTGAGC 
RV GCCACACCAACTTCAACCTT 
CDC27 FW CTTACCGAGATGCGGTTTTC 
RV TGAGCGGTAATAACAGGTTGC 
VIPR1 FW GAGGTGCAGCACAAGCAGT 
RV GGTGAGGTTGTCCCACATCT 
ING4 FW TCAGCTCATGAGGGACCTAGA 
RV GCTGCGGGCACTACTCATA 
IL32 FW TTCAAAGAGGGCTACCTGGA 
RV GGCACCGTAATCCATCTCTTT 
SNED1 FW GCACAAGCCTCAAGAAGACC 
RV AACTCGTGAGGTTGGTGGAG 
COLA5A1 FW TCTCCCGTCTTCCTCTACGA 
RV TGGACGCTGAGAGCAATTC 
EMCN FW CATTCTTTTTCTTCTGCCCAGT 
RV AATGATTCTGTGTTTGGTGTTGTT 
3.2.2   Gel electrophoresis 
DNA agarose gel electrophoresis: 
Plasmid DNA and PCR products were separated on 1.0% agarose gels using a horizontal 
gel chamber in 1 x TBE electrophoresis buffer. After electrophoresis, the gels were stained in 
a 0.02% ethidium bromide solution for 10 min. Gels were photographed under UV light using 
a Polaroid camera. 
 
RNA agarose gel electrophoresis: 
Isolated total RNA was separated in 1.0 - 2% agarose gels containing ethidium bromide run 
in horizontal gel chambers in 1x MOPS electrophoresis buffer. Each sample was diluted with 
RNA - Loading dye (6x). Following electrophoresis, gels were photographed under UV light 
using a Polaroid camera. 
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Sample loading: 
For gel experiments17-18 µl of premix loading buffer + 1.5 µg RNA = Final samples volume 
20-25 µl. 
Preparation of 10x MOPS Buffer: 1 L  
Reagents    Quantity required  Effective concentration 
MOPS     41.86 g    200 mM 
Na-Acetat    6.8 g     50 mM 
EDTA(0.5 M, pH 8)   20 ml     10 mM 
For this buffer, dissolve MOPS; Na-Acetate in 800 ml autoclaved H2O and add 20 ml of 0.5 M 
EDTA (pH 8). Adjust pH 7 using concentrated NaOH 
RNA loading buffer, premix (1 ml): 
Formamid    500 µl 
10x MOPS    100 µl 
Ethidium bromide   5 µl 
Bromophenol blue   10 µl 
H2O     385 µl 
3.2.3   Plasmids 
3.2.3.1   Luciferase reporter constructs 
The pGL3 Luciferase reporter vector (Promega USA) was used throughout this study for 
transient promoter-reporter assays. The pGL3 – Basic vector does not contain eukaryotic 
promoters or enhancer elements, while the pGL3-SV40 promoter vector contains a minimal 
SV40 –promoter. The pGL3-SV40 vector is used to study enhancer-like activity of cloned 
sequences. 
3.2.3.2   The construct pGL3/-976 CCL5 promoter  
A Xho1/Kpn1 – 1,1 kb genomic DNA fragment containing the CCL5 promoter sequence 
reaching from –976 to +58 (relatively to the transcription start site +1) was cloned into the 
pBluescript II SK vector (Stratagene). This fragment of CCL5 promoter was cut by MssHII 
and subcloned at a Mlu1 restriction site in the pGL2 –Basic vector (Promega). The promoter 
sequence was eventually sub-cloned over Sma1 and Xho1 restriction sites in the pGL3- 
Basic vector. The CCL5 promoter sequence and pGL3/-976 CCL5 promoter construct are 
shown in Figure 3.1, 3.2 and 3.3. 
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Figure 3.1  DNA sequence and consensus transcription factors binding elements of the 
immediate upstream CCL5 promoter region (-976). (TSS indicates transcription start site, 
blue DNA sequences indicate 5´- untranslated region of the CCL5 gene). 
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Figure 3.2   Luciferase-reporter-vector of the pGL3 – Basic. The plasmid pGL3-Basic is shown. It 
contains neither eukaryotic promoter nor enhancer elements. (The plasmid card was taken from the 
Promega catalogue) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3   Plasmid card of the construct pGL3/-976/CCL5. This plasmid contains human CCL5 
promoter sequence (+ 58 to - 976) and is based on the vector pGL3-Basic. 
3.2.3.3 Generation of 5-3 pGL3/-976 CCL5 promoter deletions and site-directed 
mutants 
5´- 3´ CCL5 promoter deletions: 
Promoter sequence specific primers with unique cloning sites added at the 5’ end, were used 
in PCR to amplify sequences from CCL5 promoter region to generate a family of promoter 
deletions. Amplified PCR products were subsequently cloned into the pGL3-Basic vector [41, 
46, 148]. 
 
5´- 3´ CCL5 promoter deletions          Reference 
pGL3/-434 CCL5 promoter     (Nelson PJ et al 1993) 
pGL3/-280 CCL5 promoter     (Nelson PJ et al 1993) 
pGL3/-228 CCL5 promoter     (Miyamoto et al  2000) 
pGL3/-194 CCL5 promoter     (Miyamoto et al  2000)  
pGL3/-146 CCL5 promoter     (Miyamoto et al  2000) 
pGL3/-120 CCL5 promoter     (Miyamoto et al  2000) 
pGL3/-104 CCL5 promoter     (Kumar et al. 2009) 
pGL3/-92 CCL5 promoter     (Kumar et al. 2009) 
pGL3/-83 CCL5 promoter     (Kumar et al. 2009) 
 34 
  Materials and Methods 
 
5´- 3´ CCL5 promoter deletions (-104, -92 and - 83) were generated using PCR. Forward 
primers spanning sequences downstream of the -104, -92 and -83 CCL5 promoter sequence 
were synthesized with a bgl II restriction site at the 5´ end and used in PCR amplification of 
the CCL5 promoter, from the pGL3/-194 CCL5 promoter construct. A GL2 primer (which 
binds to the pGL3 vector) was used as a reverse primer in the PCR amplification. After PCR 
amplification, the CCL5 promoter sequence contained an additional bglII site just after the 5´ 
UTR as shown below: 
 
 
 
 
 
 
-104 -92 -83
GL2 primer
-194 
Bgl II 
Bgl IIBgl IIBgl II 
5´UTR
pGL3-Basic
 
The PCR amplification products were purified and digested with bgl II and cloned in the new 
pGL3-Basic vector at bglII restriction site and DNA sequenced to verify the sequence. 
 
Primers used in the 5´ to 3´ deletion and UTR deletion: 
-104 deletion 
Fw_Primer GAA GAT CTT ATG ATA CCG GCC AAT GCT TG 
-92 deletion  
Fw_Primer  GAA GAT CTC GGC CAA TGC TTG GTT GC 
-83 deletion  
Fw_Primer  GAA GAT CTT GGT TGC TAT TTT GGA AAC TCC 
GL2 primer was used as a reverse primer which was common for all forward primers. The 5´- 
3´ CCL5 promoter deletion constructs are provided in the diagram below. 
                     
Figure 3.4 CCL5 promoter deletion constructs 
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UTR deletion in –194: 
The 5´ UTR of the CCL5 gene/promoter was deleted by the inverse PCR method. 
Forward primer: 
CAA TTC GCC CTA TAG TGA GTC GTA TTA CGC GCG 
Reverse primer: 
TCA GGC TGG CCC TTT ATA GGG CCA GTT GAG GGG CA 
3.2.3.4  Site-directed mutagenesis in the pGL3/-976 CCL5 promoter or pGL3/-194 CCL5 
promoter 
The Quick-Change Site directed mutagenesis kit (Stratagene, La Jolla, CA) was used to 
mutate specific transcription binding sites in the CCL5 promoter. The experimental procedure 
was followed as described in the manufacture’s manual. 
 
Specific mutation in -976 CCL5 promoter   Source 
IRF (-137 to -111) mutation     (Miyamoto et al 2000)  
AP1/CREB/Ets (-203 to -184) mutation   (Miyamoto et al 2000) 
NF-kB (-70 to - 58) mutation     (Kumar et al, 2009) 
SP1/KLF (-70 to -58) mutation    (Kumar et al, 2009) 
NF-kB (-56 to - 42) mutation     (Kumar et al, 2009) 
Specific mutations in -194 CCL5 promoter   Source 
NF-kB (-70 to - 58) mutation     (Kumar et al, 2009) 
SP1/KLF (-70 to -58) mutation    (Kumar et al, 2009) 
NF-kB (-56 to - 42) mutation     (Kumar et al, 2009) 
Primers used in site directed mutagenesis: 
Primers: all primer sequences are in 5´ to 3´ direction 
p65 mutation in region -70 to - 58 
FW GGT TGC TAT TTT GGC CAC TCC CCT TAG GGG 
RV CCC CTA AGG GGA GTG GCC AAA ATA GCA ACC 
(Final mutagenesis primer) 
FW   GCT ATT TTG GCC ACT CCT CTT AGG GGA TGC CCC TC 
RV GAG GGG CAT CCC CTA AGA GGA GTG GCC AAA ATA GC 
Sp1 mutation in region -70 to - 58 
FW GCT ATT TTG GAA ACT CTC CTT AGG GGA TGC CCC 
RV GGG GCA TCC CCT AAG GAG AGT TTC CAA AAT AGC 
p65 and sp1mutation in region -70 to - 58  
FW GGT TGC TAT TTT GGA CAC TCC CCT TAG GGG 
RV CCC CTA AGG GGA GTG TCC AAA ATA GCA ACC 
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FW GCT ATT TTG GAC ACT CTC CTT AGG GGA TGC CCC 
RV  GGG GCA TCC CCT AAG GAG AGT GTC CAA AAT AGC 
NF-kB mutagenesis in region -56 to - 42 
FW GGA AAC TCC CCT TAC TCG ATG CCC CTC AAC  
RV GTT GAG GGG CAT CGA GTA AGG GGA GTT TCC  
3.2.3.5   Constructs of CCL5 promoter region (-75 to - 42) in a heterologous promoter 
(pGL3-SV40) 
Dimers of the -70 to - 42 sequence taken from the CCL5 promoter were costom synthesized, 
and cloned into the pGL3- SV40 minimal promoter vector. Two additional constructs derived 
from the wild type -70 to - 42 sequence in which either region -70 to - 58 or -56 to -42 were 
mutated in the context of dimer  were generated as detailed in the diagram shown below: 
                     
Figure 3.5   Constructs of CCL5 promoter region (-75 to - 42) cloned into the heterologous 
promoter vector pGL3 – SV40  
3.2.4   Transient cell transfection 
3.2.4.1   YT cell transfection 
YT cells were transiently transfected by electroporation or using Superfect reagent (Qiagen, 
Hilden). The details of transfection procedures are as follows: 
 
Superfect as a transfection agent: 
   37
0.5x106 YT cells were seeded in each well of 48 well plates in 500µl of complete growth 
medium. Then 3 µg of plasmid DNA of interest, and 50 ng of pTk-Renilla plasmid were 
diluted in 200 µl of opt-MEM followed by the addition of 12 µl of Superfect (1:4). After 
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addition of Superfect, plasmid DNA and Superfect reagent were mixed by gentle pipeting and 
incubated at room temperature for 10 min. The transfection complex was then applied 
directly to the cell suspension drop wise with constant swirling and the cells were incubated 
with transfection complex in a 37o CO2 incubator. After 1.5 h, the  growth medium was 
discarded,  the cells were washed once with 1 x PBS, and subsequently cultured in fresh 
growth medium until the reporter gene assay was performed. 
 
Electroporation of YT cells: 
Electroporation was also used to transfect YT cells. The general method was taken from a 
previously published protocol [149] with the following modifications. 5x106 YT 
cells/electroporation were resuspended in 400 µl electroporation buffer in an Eppendorf tube, 
20 µg of test plasmid DNA was mixed with the cells along with 400 ng pRL-TK control 
plasmid. The cells were kept on ice for 10 min followed by electric pulse.  
The conditions used for electroporation are given below: 
Volt 200 
Capacitance 960 µf 
Total volume  400 µl 
 
After electroporation the cells were transferred into 2 ml of complete medium and placed in 
culture for 24 h. 
 
Electroporation buffer: 
Hepes   20 mM 
KCl   5 mM 
NaCl   137 mM 
Na2HPO4  0.7 mM 
Dextrose  6 mM 
Trehalose  50 mM 
1.25% DMSO   
3.2.4.2   Human immortalized mesangial cell (HIMC) transfection 
0.1x106 HIMC were seeded in each well of 24 well plates in complete medium one day in 
advance of the experiment. After 24 h, the medium was replaced with serum free medium 
and the cells were cultured for 24 h. Old medium was then replaced by 0.5 ml of fresh serum 
free medium and the plate was kept in the incubator until transfection. 
For each well of a six well plate, 0.75 µg of the plasmid DNA of interest, and 20 ng of pRL-TK 
diluted in opt-MEM were added with 3 µl of Superfect and mixed by pipetting. The samples 
were incubated for 10 min at room temperature. After 10 min the transfection complex was 
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directly added to the cells drop-wise with constant swirling to ensure homogeneous 
distribution of transfection complex. The cells were then incubated for 3 h, after which  the  
transfection complex was replaced with fresh serum free medium followed and the cells were 
stimulated. 
3.2.4.3   siRNA transfection in HIMC 
siRNA transfection experiments were performed using SiPort (Ambion) according to the 
technical manual provided by the company with the following modifications. For the 
mesangial cell experiment, 80% confluent HIMC were detached and resuspended in 
complete medium (Cell dilution 0.25x106/ml). Four µl of 20µM siRNA were diluted into 200 µl 
of opt-MEM. Seven µl of SiPORT was added to the diluted siRNA, mixed well and incubated 
for 10 min at room temperature. After 10 min, transfection complex was added to the bottom 
of 6 well plates. Then 2.3 ml of cell suspension (0.25x106 cells/ml) were directly applied on 
the transfection complex with continuous swirling to maintain the homogeneous mixing of 
transfection complex and cell suspension. After 24 h of incubation, the transfected cells were 
detached and resuspended in 2.3 ml of serum free medium, and re-transfected as detailed 
above - but with 50% reduced siRNA and SiPort. After 8 h of re-transfection, the medium 
was replaced by fresh serum free medium, followed by 24 h culture. The cells were ready for 
stimulation. For the second round of transfection, 2 µl of 20 µM siRNA and 3.5 µl SiPort was 
used. 
All siRNA transfections were performed in 6 well plates, and during the second transfection, 
the cells was divided into multiple wells of 12 well plates, 24 well plates or 48 well plates 
according to the experimental requirements. The cells from a single well of six well plates 
were divided into two wells of 12 well plates, four wells of 24 well plates, or four wells of 48 
well plates. 
3.2.5   Chromatin immunoprecipitation (ChiP) assay 
YT cells (1x107 cells) were crosslinked by adding 1% formaldehyde directly to the tissue 
culture media for 10 min at room temperature. The crosslinking reaction was stopped by 
adding glycine to a final concentration of 0.125 M (1 ml of 1.25 M stock in 10 ml medium). 
The cells were then lysed in 1 ml cell lysis buffer and incubated at 4°C for 10 min. After 10 
min, the lysed cells were centrifuged at 3000 rpm for 10 min and the supernatant discarded. 
The nuclei pellet was lysed in 200 µl of nuclei lysis buffer/20x106 cells. Chromatin was 
subsequently sonicated to an average length of 600 bp using empirically defined conditions. 
The chromatin was precleared by adding 50 µl of BSA/herring sperm DNA blocked Staph A 
cells. The supernatant was transferred to a fresh tube, diluted 5-fold in ChIP dilution buffer 
and divided by 10x106 cells/tube. Five µl SP1 antibody or isotype control antibody was added 
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to the samples and rotated overnight at 4°C. Immune precipitated antibody/protein/DNA 
complex was then washed consecutively for 3-5 min on a rotating platform with 1 ml of each 
solution: 2x low salt wash buffer, 2x high salt wash buffer and 1x LiCl wash buffer and eluted 
using elution buffer. Reverse crosslinking and RNA digestion was performed by adding NaCl 
to a final concentration of 0.3 M and 1 µl of concentrated RNAse A (10 mg/ml) with 
incubation at 65°C for 4-5 h. Purified DNA was then treated with protenase K at 42°C for 1 h. 
DNA was extracted with phenol/chloroform and precipitated with ethanol/carrier tRNA/NaCl. 
DNA was eluted in sterile H2O and PCR performed as described. PCR primers flanking the 
proximal CCL5 promoter and the TATA box from bp -209 to -100 (-209 primer, 
 5-CACCATTGGTGCTTGGTCAAAGAGG-3, -100 primer, 5-
GCAGTAGCAATGAGGATGACAGCGA-3) were used. As a negative control, primers 
corresponding to a genomic region distal to the CCL5 promoter from -3789 to -3459 were 
used (primer, -3789, 5-GCAGATTACGAGGTCAGGAG-3, primer, -3459, 5-TTATG 
CTTTTCAACAGTCT-3). 
 
Table 3.6   Buffers for Chip assay 
Cell lysis buffer Nuclei lysis buffer ChIP dilution buffer 
20 mM TrisHCl,  
85 mM KCl pH 8.0,  
0.5% NP40  
and protease inhibitors  
 
50 mM Tris-Cl pH 8.0,  
10 mM EDTA,  
1% SDS and  
protease inhibitors  
 
0.01% SDS,  
1.1% Trition X 100,  
1.1 mM EDTA,  
20 mM Tris-Cl pH 8.0,  
167 mM NaCl) 
Low salt wash buffer High salt wash buffer LiCl wash buffer 
0.1% SDS,  
1% Trition X 100,  
2 mM EDTA,  
150 mM NaCl),  
 
0.1% SDS,  
1% Trition X 100,  
2 mM EDTA,  
500 mM NaCl  
0.25 M/0.5M LiCl,  
1% NP40,  
1% deoxycholate  
Elution buffer 50 mM NaHCO3, 1% 
SDS 
3.2.6   Analysis of protein expression 
3.2.6.1   Intracellular CCL5, perforin and granzyme B staining by flow cytometry  
Primary NK cells (1x106) were fixed with 1% PFA and permeabilized with 0.1% saponin, 
washed with 0.35% saponin and stained for 30 min with primary antibody; mouse-IgG2b-α-
human CCL5 hybridoma VL1 supernatant (diluted 1:2 in 0.35% saponin/PBS/2% HS, mouse-
α-human perforin (1:100), mouse-IgG1-α-human granzyme B-PE (1:10) or the corresponding 
isotype controls. After staining, the cells were washed and unlabeled primary antibody VL1 or 
perforin were detected with the secondary reagent goat-α-mouse IgG2b Alexa 488 (1:500; 
Invitrogen) for another 30 min followed by a final wash step. Data acquisition was performed 
with the BD LSRII cytometer (BD Biosciences). Analysis was done with FlowJo Flow 
 40 
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Cytometry Analysis Software (Tree Star, Inc., Ashland, USA). Δ Median fluorescence 
intensity (ΔMFI) was calculated by subtracting the median fluorescence intensity of the 
isotype control antibody from the median fluorescence intensity of the specific antibody 
staining. 
3.2.6.2   Immunohistochemical detection of DDX58 (Rig-I) and IL32 in patient samples. 
These assays were performed in collaboration with Prof. Hermann-Josef Gröne, DKFZ, 
Heidelberg who also provided the relevant biopsy samples. 
3.2.6.2.1   General histology 
Human renal biopsy specimens were processed for histology, immunohistology, and 
molecular analysis. For histology the specimens were cut into 1-mm slices and either 
immersion-fixed in 4% formaldehyde in phosphate-buffered saline (PBS) for 24 hours at 4°C, 
or fixed in Methacarn (60% methanol, 30% chloroform, 10% acetic acid) for 8 hours and then 
embedded in paraffin. In addition, tissue slices were frozen in liquid nitrogen and stored at –
80°C, until used for immunohistology.  
Light microscopy evaluation was performed on 3 µm sections stained by periodic acid-Schiff 
(PAS). Kidneys were assessed for acute and chronic vascular, glomerular, as well as 
tubulointerstitial damage, as described [64, 150] and as detailed below. 
3.2.6.2.2   Immunohistochemistry  
Immunohistochemistry (IHC) was used to localize proteins in a tissue section using an 
antigen-specific antibody. Visualizing of antibody-antigen interaction was accomplished in a 
number of ways as described below. Generally, an antibody is conjugated to an enzyme, 
such as peroxidase, that can catalyze a color-producing reaction, ending with the local 
precipitation of a water-insoluble stain. Immunohistochemistry was performed on paraffin 
embedded formaldehyde-fixed tissue sections prepared as described in [64, 150] and as 
detailed below. 
3.2.6.2.3   Sample preparation 
To remove the paraffin from tissue, two washing steps in xylol were performed, with 10 min 
washing for each step,. Rehydration of the sections was achieved by incubation three times 
for 5 min in EtOH 100%, twice in EtOH 96%, once in EtOH 80% and once in EtOH 70%. To 
remove residual EtOH, one H20 washing step followed. For unmasking of the antigen, 
sections were incubated in 0.01 M sodium citrate solution pH 6 or Tris buffer pH 9, in a 
steamer for 20 min approximately 70°C, or in a microwave for 1 h at 98°C. Exact conditions 
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for each antibody are reported below. The sections were then cooled to room temperature 
and washed once in H20. Depending on the antibody, an alternative unmasking step had to 
be performed. In the first step, the sections were digested with protease XXIV (Sigma P8038) 
solution for 10 min. Reaction was stopped by two washing steps in EtOH 100%.  
After antigen retrieval, sections were allowed to air dry and encircled with a liquid blocker pen 
to ensure that the small amounts of antibody solutions would remain on the tissue and not 
blend across the cover slide.  
3.2.6.2.4   Detection of the antigen 
Sections were rehydrated by two PBS/Tween washing steps. After rehydration, several 
blocking steps followed. All incubations were performed in a humid chamber, consisting of a 
metal box covered with wet pulp and a cover that ensured high humidity within the box and 
prevented the tissue from dehydrating during incubation periods. To prevent background 
reaction, it was necessary to block the endogenous peroxidase of the tissue. For this 
purpose, the sections were incubated in PBS containing 3% of hydrogen peroxide for 10 min. 
The sections were then washed twice with fresh PBS/Tween and blocked again with PBS 
containing 2% of blocking serum from the VECTASTAIN® Universal Quick kit for 10 min, 
followed again by two PBS/Tween washing steps. Before the antibody could be added 
endogenous biotin had to be blocked using the Avidin/Biotin Blocking Kit.  
The general protocol for the antibody staining consisted of an incubation of the section with a 
primary antibody, followed by washing steps. Then, the secondary biotinylated antibody was 
incubated. All antibodies were prepared in antibody diluent (Dako).  
Concentrations of antibody are summarized below: 
 
Primary Antibody Retrieval Buffer  Dilution 
DDX58 (RIG-I) Steamer Citrate 1/20 (50 ng/ml) 
IL 32 Steamer Citrate 1/20 (50 ng/ml) 
 
All primary antibodies were incubated at room temperature for 2 h. Incubation was followed 
by two PBS/Tween washing steps before the second biotinylated antibody (1:150), directed 
against the species of the primary antibody, was added for 30 min at room temperature. 
When the Avidin-Biotin-Complex method (AB Complex) was employed. Horse radish 
peroxidase (HRP) is complexed with streptavidin and conjugated to the biotinylated antibody. 
Sections were incubated for 60 min at room temperature in the ABC-HRP solution. After 
incubation, the slides were washed twice with PBS/Tween and once with H20. Then the slide 
was incubated using the AEC substrate kit for an initial 3 min and the staining was controlled 
using light microscopy (Laborlux D, Leitz, Wetzlar). If necessary, the staining reaction could 
be prolonged for up to 10 min in total. The AEC substrate was oxidized to a red stain. 
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Before the counterstaining of the nuclei with Mayers Haemalaun, the slides were washed 
once with H2O. Slides were dipped for several seconds in Mayers Haemalaun and then 
incubated in tap water for about 10 min, resulting in a blue staining of the nuclei. A drop of 
mounting medium and a cover slide were added to protect the section. Slides were stored at 
room temperature.  
3.2.6.3   Immune fluorescence staining and confocal laser microscopy 
Freshly isolated NK cells (5x105) were allowed to settle on poly-L-lysine-coated slides for 20 
min prior to fixation in 100% acetone on ice. Non-specific binding sites were saturated with 
2% BSA in PBS. Cells were stained with the primary antibodies against mouse-IgG2b-α-
human CCL5 hybridoma VL2 supernatant (diluted 1:2 in PBS/10% human serum), mouse 
IgG1-α-human granzyme B (1:100) and rabbit-α-human CD8 (1:50) (to exclude T cells) for 1 
h. Primary antibody binding was revealed with goat- α-mouse-IgG2b AlexaFluor 488 (1:500), 
goat-α-mouse-IgG1 AlexaFluor 568 (1:500) and goat-α-rabbit Cy5 (1:100). Cells were 
washed, fixed with 4% PFA, counterstained with DAPI (15µg/100ml, Sigma Aldrich) and 
mounted using Vectashield mounting medium (Vector Laboratories, Inc. Burlingame, CA). 
Fluorescence images were captured with a Leica TCS SP2 confocal system, equipped with 
lasers exciting at 488 nm and 543 nm (Ar/Kr), 633 nm (HeNe) and 405 nm (diode laser) on a 
Leica DM IRBE microscope stand with HCX PL APO 63x1.40 NA oil immersion objective 
lens (Leica Microsystems, Heidelberg, Germany). Cells were examined with pinhole 1.0 Airy 
units, 1024x1024 pixel image format, six frame averaging and a TD488/568/633 dichroic 
beam splitter. To avoid possible cross-talk of the various fluorochromes, the width of the 
detection channels and filter settings were carefully controlled and furthermore, images for 
A488, A568, Cy5 and DAPI were acquired using the sequential image recording method. For 
evaluation of co-localization single z-planes were analyzed with Leica confocal software 
LCSLite (Leica Microsystems, Heidelberg, Germany). For image presentation, size and 
contrast were adjusted with Adobe Photoshop CS software (Adobe Software, Palo Alto, 
USA). These experiments were performed in collaboration with PD Dr. Elfreide Noessner, 
HelmholtzZentrum, Munich. 
3.2.6.4   Enzyme-linked immunosorbent assay (ELISA) 
Measurement of CCL5 protein was performed using Duo Set ELISA Development System 
(R&D). This assay uses the quantitative sandwich immunoassay technique. Briefly, 96 well-
plate were incubated overnight with capture antibody at room temperature (RT) washed with 
wash buffer and blocked with blocking buffer for a minimum of 1 h at room temperature. 100 
µl of samples or the standard were incubated for 2 h at RT and then washed and incubated 
with detection antibody for other 2 h. 
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Streptavidin conjugated with horseradish-peroxidase was use to detect the secondary 
antibody by incubation 20 min in dark followed of washing and incubation with Substrate 
Solution other 20 min also in dark. By comparing the OD of the samples to the standard 
curve, the concentration of CCL5 in cultured supernatant was analyzed (Concentration of the 
antibodies can be found in manufacturer’s instructions). The minimum detectable 
concentration of CCL5 was 32.5 pg/ml. 
 
Table 3.7   Buffer used in CCL5 ELISA 
10X PBS (1 litre) Blocking buffer 
NaCl    80g 
Na2HPO4  11.5g 
KCl   2g 
KH2PO4  2g 
1% BSA 
0.05% NaN3 
in 1x PBS 
 
Washing buffer Reagent diluent 
1x PBS with 0.05% Tween 20 Ix PBS with 1% BSA 
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3.2.6.5   Western blotting (Immunoblotting) 
Western blotting was used to determine the level of specific protein in whole 
cell/cytosolic/nuclear extracts. The general protocol used for Western blotting is detailed 
below. 
 
 Preparation of cell lysates:  
• The cells were collected, washed and pelleted.  
• The pellet was lysed with RIPA lysis buffer on ice or at 4°C for 30 min with 
rotation (For 500,000 cells, lyse with 20 µl). 
• The lysate was centrifuged at 14,000 rpm (16,000 g) in an Eppendorf microfuge 
for 10 min at 4°C.  
• The supernatant was transfered to a new tube and the pellet discarded  
• The protein concentration was determined (Bradford assay, A280, or BCA)  
and the protein extract was mixed with 2x sample buffer.  
• The samples were heated for 5 min at 95°C followed by cooling to 4°C.  
• The samples were flash centrifuged to bring down condensation prior to loading 
on the gel. 
Table 3.8   Polyacrylamide gel preparation (1.5 mm thick and 14.5 cm x 16.5 cm total 
area) 
Preparation of resolving gel (20 ml): 
Gel % 6% 8% 10% 12% 15% 
H2O 10.6 ml 9.3 ml 7.9 ml 6.6 ml 4.6 ml 
30% Acrylamide 4 ml 5.3 ml 6.7 ml 8 ml 10 ml 
Tris-HCl (1.5 M, PH 8.8) 5 ml 5 ml 5 ml 5 ml 5 ml 
10% SDS 200 µl 200 µl 200 µl 200 µl 200 µl 
10% APS 200 µl 200 µl 200 µl 200 µl 200 µl 
 
 
30% 
Acrylamide 
TEMED 20 µl 20 µl 20 µl 20 µl 20 µl 
Preparation of stacking gel (5%): 
Volume 1 ml 3 ml 5 ml 8 ml 10 ml 
H2O 6.8 ml 2.1 ml 3.4 ml 5.5 ml 6.8 ml 
30% Acrylamide 0.17 ml 0.5 ml 0.83 ml 1.3 ml 1.7 ml 
Tris-HCl (1 M, PH 6.8) 0.13 ml 0.38 ml 0.63 ml 1 ml 1.25 ml
10% SDS 10 µl 30 µl 50 µl 80 µl 100 µl 
10% APS 10 µl 30 µl 50 µl 80 µl 100 µl 
 
 
30% 
Acrylamide 
TEMED 1 µl 3 µl 5 µl 8 µl 10 µl 
 
Running the gel: 
• After flash centrifugation, the samples were loaded into wells with 5 µl of 
molecular size marker loaded on the last lane of the gel.  
•  The gel was run with constant current (80 V for stacking and 120 V for resolving).  
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• Usual running time was approximately 1.5 h.  
 
Preparation of membrane: 
• A piece of PVDF membrane (Millipore Immobion-P #IPVH 000 10) was cut to the 
size of the gel.  
• The membrane was pre-wet for approximately 2-5 min in methanol on a rocker 
platform at room temperature.  
• The methanol was removed, and 1x Blotting buffer added until ready for use.  
 
Proteins transfer/blocking: 
• The Semi-dry method for protein transfer was used as described in the manual 
(Bio-Rad Semi Dry gel transfer apparatus)  
• The protein was transfered to the membrane at 22 Volts for 45 min. 
• When finished, the membrane was immersed in blocking buffer and blocked for 
one hour or overnight depending on the specific antibody used.  
 
Antibodies and detection: 
• The membrane was incubated with the primary antibody diluted in blocking buffer 
for 60 min at room temperature or overnight depending on the antibody used.  
• The membrane was then washed 1 x 10 min with 0.05% Tween 20 in TBS.  
• The membrane was then incubated with the secondary antibody diluted in 
blocking buffer for 45 min at room temperature.  
• The membrane was then washed 3x 10 min with 0.05% Tween 20 in TBS.  
• The presence of the antibody complex was then detected using the Amersham 
ECL Kit (RPN 2106) as per the company’s instructions.  
 
Stripping and re-probing: 
• The blot was rinsed with 0.05% Tween 20 in TBS.  
• The blot was placed into a Kapak bag cut to a slightly bigger size than the blot.  
• Between 25 to 50 ml of Stripping buffer was added, the air was removed from the 
bag, and the bag was sealed.  
• The bag was immersed in a 50°C water bath and incubated for 45 min.  
• The blot was then rinsed with 0.05% Tween 20 in TBS.  
• The blot was then blocked for approximately 1 h with 5% BSA/milk or 3% milk in 
TBST 
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Table 3.9   Buffers used for Western blotting 
 
1x Modified RIPA buffer: 100 ml 
790 mg Tris base (50 mM) dissolved in 75 ml sterile H2O and pH adjusted to 7.4  
10 ml of 10 % NP-40 (1%) 
2.5 ml of 10% Na-deoxycholate (0.25%)  
900 mg NaCl  (150 mM ) 
1 ml of 100 mM EDTA  (1 mM) 
Add protease and phosphotase inhibitors just before use. Store at 4ºC 
10x Running buffer: 1 L  10x Blotting buffer: 1 L 
30.3 g Trizma base (0.25 M)  
144.2 g Glycine (1.92 M)  
10 g SDS (1%)--add last  
Do not adjust the pH 
1x TBST: 1 L 
100 ml 10x TBS + 900 ml of sterile H2O 
Then add 0.05-0.1% Tween 20.
30.3 g Trizma base (0.25 M)  
144.2 g Glycine (1.92 M)  
3.5.0 g SDS (0.035%) 
pH should be 8.3; do not adjust  
To make 2 L of 1x Blotting buffer:  
400 ml Methanol 
200 ml 10x Blotting buffer and 
1400 ml water  
10x TBS: 1 L 
80.06 g NaCl (1.37 mM) 
24.23 g Trizma-base (200 mM) 
Dissolve in 800 ml of sterile H2O and adjust 
pH to 7.6 with concentrated HCl. Top up to 1 L 
1x Blocking buffer: 
3-5% BSA (Fraction V) or 3-5% fat free 
milk 
Make up in TBST and sterile filter.  
Keep at 4°C to prevent bacterial 
contamination. 
1x Stripping buffer: 100 ml 
10 ml - 20% SDS 
6.25 ml 1M TRIS-HCl (pH 6.8) 
83 ml - sterile H2O and 0.8 ml of 100% β-
mercaptoethanolin (in fume hood) and sterile 
filter the solution - keep at 4°C. Before use, 
warm buffer to 50°C 
2x Sample buffer: 
Tris-Cl, pH8.0  130 mM  
Glycerol   20%(v/v)  
SDS   4.6% (w/v)   
Bromophenol blue 0.02%   
DTT   2%  
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3.2.7   Electrophoretic mobility shift assay (EMSA) 
The electrophoretic mobility shift assay (EMSA) was used to examine the interaction 
between specific DNA sequence and nuclear-DNA binding proteins. The method 
demonstrates which proteins can interact with the specific DNA sequence in vitro. 
 
EMSA was performed in the following steps: 
• Annealing of complementary oligonucleotides 
• Labelling of annealed oligonucleotides 
• Isolation of nuclear proteins 
• DNA – nuclear proteins binding reaction 
• Native-gel preparation and gel running 
• Drying of the gel 
• Exposure of the gel and scanning 
3.2.7.1   Preparation of probes 
Oligomers with complementary sequences were reconstituted in H2O at a concentration of 
100 pmol/µl. The hybridization of single strands into double strands (annealing) took place in 
a salt-concentration of 0.4 M NaCl 
 
Annealing reaction: 
6 µl oligomers 1 (100 pmol/µl) 
6 µl oligomers 2 (100 pmol/µl) 
1.6 µl 5 M NaCl 
6.4 µl H2O 
Total volume  20 µl 
 
The reaction was incubated for 10 min at 95oC. Then the temperature was gradually reduced 
over several hours to a final temperature of 40oC to allow annealing of the complementary 
oligonucleotides 
 
Labelling of oligonucleotides: 
Only oligomers with blunt ends after hybridization were used for EMSA analysis. They were 
labelled by the transfer of radioactive phosphate group by the polynucleotide kinase of the 
phage T4 (T4-PNK) 
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Labelling reaction: 
2 µl double stranded oligomer (3 pmol/µl) 
3 µl 10X PNK buffer  
4 µl of γ32P-ATP (6000 Ci/mmol) 
2 µl T4-PNK (10 U/µl) 
19 µl H2O 
Total volume 30 µl 
The reaction was incubated at 37oC for 1 h. 
 
After 1 h, the labelled oligonucleotides were purified using the combination of Nuc Trap 
Probe Purification Column and Push Column Beta Shield Device (Stratagene, La Jolla) 
according to the procedure as described in the manufacture’s manual. 
3.2.7.2   Isolation of nuclear proteins 
Cells were washed with ice cold PBS, then buffer A supplemented with proteases and 
phosphatase inhibitors was added. The cells were scraped from the plate (for adherent 
cells), or directly resuspended (for cells grown in suspension), and then incubated at 15 min 
on ice. Homogenates were centrifuged at 2,000 rpm at 4°C for 15 min, and the resultant 
“nuclear pellets” were resuspended in buffer B. Buffer B is essentially buffer A except that it 
contains 500 mM NaCl. The nuclear proteins were then extracted by high salt in buffer B by 
incubation on ice with intermittent tapping for 1 h. Lysates were then centrifuged at 13,000 
rpm (4°C) for 15 min and the supernatants were aliquoted and snap-frozen at -80°C until 
used. 
Quantitation of nuclear proteins was performed using Bio-Rad protein quantitation kit 
(Bradford Assay) according to the procedure described in the manual. 
3.2.7.3   DNA – nuclear proteins binding reactions 
The DNA –Protein binding conditions for specific transcription factors varies and optimal 
condition were optimized for each shift. The optimized conditions identified for each of the 
transcription factors are given below: 
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Table 3.10   Optimized DNA binding conditions for specific transcription factors 
NF-kB/SP1 AP1/CREB IRF1 
5 mM HEPES (pH 7.9),  
5% glycerol, 
0.5 mM EDTA,  
1 µg dIdC,  
1 mM DTT,  
1.5 mM MgCl2,  
80 mM NaCl, 
5 µg Nuclear extract 
in 25 µl total 
20 mM HEPES (pH 7.9), 
5% glycerol, 
2 mM EDTA,  
5 mM Spermidin 
1 mM DTT, 
5 mM KCl,  
1 mM MgCl2, 
5 µg Nuclear extract 
in 25 µl total 
5 mM HEPES (pH 7.9),  
5% glycerol, 
0.5 mM EDTA,  
1 µg dIdC,  
1 mM DTT,  
1.5 mM MgCl2,  
80 mM NaCl, 
5 µg Nuclear extract 
in 25 µl total 
 
The DNA – Nuclear protein binding reactions were performed as follows: 
The specific binding reaction mix was prepared as described in the table above. To initiate 
binding, 1-2 µl probe was added to the binding reactions (radioactive labelled 
oligonucleotide). For probe competition experiments, 100-1000 fold additional unlabelled 
oligonucleotides were added 10-15 min prior to the addition of labelled oligonucleotides. For 
supershift/blocking experiments, 1-2 µg of corresponding antibody/antisera was added 10-15 
min prior to the addition of labelled oligonucleotides. The DNA – protein reaction mix was 
then incubated on ice for 45 min. 
The DNA – protein complexes were separated on a 5% non-denaturing gel run for 90 min at 
240 V using 0.5X TBE as running buffer. A protein II gel-apparatus (Bio-Rad) with 1.5 mm 
spacers and 20 wills was used throughout these experiments. After elecrophoresis, the gel 
was transferred  on to a Whatman 3 MM paper and dried on a vacuum gel dryer (Gel Dryer 
583, Bio-Rad) for 2 h at 80oC. Afterwards, the dried gel was either exposed on X-ray film 
(Kodak) or imaging plate over-night and either developed (film), or scanned using phospho-
image scanner (Molecular Dynamics). 
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Table 3.11   Buffers used in EMSA 
10x TBE 
Tris  108 g 
Boric acid 55 g 
EDTA (pH 8, 0.5M)  40 ml 
Add sterile H2O till 1 litre 
6X DNA-Loading Buffer 
Ficoll  15% 
Xylen cyanol 0.25% 
Bromophenol blue   0.25% 
Preparation of 5% non-Denaturing 
polyacrylamid Gels (60 ml) 
Acrylamid solution (40%) 10 ml 
10X TBE 3 ml 
H2O  47 ml 
APS (10%) 500 µl 
TEMED 50 µl 
Celly Lysis Buffer (Buffer A) 
20 mM  HEPES, pH 7.9, 20% Glycerol,  
10 mM  NaCl, 1.5 mM MgCl2,  
0.2 mM EDTA (pH 8), 1 mM DTT,  
0.1% Triton X-100 
Add protease inhibitors just prior to use  
Pefbloc 2 mM 
Aprotanin 5 mg/ml 
Antipain 5 mg/ml 
Pepstatin 2.5 mg/ml 
Leupeptin 0.5 mg/ml 
Chymostatin 0.1 mg/ml 
Nuclei Lysis Buffer (Buffer B) 
20 mM HEPES, pH 7.9, 20% Glycerol 
500 mM NaCl, 1.5 mM  MgCl2
0.2mM  EDTA (pH 8), 1mM DTT 
0.1% Triton X-100, 
Add protease inhibitors just prior to use 
Pefbloc 2 mM 
Aprotanin 5 mg/ml 
Antipain 5 mg/ml 
Pepstatin 2.5 mg/ml 
Leupeptin 0.5 mg/ml 
Chymostatin 0.1 mg/ml 
3.2.8   Bioinformatics tools and promoter modelling 
Potential control elements and consensus sites were analyzed using MatInspector 
Professional software (Genomatix, Munich, Germany). In promoter modelling studies, the 
CCL5 promoter sequence provided the strand orientation, relative order and approximate 
distances between binding sites. The ModelInspector (ModelInspector release 5.4.4) scoring 
algorithm combines measures of binding site matrix similarity with distance information into a 
model score used to scan databases. Models were generated using FastM with default 
matrix similarity thresholds that were slightly lower (AP1/CREB CS>0.750/MS>0.700, IRF-
A/B CS>0.850/MS>0.750, NF-kB CS>0.850/MS>0.750,  SP1 CS>0.850/MS:>0.750, NF-kB 
CS>0.750/MS>0.750 and TATA CS>0.850/ MS0.850) than the scores found within the CCL5 
promoter sequence (AP1 CS: 0.750/MS:0.761, CREB CS: 0.738/MS: 0.771, IRF-A 
CS:1.00/MS:0.914, IRF-B CS: 1.00/MS: 0.868, NF-kB CS: 1.00/MS: 0.972,  SP1 CS: 
1.00/MS: 0.956, NF-kB CS: 0.904/MS: 0.912 and TATA CS: 1.00/ MS: 0.952). Promoter 
modelling and database searches were carried out using the GEMS Launcher 4.6.0 software 
package, Genomatix Software GmbH, Munich (http://www.genomatix.de). The human 
section of the Genomatix promoter database (Promoters of annotated genes) was used for 
model searches. 
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3.2.8.1 Localization of relevant upregulated genes by hierarchical clustering of 
expressed genes 
The microarray data from all patients (IgA nephropathy and LD-living donor) for all probe sets 
above cut-off (13,282) were clustered using Euclidean distance as metric 
and single linkage for aggregating clusters and searched for the location of upregulated 
genes (only those genes defined by the Gene Ontology (GO) filter were searched in the 
cluster). 
3.2.8.2   Gene Ontology (GO) analysis  
A network of genes based on literature co-citations was built-up using BiblioSphere/DAVID 
software (Genomatix Software GmbH, Munich, Germany; david.abcc.ncifcrf.gov; Frederick; 
USA). Based on these networks, the distribution of differentially regulated genes were 
grouped according to functional and biologic categories. 
3.2.9   Statistical analysis 
Statistical analyses were performed using Graph Pad Prism 4.03. For expression values of 
qRT-PCR, ELISA and reporter gene assays data, a non-parametric analysis of variance 
(ANOVA/Tukey's Multiple Comparison Test) was performed to test for significant differences 
between the different samples. p-values less than 0.05 were considered to indicate 
statistically significant differences. Significant differences are denoted by an asterisk (*) 
denotes a statistically significant difference with a p value < 0.05, ** denotes a statistically 
significant difference with a p value < 0.01 and *** denotes a statistically significant difference 
with a p value < 0.0001. 
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4   Results 
4.1  CCL5 is constitutively expressed by peripheral blood NK cells 
Transcriptional regulation of CCL5 in NK cells was investigated in detail. CCL5, as well as 
the cytotoxins (perforin, the granzymes and granulysin) have been shown to be upregulated 
during the functional maturation of CD8 T cells that occurs three to seven days after their 
initial TCR activation by presented antigen [42, 69, 151]. By contrast, NK cells display 
effector function when directly isolated from the peripheral blood. In the first set of 
experiments the regulation of CCL5 in NK cells was compared and contrasted with the 
cytotoxins perforin and granzyme B to learn more about how CCL5 expression can be linked 
to the development of effector function in NK cells. 
To examine CCL5 protein expression intracellular flow cytometry (FACS) was performed to 
measure levels of CCL5, and at the same time, levels of perforin and granzyme B protein in 
freshly isolated primary NK cells (Figure 4.1 A and B). 
In parallel, confocal laser microscopy was used to determine the intracellular distribution of 
CCL5 and granzyme B (Figure 4.1 C). Freshly isolated primary NK cells were found to 
constitutively express CCL5, perforin and granzyme B proteins. CCL5 was found to be 
sequestered in secretory vesicles that differ from those containing granzyme B. Additionally, 
TaqMan RT-PCR was used to determine the levels of CCL5, perforin, and granzyme B 
mRNA in peripheral blood NK cells (Figure 4.1 D). A comparison of protein and transcript 
levels revealed an inverse relationship with higher protein than transcript levels for perforin 
and granzyme B. By contrast, relatively low protein but high transcript levels for CCL5 were 
seen suggesting that cytotoxins and CCL5 are regulated at different levels including 
translational control 
 
 
 
 
Results 
 
          
Figure 4.1   Constitutive expression of CCL5 and cytotoxins in freshly isolated NK cells. (A) 
Freshly isolated NK cells were stained for intracellular CCL5, perforin and granzyme B using flow 
cytometry. For data acquisition and analysis the BD LSRII cytometer and FlowJo software were used. 
Histograms show the fluorescence intensity of intracellular CCL5, perforin and granzyme B of 
unstimulated cells without inhibitor treatment. In all histograms, shaded lines represent the 
fluorescence intensity of isotype control antibodies (B) The bar diagram represents the Δ median 
fluorescence intensity (ΔMFI) which was calculated by subtracting the median fluorescence intensity of 
the isotype control antibody from the median fluorescence intensity of the specific antibody staining. 
(C) Multicolor immune fluorescence staining and confocal microscopy of freshly isolated NK cells. NK 
cells were fixed and permeabilized with ice cold acetone and stained with mouse IgG2b-α-human 
CCL5 VL1 hybridoma supernatant and mouse IgG1-α-human granzyme B followed by goat-α-mouse 
IgG2b-AlexaFluor 488 (depicted in green) and goat-α-mouse IgG1-Alexa 568 (depicted in red) as 
secondary reagents. The nucleus was stained with DAPI (depicted in grey). One confocal z-section is 
shown. White bar equals 2 µm. (D) Freshly isolated NK cells were lysed and total RNA was isolated, 
reverse transcribed and analyzed for the CCL5, perforin and granzyme B mRNA levels by qRT-PCR. 
For statistical analysis, the ANOVA/Tukey’s multiple comparison non-parametric test was applied to 
analyze the differences between the expression of individual genes. Significant differences are 
denoted by an asterisk. * denotes a statistically significant difference with a p value < 0.05, ** denote a 
statistically significant difference with a p value < 0.01, *** denote a statistically significant difference 
with a p value < 0.0001 and n.s represents no significant difference. (Error bars represent standard 
deviation) 
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4.2   CCL5 is transcriptionally regulated in NK cells  
In the next set of experiments, the transcriptional and translational regulation of CCL5 in NK 
cells was characterized in detail and compared to that seen for perforin and granzyme B. 
CCL5 mRNA is extremely stable in CTL, and important aspects of the regulation of this 
chemokine in T cells can be linked to translational control [152, 153]. To determine if mRNA 
(and protein) was also stable in NK cells, primary NK cells were treated with the 
transcriptional blocker actinomycin D (Act D) or the translational inhibitor cycloheximide 
(CHX). The mRNA and intracellular protein levels for CCL5, perforin and granzyme B were 
then measured 12 h later. Steady state mRNA as well as protein levels of CCL5 in NK cells 
appeared to be largely dependent on constitutive transcription and translation as levels were 
dramatically reduced after 12 h of treatment (Figure 4.2 A, B, C and D).  
                          
Figure 4.2   Steady state expression of CCL5 requires constitutive transcription and translation. 
(A) Freshly isolated NK cells were treated with actinomycin D (10 µg/ml) or left untreated for 12 h and 
then stained for intracellular CCL5 and analyzed by flow cytometry as described in legend to Fig 1. (B) 
In parallel, cells were lysed and total RNA was isolated, reverse transcribed and analyzed for CCL5 
mRNA level. (C) Freshly isolated NK cells were treated with cycloheximide (10 µg/ml), or left untreated 
for 12 h, and stained for intracellular CCL5 and analyzed by flow cytometry as described in legend to 
Fig 1. (D) In parallel, cells were lysed and total RNA was isolated, reverse transcribed and analyzed 
for CCL5 mRNA level. For statistical analysis, the ANOVA/Tukey’s multiple comparison non-
parametric test was applied to analyze the differences between the individual samples. Significant 
differences are denoted by an asterisk. * denotes a statistically significant difference with a p value < 
0.05, ** denote a statistically significant difference with a p value < 0.01, *** denote a statistically 
significant difference with a p value < 0.0001 and n.s represents no significant difference. (Error bars 
represent standard deviation) 
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The role of transcription and translation in the expression of perforin and granzyme were also 
analyzed. Unlike CCL5, perforin and granzyme proteins levels were stable in the NK cells as 
they are unchanged with Act D or CHX treatment (Figure 4.3 A, B, C and D). 
 
                  
Figure 4.3  Levels of perforin and granzyme B proteins are stable and independent of 
transcription and translation within the evaluated 12 h time-period. (A) and (B) Freshly isolated 
NK cells were either left untreated for 12 h or were treated for 12 h with actinomycin D (10 µg/ml) or 
cycloheximide (10 µg/ml) (C) and (D). Thereafter, cells were fixed and permeabilized and stained for 
intracellular antigens by incubation with primary antibody mouse-α-human perforin (IgG2b, 1:100), 
mouse-α-human granzyme B-PE (IgG1, 1:10) or the corresponding isotype control for 30 min, followed 
by goat-α-mouse IgG2b (AlexaFluor 488). Data acquisition and analysis was performed using a BD 
LSRII cytometer and FlowJo software. The Δ median fluorescence intensity (ΔMFI) was calculated by 
subtracting the median fluorescence intensity of the isotype control from the median fluorescence 
intensity of the specific antibody. 
 
Indeed, Act D or CHX did not show any effect on the perforin and granzyme proteins levels, 
Act D was found to reduce perforin mRNA expression whereas no effect of CHX was 
observed (Figure 4.4 A and B). Thus, Figure 4.2 A, B, C and D and Figure 4.3 A, B, C and D 
suggests that the constitutive CCL5 expression in NK cells is dependent on constitutive 
transcription and translation, which is different from perforin and granzyme B expression. In 
the next phase of experiments, the potential regulation of CCL5 expression was examined 
from the standpoint of the MAPK pathways and again compared to the regulation of the 
cytotoxins. 
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Figure 4.4   Act D reduces mRNA expression, while CHX does not modulate perforin mRNA 
expression within the evaluated 12 h time-period. (A) and (B) Freshly isolated NK cells were treated 
with actinomycin D,  (10 µg/ml), cycloheximide (10 µg/ml) or left untreated for 12 h and then cells were 
lysed and total RNA was isolated, reverse transcribed and analyzed for perforin mRNA level. For 
statistical analysis, the ANOVA/Tukey’s multiple comparison non-parametric test was applied to 
analyze the differences between the individual samples. Significant differences are denoted by an 
asterisk. * denotes a statistically significant difference with a p value < 0.05, ** denote a statistically 
significant difference with a p value < 0.01, *** denote a statistically significant difference with a p 
value < 0.0001 and n.s represents no significant difference. (Error bars represent standard deviation) 
4.2.1   Constitutively activated JNK MAP kinase pathway is required for CCL5 
expression in NK cells 
We speculated that MAPKs may control CCL5 expression in NK cells. A series of regulatory 
pathways including the MAP kinases have been linked to the induced expression of CCL5 in 
CTL [71]. Specific inhibitors of the JNK, ERK and p38 MAP kinase pathways were used to 
characterize the potential role of MAP kinases in the constitutive expression of CCL5 by NK 
cells. Freshly isolated primary NK cells were treated with the MAP kinase inhibitors in the 
absence of serum. After 12 h, intracellular CCL5 protein was measured by flow cytometry 
and mRNA was extracted in parallel for analysis of steady state CCL5 mRNA levels. As 
shown in Figure 4.5 A and B, JNK inhibition reduced both steady state mRNA and 
intracellular CCL5 protein level. Inhibitors of ERK and p38 MAP kinase pathways had no 
effect on CCL5 expression. The reduced intracellular protein levels caused by JNK inhibition 
were not due to increased protein secretion, as protein levels in the culture supernatants 
remained unchanged (Figure 4.5 C).  
Similar experiments were performed using the NK cell line YT. Unlike primary NK cells, the 
YT NK cell line secretes CCL5 constitutively (Figure 4.5 D and E). JNK inhibition was again 
found to reduce the steady mRNA level as well as CCL5 secretion while no significant effect 
of ERK or p38 inhibition was observed.  
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Figure 4.5   Requirement of JNK signal for CCL5 expression in primary NK cells and YT cell 
line. (A) Freshly isolated primary NK cells were cultured in the presence of JNK inhibitor (SP600125 - 
50 µM), ERK inhibitor (PD 98059 - 50 µM) and p38 inhibitor (SB 203580 - 20 µM) or DMSO vehicle in 
the absence of serum for 12 h. The cells were used for RNA isolation and reverse transcription to 
analyze CCL5 mRNA level by qRT-PCR. (B) Inhibitor treated cells were fixed stained for intracellular 
CCL5 and median fluorescence intensity was determined by BD LSRII cytometer and FlowJo 
software. (C) Simultaneously, cell supernatants were analyzed for the secreted CCL5. (D) YT NK cells 
were cultured in the presence of JNK inhibitor (SP600125 - 25, 50 and 100 µM), ERK inhibitor (PD 
98059 - 25, 50 and 100 µM) p38 inhibitor (SB 203580 - 10 and 20 µM) or DMSO vehicle in the 
absence of serum for 12 h. The cells were then used for RNA isolation and reverse transcription to 
analyze CCL5 mRNA expression level. (E) In parallel, supernatants were analyzed for the presence of 
released CCL5 by specific ELISA. For statistical analysis, the ANOVA/Tukey’s multiple comparison 
non-parametric test was applied to analyze the differences between the individual samples. Significant 
differences are denoted by an asterisk. * denotes a statistically significant difference with a p value < 
0.05, ** denote a statistically significant difference with a p value < 0.01, *** denote a statistically 
significant difference with a p value < 0.0001 and n.s represents no significant difference. (Error bars 
represent standard deviation). 
It has been previously shown that NK cell receptors can activate ERK2 and JNK1 pathways 
which in turn trigger microtubule organizing centre and granule polarization, and cytotoxicity.  
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Like CCL5, the involvement of MAP kinase pathways in constitutive perforin and granzyme 
expression can not be excluded. To determine whether MAP kinase pathways also plays a 
role in constitutive perforin and granzyme expression, the effects of MAP kinase inhibitors on 
perforin and granzyme expression were analyzed. Perforin and granzyme B mRNA and 
intracellular protein levels were found to be unchanged by JNK, ERK and p38 MAP kinase 
inhibition in primary NK cells (Figure 4.6 A, B, C and D). 
 
            
            
Figure 4.6   Perforin and granzyme B expression is independent of JNK signal. (A) and (B) 
Freshly isolated primary NK cells were cultured in the presence of JNK inhibitor (SP600125 - 50 µM), 
ERK inhibitor (PD 98059 - 50 µM) and p38 (SB 203580 - 20 µM) or DMSO vehicle in the absence of 
serum for 12 h. Cells were used for RNA isolation and reverse transcription to analyze perforin and 
granzyme B mRNA levels by qRT-PCR. (C) and (D) Simultaneously, inhibitors treated cells were fixed, 
permeabilized and stained for perforin and granzyme and median fluorescence intensity was 
measured using BD LSRII cytometer and FlowJo software. (Error bars represent standard deviation). 
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4.2.2   The JNK MAP kinase pathway is constitutively active in primary NK and 
YT cells 
JNK inhibition reduced steady state CCL5 mRNA and protein levels in freshly isolated NK 
cells. Importantly, this occurred in the absence of NK cell activation suggesting that 
constitutively activated JNK MAP kinase pathway may be important in NK cells function [154-
156]. To test for JNK activity in primary NK cells, freshly isolated primary NK cells were 
treated with JNK, ERK and p38 inhibitor or vehicle control for 12 h in the absence of serum. 
After 12 h, the cells were lysed and analyzed for phosphorylated JNK vs. total JNK protein by 
immuno-blotting. JNK2 MAP kinase appears to be constitutively phosphorylated in freshly 
isolated primary NK cells (Figure 4.7 A). Similar experiments performed in YT cells also 
demonstrated constitutive activation of JNK1/2 (Figure 4.7 B).  
To determine whether JNK inhibition could also directly inhibit CCL5 promoter activity, a 
fragment of the CCL5 immediate upstream region extending from -976 to +59 was cloned 
into a luciferase reporter gene and transiently transfected into YT cells. Two h after 
transfection, the cells were treated with increasing levels of the JNK inhibitor. After 12 h, the 
cells were lysed and luciferase activity was measured. As shown in Figure 4.7 C, the JNK 
inhibitor inhibited CCL5 promoter-reporter activity in a dose dependent manner suggesting a 
direct effect on CCL5 transcription.   
          
                                        
 60 
  Results 
Figure 4.7   Constitutive activation of JNK in primary NK cells and the YT cell line and JNK 
signal is required for constitutive CCL5 promoter activity. (A) Freshly isolated NK cells were 
treated with JNK inhibitor (50 µM), ERK inhibitor (50 µM), and p38 inhibitor (20 µM) or DMSO vehicle 
in the absence of serum for 12 h. The cells were lysed and phosphorylated JNK and total cellular JNK 
were measured by Western blotting using a p-JNK antibody. (B) YT cells were treated either with 100 
µM JNK, ERK inhibitor and 20 µM p38 inhibitor or DMSO vehicle for 12 h in the absence of serum. 
After 12 h, cells were lysed and checked for the p-JNK antibody and total cellular JNK by Western 
blotting.(C) YT cells were transfected with CCL5 promoter-reporter construct (pGL3/-976), after 3 h of 
transfection the cells were treated with JNK inhibitors (2, 25 and 50 µM) or left untreated for 12 h. The 
cells were then lysed and analyzed for Photinus- and Renilla-luciferase activity. For statistical analysis, 
the ANOVA/Tukey’s multiple comparison non-parametric test was applied to analyze the differences 
between the individual samples. Significant differences are denoted by an asterisk. * denotes a 
statistically significant difference with a p value < 0.05, ** denote a statistically significant difference 
with a p value < 0.01, *** denote a statistically significant difference with a p value < 0.0001 and n.s 
represents no significant difference. (Error bars represent standard deviation) 
4.2.3   Identification of the minimal optimal CCL5 promoter in NK cells 
The experiments outlined in Figure 4.7 C suggested a direct effect of JNK inhibition on CCL5 
reporter-promoter activity in NK cells. The minimal optimal functional region of the CCL5 
promoter in NK (YT) cells was then determined. YT cells were transiently transfected with a 
series of 5' to 3' CCL5 promoter-reporter deletions driving the luciferase reporter gene 
(Figure 4.8 A). After 24 h, the cells were lysed and reporter gene activity was measured. The 
reporter gene activity was essentially unchanged when promoter sequences were deleted 
from -976 to -83 (Figure 4.8 B). 
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Figure 4.8   The -83 to +58 region contributes to constitutive CCL5 promoter activity.(A) 
Schematic presentation of the CCL5 - promoter region and its 5´- truncated forms. (B) Transient 
transfection of Full length (-976) and 5' to 3' CCL5 promoter deletion constructs. The transfected cells 
were cultured for 24 h and cell lysates assayed for Photinus- and Renilla-luciferase activity.(C) 
Schematic presentation of -194 bp proximal region of the CCL5 promoter and potential transcription 
factor binding sites. (Error bars represent standard deviation) 
 
4.2.4  SP1/KLF binding element in the CCL5 promoter region is required for 
constitutive promoter activity 
Bioinformatics analysis of the 83 bp proximal region of the CCL5 promoter for potential 
transcription factor binding sites using Matinspector (Genomatix GmbH) identified the two 
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previously identified binding sites for NF-kB (-70 to - 58 and - 55 to -42), a SP1/KLF binding 
site (-70 to -58) (Figure 4.8 C). To characterize the functionality of these elements in the 
context of NK cells, serial mutations of each element (based on Sequence Shaper, 
Genomatix GmbH) as well as a deletion of the 5’ UTR region were generated within the -194 
CCL5 reporter-promoter construct (Table 4.1) (Figure 4.9 A). The reporter gene constructs 
were then transiently transfected into YT cells and after 24 h the cells were lysed and 
analyzed for reporter gene activity. As shown in (Figure 4.9 B), mutation of the p65 site at -70 
to -58 and complete mutation of the second NF-kB binding site at -55 to -42 in the promoter 
did not influence reporter gene activity. However, mutation of the SP1 binding site at -70 to -
58 resulted in 75%-80% reduced promoter-reporter activity. Mutation of the c-MYB, PAX6 
and SRF binding sites or deletion of the 5´untranslated region did not lead to a change in 
promoter-reporter activity (Figure 4.9 C). 
Table 4.1   Wild type and mutant sequences of CCL5 promoter
Type of mutations Sequence 
Wild type SP1 + NF-kB (in -70 to -58)     -76     GCTATTTTGGAAACTCCCCTTAGGGGATGCCCC    -43 
    CGATAAAACCTTTGAGGGGAATCCCCTACGGGG 
SP1 mutation (in -70 to -58)  -76      GCTATTTTGGAAACTCTCCTTAGGGGATGCCCC    -43 
  CGATAAAACCTTTGAGAGGAATCCCCTACGGGG 
NF-kB mutation (in -70 to -58)     -76       GCTATTTTGGCCACTCCTCTTAGGGGATGCCCC    -43 
       CGATAAAACCGGTGAGGAGAATCCCCTACGGGG 
SP1+NF-kB mutation (in -70 to -58)     -76       GCTATTTTGGACACTCTCCTTAGGGGATGCCCC    -43 
       CGATAAAACCTGTGAGAGGAATCCCCTACGGGG 
Wild type NF-kB (in -55 to -42)      -68          GGAAACTCCCCTTAGGGGATGCCCCTCAAC        -39 
   CCTTTGAGGGGAATCCCCTACGGGGAGTTG 
NF-kB mutation (in -55 to -42) -68 GGAAACTCCCCTTACTCGATGCCCCTCAAC         -39 
               CCTTTGAGGGGAATGAGCTACGGGGAGTTG 
c-Myb mutation -54   GGGGATGCCCCTCAACTCACCCTATAAAGGGCCAGCC   -17
   CCCCTACGGGGAGTTGAGTGGGATATTTCCCGGTCGG 
c-Myb + SRF mutation -54    GGGGATGCCCCTCAACAAGCCCTATAAAGGGCCAGCC   -17 
CCCCTACGGGGAGTTGTTCGGGATATTTCCCGGTCGG 
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Figure 4.9   A SP1 binding element in the CCL5 promoter is essential for constitutive promoter 
activity. (A) Sequence of the -75 to -26 promoter region showing potential binding sites for 
transcription factors. Schematic presentation of site directed mutations in the CCL5 promoter region -
83 to +58 and UTR deletion mutation. (B) and (C) The wild-type (-194 promoter region) or site directed 
mutants constructs and pRL-TK were transfected into YT cells, the transfected cells were cultured for 
24 h and cell lysates were assayed for firefly and Renilla luciferase activities. For statistical analysis, 
the ANOVA/Tukey’s multiple comparison non-parametric test was applied to analyze the differences 
between the individual samples. Significant differences are denoted by an asterisk. * denotes a 
statistically significant difference with a p value < 0.05, ** denote a statistically significant difference 
with a p value < 0.01, *** denote a statistically significant difference with a p value < 0.0001 and n.s 
represents no significant difference. (Error bars represent standard deviation) 
4.2.5  CCL5 promoter region -75 to - 39 confers inducibility to a SV40 enhancer-
less promoter 
To further assess the functionality of the -75 to -39 promoter region, a series of heterologous 
promoter-reporter gene constructs were tested in the YT cell line. A dimer of the -75 to -39 
region was cloned in front of an “enhancerless” SV40 promoter (pGL3-Promoter, Promega) 
(Figure 4.10 A). Transient transfection of the constructs into YT cells demonstrated that the 
region could efficiently confer increased promoter activity to a heterologous reporter 
promoter. To determine whether the JNK inhibitor could inhibit the -75 to -39 mediated 
promoter-reporter activity, transfected cells were treated with increasing concentrations of 
the JNK inhibitor. The heterologous promoter-reporter activity was inhibited in a dose 
dependent manner (Figure 4.10 B). In two additional constructs, either the -70 to -58 or -55 
to -42 region were mutated in the context of the dimer. The selective mutation of -75 to -58 
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resulted in loss of the increased promoter activity while mutation of -55 to -42 did not have an 
effect on the heterologous promoter-reporter activity (Figure 4.10 C). 
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Figure 4.10   Region -75 to -39 confers constitutive inducibility to a heterologous promoter 
which requires -70 to -58 promoter region. (A) Dimer of region -75 to -39, or dimers containing 
mutations in either -70 to -58 or -55 to -42 were cloned into pGL3/SV40 “enhancerless” vector. (B) YT 
cells were transiently transfected with wild type -75 to -39 promoter reporter construct, 2 h after 
transfection cells were treated with different concentration of JNK inhibitor for 12 h in the absence of 
serum. 12 h after treatment with inhibitor the cells were lysed and assayed for Photinus- and Renilla-
luciferase reporter activity. (C) The wild -75 to -39 type/mutant dimer constructs and pRL-TK were 
transfected into YT cells. The transfected cells were cultured for 24 h and cell lysates were assayed 
for Photinus- and Renilla-luciferase activity. For statistical analysis, the ANOVA/Tukey’s multiple 
comparison non-parametric test was applied to analyze the differences between the individual 
samples. Significant differences are denoted by an asterisk. * denotes a statistically significant 
difference with a p value < 0.05, ** denote a statistically significant difference with a p value < 0.01, *** 
denote a statistically significant difference with a p value < 0.0001 and n.s represents no significant 
difference. (Error bars represent standard deviation) 
4.2.6   The -75 to - 56 region binds SP1 in EMSA 
Electrophoretic mobility shift assays (EMSA) were then used to study in vitro factor binding to 
the -70 to -56 region. An oligonucleotide probe spanning -75 to -56 and representing the 
binding sites for the SP1/NF-kB elements showed only one prominent band in EMSA. The 
band was specific as it could be completely competed with an excess of cold “self” probe. In 
addition, the band was completely competed with a consensus oligonucleotide probe for SP1 
but not with a mutant version of the SP1 consensus probe or with a NF-kB consensus 
oligonucleotide. Supershift/blocking with antisera directed against either Rel p50, Rel p52, 
Rel p65, B Rel, SP1, SP3, and KLF 13 further demonstrated that that the complex was 
formed by SP1 as it was completely blocked by anti-SP1 antibodies while the other antibody 
reagents did not effect the complex (Figure 4.11). 
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Figure 4.11   CCL5 promoter region -75 to - 56 binds SP1 in YT cell nuclear extracts. (A) EMSA 
competition experiment with -75 to - 56 as probe and nuclear extracts from YT cells; 50 ng of 
unlabeled -75 to - 56 oligonucleotide or 40 ng of consensus (SP1, NF-kB) or mutant competitor were 
added to the binding reactions prior to incubation with probe. (B) EMSA supershift/blocking analysis 
with -75 to -56 as probe and nuclear extracts derived from YT cells.  
4.2.7   SP1 binds in vivo near the TATA box on the CCL5 promoter 
In order to verify that SP1 binds to the immediate upstream region of the CCL5 promoter in 
native chromatin, chromatin immunoprecipitation (ChiP) assay was employed [157]. SP1 
antibody was used to immunoprecipitate the CCL5 promoter DNA from YT cells. CCL5 
specific PCR was then used to demonstrate the presence of the CCL5 promoter region in the 
precipitate. Two primer pairs were applied to perform the PCR reactions. One primer set 
annealed from bp –209 to +100 near the CCL5 TATA box, while the second primer pair 
corresponding to a genomic region distal to the CCL5 promoter (from -3789 to -3459) were 
used as a negative control (Figure 4.12 A). Precipitation controls with either no antibody or 
isotype control antibody added during the immunoprecipitation step showed no specific 
CCL5 promoter PCR product. The input DNA control with PCR performed on cross-link 
reversed total DNA demonstrated a control PCR reaction. Only the primer pairs annealing 
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from -209 to +100 PCR lead to the amplification of CCL5 promoter sequence establishing 
that SP1 binds to CCL5 promoter near to TATA box (Figure 4.12 B). 
                        
Figure 4.12   Binding of SP1 to the -70 to -58 region of CCL5 promoter region in vivo (A). 
Schematic presentation of the CCL5 - promoter region and (B) Lane 1, 2 and 3 of uppermost gel 
picture represent the no antibody control, isotype antibody control, and DNA immunoprecipitated by 
SP1 antibodies. The lower gel picture represents the input DNA control amplified for 35 cycles using 
pairs of DNA primers binding proximal to the TATA box of CCL5 promoter region. A second control 
primer pair was applied as described in Materials and Methods. 
4.2.8   JNK inhibition reduces expression of SP1 
To gain insight into the mechanism by which JNK may regulate CCL5 transcription via SP1, 
nuclear proteins isolated from JNK inhibited NK cells were then analyzed by Western blot 
and EMSA (using an oligonucleotide probe spanning -75 to -56). A reduced level of SP1 
protein was detected in the cell extracts from the JNK inhibitor treated samples (Figure 4.13 
A and B). In parallel, reduced SP1 binding activity to the -75 to -56 oligonucleotide probe was 
observed after JNK inhibition (Figure 4.13 C). 
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Figure 4.13   JNK inhibitor reduces SP1 expression. (A) and (B) Freshly isolated NK cells or YT 
cells were treated with either DMSO vehicle or JNK, ERK inhibitor (50 µM for primary NK cells and 
100 µM for YT cell line) and p38 inhibitor (20 µM for both cell types) for 12 h. The cells were lysed and 
analyzed for intracellular SP1 levels by Western blot. (C) YT cells were treated with either DMSO 
vehicle or 100 µM JNK, ERK or 20 µM p38 inhibitor for 12 h. Nuclear proteins were isolated and 
electrophoretic mobility shift assay performed utilizing 
32
P-labelled -75 to -56 oligonucleotide probe. 
4.3   JNK independent post-transcriptional regulation of CCL5 
While NK cells have natural cytolytic activity, but can they also be activated by various 
factors and receptors. IL 2 and PMA/Ionomycin has been shown to activate cytolytic activity 
of NK cells through induction of perforin and granzyme transcription. CCL5 transcription has 
been shown to be regulated by both constitutive as well as inducible transcription factors [46, 
70, 148]. The results detailed here have dealt exclusively with the molecular mechanisms 
controlling the constitutive expression of CCL5 by NK cells. Therefore, a synergistic effect of 
induced transcription factors CCL5 transcription can not be excluded. To address the 
question of inducible CCL5 transcription, the effect of IL-2 stimulation and activation via the 
phorbol ester PMA and ionomycin was examined. Most examples of NK receptor triggering 
leads to the activation of MAP kinase, PKC and PI-3K pathways. PMA/Ionomycin has been 
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shown to activate these pathways. PMA/Ionomycin was then used to mimic receptor 
activation [158]. 
4.3.1   IL2 stimulation and CCL5, perforin and granzyme expression 
IL-2 stimulation showed an increase in the mRNA expression in both perforin and granzyme 
B which is consistent with previously shown effects of IL2 on perforin and granzyme mRNA 
expression; while it did not influence CCL5 mRNA levels (Figure 4.14 A, B and C).  
 
Figure 4.14 IL-2 induces perforin and granzyme mRNA levels but does not influence CCL5 
mRNA expression. (A), (B) and (C) Freshly isolated primary NK cells were cultured either in the 
presence of IL-2 (200 Units/ml) or left untreated for 24 h. After 24 h, cells were used for RNA isolation 
and reverse transcription to analyze for CCL5, perforin and granzyme B mRNA level by qRT-PCR. For 
statistical analysis, the ANOVA/Tukey’s multiple comparison non-parametric test was applied to 
analyze the differences between the individual samples. Significant differences are denoted by an 
asterisk. * denotes a statistically significant difference with a p value < 0.05, ** denote a statistically 
significant difference with a p value < 0.01, *** denote a statistically significant difference with a p 
value < 0.0001 and n.s represents no significant difference. (Error bars represent standard deviation) 
4.3.2   PMA/Ionomycin induces CCL5 release with little change in the mRNA 
expression 
A moderate increase in steady-state mRNA level (about 0.5 fold) seen after combined 
stimulation with PMA and ionomycin and was found to be suppressed by JNK inhibition, 
whereas inhibitors of PKC and PI-3K did not show any effect (Figure 4.15 A). The effect of 
PMA/Ionomycin stimulation on CCL5 release was also analyzed in parallel. PMA/Ionomycin 
stimulation of freshly isolated NK cells showed an induced release of CCL5 (about 3-4 fold) 
which was not comparable to the mRNA induction seen by PMA/Iono (Figure 4.15 B).  
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Figure 4.15   PMA/ionomycin-induced CCL5 release is dependent on protein kinase C pathway 
(A) Freshly isolated primary NK cells were pretreated either with JNK inhibitor (SP600125 - 50 µM), 
PKC inhibitor 1 (Gö6976 - 1 µM), PKC inhibitor 2 (Gö6983 - 1 µM), and PI-3K inhibitor (Ly294002 - 
10 µM) or control followed by PMA (5 ng/ml) and ionomycin (500 ng/ml) stimulation or left untreated. 
After 4 h, cells were used for RNA isolation and reverse transcription to analyze CCL5 mRNA level by 
qRT-PCR. (B) In parallel, cell supernatants were collected and used for the detection of released 
CCL5. For statistical analysis, the ANOVA/Tukey’s multiple comparison non-parametric test was 
applied to analyze the differences between the individual samples. Significant differences are denoted 
by an asterisk. * denotes a statistically significant difference with a p value < 0.05, ** denote a 
statistically significant difference with a p value < 0.01, *** denote a statistically significant difference 
with a p value < 0.0001 and n.s represents no significant difference. (Error bars represent standard 
deviation) 
4.3.3   PMA/Ionomycin induced CCL5 release requires new protein synthesis 
To address the question of post-transcriptional control of CCL5 expression, peripheral NK 
cells were pretreated with either a general transcriptional inhibitor Act D, translational 
inhibitor CHX or left untreated followed by PMA/Iono stimulation alone or in combination for 3 
and 6 h. Three or 6 h later cells supernatant were collected and analyzed for released CCL5. 
As shown in (Figure 4.16) CHX completely blocked the PMA/Iono induced CCL5 release, 
whereas Act D also showed a moderate effect but at later stage suggesting that, the 
PMA/Iono induced CCL5 release largely dependent on new protein synthesis, as well also 
need constitutive transcription. 
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Figure 4.16   PMA/ionomycin-induced CCL5 release needs new protein synthesis. 
Freshly isolated primary NK cells were pretreated either with Cycloheximide (10 µg/ml), Actinomycine 
D (10 µg/ml) or control followed by PMA (5 ng/ml)/ionomycin (500 ng/ml) stimulation in combination 
and PMA (5 ng/ml) and ionomycin (500 ng/ml) alone or left untreated. After 3 and 6 h time points, 
supernatants were collected and analyzed for CCL5 release. Values represent the average of three 
wells. 
4.4   Dual stimulation with TNF-α and IFN-γ optimally induces CCL5 
expression in human mesangial cells 
With characterization of the transcriptional regulation of CCL5 in NK cells and concurrent 
demonstration of the role of JNK in this regulation, the focus of this thesis was then 
redirected toward the characterization of CCL5 in mesangial cells in order to contrast the 
mechanisms of regulation of CCL5 in an inducible setting. 
We have previously shown that mesangial cells require multiple proinflammatory signals to 
upregulate the expression of CCL5 [45]. The basis for the response of mesangial cells to 
signals from TNF-α and IFN-γ stimulation was characterized, and the potential role of MAP 
kinase regulation determined. Serum starved HIMC were stimulated for 24 h with increasing 
concentrations (0-25 ng/ml) of TNF-α or IFN-γ alone and in combination. CCL5 secreted into 
the growth media was determined by specific ELISA. TNF-α induced a low dose-dependent 
increase in CCL5 secretion as did treatment with IFN-γ (Figure 4.17 A). Combined 
stimulation with TNF-α and IFN-γ resulted in a more than additive increase in CCL5 
secretion. A similar pattern of induction was found at the mRNA level as evaluated by qRT-
PCR (Figure 4.17 B). 
To determine whether TNF-α and IFN-γ activate the CCL5 promoter in a similar manner, a 
fragment of the promoter region extending from -976 to +58 fused to a luciferase reporter 
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gene was transiently transfected into HIMC and 3 h later, subjected to stimulation by TNF-α 
and IFN-γ. After 24 h the cells were lysed and assayed for reporter gene activity. As shown in 
Figure 4.17 C, reporter gene activity increased when the transfected cells were stimulated 
with either TNF-α alone or in combination with TNF-α and IFN-γ. IFN-γ stimulation alone did 
not show significant increase in the reporter gene activity. 
                 
Figure 4.17   Gene expression of CCL5 (A) Serum starved HIMC were stimulated with increasing 
concentrations of either TNF-α (0, 5, 10, 25 ng/ml) or IFN-γ (0, 5, 10, 25 ng /ml) and in combination for 
24 h. Cell supernatants were collected and analyzed for the presence of released CCL5 by specific 
ELISA. (B) In parallel, the stimulated cells were used to analyze for CCL5 mRNA expression. (C) 
Serum starved HIMC were transfected with CCL5 promoter-reporter construct (pGL3/-976) and pRL-
TK. After 3 h of transfection the cells were treated with either TNF-α (0, 5, 10, 25 ng/ml), IFN-γ (0, 5, 
10, 25 ng /ml) alone and in combination or left unstimulated (control) for 24 h, cells were lysed and 
analyzed for Photinus- and Renilla-luciferase activity.(Error bars represent standard deviation) 
4.5  JNK MAP kinase pathway is essential for TNF-α and IFN-γ 
induced CCL5 expression 
To determine the potential role of MAP kinase pathway activation in mesangial cell derived 
CCL5 expression, specific inhibitors of MAP kinase pathways were applied. Serum starved 
HIMC were treated with specific inhibitors of JNK, ERK and p38 MAP kinases 1 h before 
TNF-α/IFN-γ stimulation. After 24 h, culture supernatant was collected and CCL5 release 
measured by ELISA. In parallel, mRNA was isolated for analysis of CCL5 mRNA expression. 
JNK blockade reduced CCL5 release and steady state mRNA expression. No effect of ERK 
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and p38 inhibitors on CCL5 expression were observed (Figure 4.18 A, B). Similar results 
were obtained in transient transfection experiments using a CCL5 promoter-reporter gene, 
suggesting a direct effect of JNK inhibition on CCL5 transcription (Figure 4.18 C).  
 
Figure 4.18 JNK dependant activation of CCL5 expression. (A) Serum starved HIMC were 
pretreated with MAP kinase inhibitors (JNK inhibitor: SP600125 - 25 µM, ERK inhibitor: PD 98059 - 50 
µM, p38 inhibitor: SB 203580 - 10 µM and DMSO Control) 1 h before TNF-α/IFN-γ stimulation or left 
unstimulated (Unst). After 24 h the cell supernatants were collected and analyzed for the presence of 
released CCL5 by specific ELISA. (B) In parallel, cells were lysed and total RNA was isolated, reverse 
transcribed and analyzed by qRT-PCR for CCL5 mRNA levels. (C) Serum starved HIMC were 
transiently transfected with wild type promoter reporter construct -976 to +58. Three h after 
transfection the cells were pretreated with JNK inhibitor (25 µM) or DMSO Control 1 h before TNF-
α/IFN-γ stimulation for 24 h or left unstimulated (Unst). The cells were then lysed and assayed for 
Photinus- and Renilla-luciferase reporter activity. For statistical analysis, the ANOVA/Tukey’s multiple 
comparison non-parametric test was applied to analyze the differences between the individual 
samples. Significant differences are denoted by an asterisk. * denotes a statistically significant 
difference with a p value < 0.05, ** denote a statistically significant difference with a p value < 0.01, *** 
denote a statistically significant difference with a p value < 0.0001 and n.s represents no significant 
difference. (Error bars represent standard deviation) 
IFN-γ regulates target genes via JAK/STAT-IRF pathways, while TNF-α signaling is more 
complex. The hallmark of TNF-α signaling is activation of the NF-kB pathway. In addition to 
the NF-kB pathway, TNF-  can also activate at least three mitogen-activated protein kinase 
(MAPK) cascades in mammalian cells. The SAPK/JNK MAPK pathway is involved in 
regulation of TNF-  induced gene expression by phosphorylation of AP1 family of 
transcription factors. MAPK pathway can also lead to the activation of NF-kB [159, 160].  
To gain insight into the mechanism by which JNK may regulate CCL5 transcription, 
regulatory pathways controlling CCL5 transcription in mesangial cells were characterized. 
4.6   The identification of regulatory regions in the CCL5 promoter 
associated with TNF-α and IFN-γ induced expression  
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To identify the “minimal optimal promoter” region required in HIMC, the cells were transiently 
transfected with a series of 5' to 3' CCL5 promoter-reporter deletions (Figure 4.19 A). The 
  Results 
reporter gene activity was essentially unchanged when promoter sequences were deleted to 
-434. Deletion to -194 resulted in partial loss of reporter gene activity (Figure 4.19 B). A 
further set of deletions were used to map control elements between -434 and -120. Deletion 
of the sequence between -228 and -194 had an effect on basal as well as TNF-α/ IFN-γ 
induced reporter gene activity. A further loss of basal activity was seen between -145 and -
120 (Figure 4.19 C). 
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Figure 4.19   The -228 to -194 and -145 to -120 CCL5 promoter regions contribute to the TNF-α and 
IFN-γ induced regulation of CCL5 promoter activity. (A) Schematic presentation of the CCL5 promoter 
region and its 5´ truncated forms. (B) and (C) Transient transfection of 5' to 3' CCL5 promoter deletion 
constructs and pRL-TK. After 3 h the cells were stimulated with TNF-α (25 ng/ml), IFN-γ (10 ng/ml) 
alone and in combination or left unstimulated (control) for 24 h. Cells were then lysed and analyzed for 
Photinus- and Renilla-luciferase activity. (Error bars represent standard deviation) 
Analysis of the promoter sequence for potential transcription factor binding sites 
(Matinspector, Genomatix GmbH) identified sites for AP1/CREB/Ets (-203 to -186), IRF (-137 
to -119), dual NF-kB elements (-70 to -58 and -55 to -42) and an overlapping SP1/KLF 
binding site at (-70 to -58). The functionality of these elements in the HIMC were determined 
by systematic mutation using site-directed mutagenesis in the context of the -976 CCL5 
reporter promoter construct (mutants were designed using SequenceShaper, Genomatix as 
described in Table 4.2) (Figure 4.20 A). The mutant promoter constructs were transfected 
into HIMC and reporter activity tested in response to TNF-α and IFN-γ treatment. The Ets 
mutation did not result in loss of promoter reporter activity. Mutation of the Cre/AP1-like 
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region led to reduced inducible promoter activity (Figure 4.20 B). Loss of the IRF binding 
sites (-137 to -119) reduced TNF-α and IFN-γ induced CCL5 promoter activity (Figure 4.20 
C). Selective mutation of the SP1-like element (-70 to -58) or each of the NF-kB elements (-
70 to -58 and -55 to -42) alone, or in combination, resulted in loss of induced promoter 
activity (Figure 4.20 D). 
Table 4.2   Wild type and mutant sequences of CCL5 promoter 
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Figure 4.20   AP1/Cre (-203 to -186), IRF (-137 to -119), NF-kB/SP1 (-70 to - 58) and NF-kB (-56 to 
- 42) binding elements are essential for TNF-α and IFN-γ induced CCL5 promoter activity. 
(A) Schematic presentation of site directed mutations in the CCL5 promoter region -976 to +58. (B), 
(C) and (D). The wild-type or mutant constructs, in combination with the pRL-TK control plasmid were 
transfected into serum starved HIMC. After 3 h the cells were stimulated with TNF-α (25 ng/ml), IFN-γ 
(10 ng/ml) alone and in combination or left unstimulated (control) for 24 h. The cells were then lysed 
and analyzed for Photinus- and Renilla-luciferase activity. (Error bars represent standard deviation) 
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4.7 Characterization of regulatory pathways controlling CCL5 
transcription in mesangial cells  
The in vitro binding activity of NF-kB, SP1/KLF13, IRF and CREB/AP1 to their cognate 
binding sites in the CCL5 promoter in the context of TNF-α and IFN-γ stimulation were 
evaluated by electrophoretic mobility shift assay (EMSA). In parallel, the signal transduction 
pathways linked to control of the transcription factors were characterized using specific 
inhibitors and Western blot. 
4.7.1   The -219 to -186 promoter region binds Fra1/JunD/CREB and mediates 
transcription through the JNK MAP kinase pathway and phosphorylation of 
Jun D 
EMSA performed using a probe representing the AP1/Cre-like region -219 to -186 resulted in 
complexes that could be specifically competed with a 100-fold molar excess of cold 
consensus oligonucleotide for AP-1 or Cre. However, only a weak induction in the 
AP1/CREB complex was seen in response to TNF-α/IFN-γ stimulation (Figure 4.21 A). 
Supershift analysis identified the bands on region -219 to -186 as a heterotrimer complex of 
Fra-1/Jun D and CREB (AP1/CREB). Fra-1/Jun D and CREB (AP1/CREB) observed in 
EMSA appeared to bind to their cognate binding elements in the CCL5 promoter 
constitutively, suggesting a role of posttranslational mechanisms of AP1 regulation. TNF-α 
can regulate AP1 (c Jun, Jun D and Fra 1) through phosphorylation mediated by three 
potential MAP kinase pathways leading to enhanced transactivation potential of AP1 (Jun D). 
A role for JNK MAP kinase pathways in the TNF-α/IFN-γ induced CCL5 regulation through 
AP1 (Jun D) phosphorylation may be important in this activities. 
To characterize AP1 (Jun D) phosphorylation by JNK activation, serum starved HIMC were 
stimulated with TNF-α and IFN-γ (for 0, 20, 40 and 60 min). The cells were lysed and 
evaluated by immunoblotting using a Ser73-specific anti phospho c-Jun antibody which 
recognizes phosphorylation of c-Jun at Ser73 (48 kd) as well as phosphorylation of Jun D at 
Ser100 (38 kd). As shown in (Figure 4.21 B), TNF-α and IFN-γ activation of JNK MAP 
kinases coincided with phosphorylation of Jun D. Specific blockade of JNK inhibited 
phosphorylation of Jun D in conjunction with JNK activation. In addition to phosphorylation of 
Jun D, phosphorylation of c-Jun was observed. JNK blockade was found to inhibit 
phosphorylation of c-Jun (Figure 4.21 B).  
Results 
          
Figure 4.21   AP1/CREB constitutively binds to CCL5 promoter region -219 to -186 and JNK a 
MAP kinase activation is required for AP1 mediated CCL5 transcription. (A) EMSA 
competition/supershift experiment with -219 to -186 as probe and nuclear extracts from serum starved, 
unstimulated or TNF-α and IFN-γ stimulated HIMC; 50 ng of unlabeled -219 to -186 oligonucleotide or 
40 ng of consensus (AP1 and Cre) or mutant competitors were added to the binding reactions prior to 
incubation with probe. For supershift experiments 1-2 µg of antibodies were added to the binding 
reactions prior to incubation with probe. (B) Serum starved HIMC were stimulated with TNF-α and IFN-
γ for 0-60 min either in the presence of vehicle control or JNK inhibitor (25 µM). Cellular proteins were 
isolated at 0, 20, 40, and 60 min post stimulation and activation of JNK MAP kinase and phopho-Jun D 
were analyzed by western blotting.  
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4.7.2   Region -137 to -119 binds IRF-1 following stimulation with TNF-α and 
IFN-γ 
EMSA using an oligonucleotide probe spanning -137 to -119 showed one prominent complex 
following IFN-γ stimulation and a minor contribution by TNF-α (Figure 4.22 A). The complex 
was completely competed with an excess of cold “self” probe or consensus oligonucleotide 
probe for IRF proteins (Figure 4.22 B). Antibody supershift/blocking experiments 
demonstrated that the complex contains IRF-1 protein but not IRF-2, IRF-3, IRF-7 or Ets1/2 
(Figure 4.22 B). TNF-α and IFN-γ are known activators of the JAK/STAT-IRF pathways [161-
163]. Nuclear translocation of IRF proteins was evaluated by Western blot (of nuclear 
extracts). IFN-γ induced nuclear translocation of IRF-1, while TNF-α showed a limited effect 
(Figure 4.22 C). No effect of TNF-α or IFN-γ stimulation were observed on expression or 
translocation of IRF 2, IRF 3 and IRF 7.   
         
Figure 4.22 TNF-α and IFN-γ induces IRF1 protein expression and binding to the -137 to - 
119 CCL5 promoter region. (A) and (B) EMSA competition/supershift experiment with -137 to -119 
as probe and nuclear extracts from serum starved, unstimulated or TNF-α and IFN-γ stimulated HIMC; 
50 ng of unlabeled -137 to -119 oligonucleotide or 40 ng of consensus (IRF) or mutant competitors 
were added to the binding reactions prior to incubation with probe. For supershift studies 1-2 µg of 
antibodies were added to the binding reactions prior to incubation with probe. (C) Serum starved HIMC 
were stimulated with TNF-α and IFN-γ for 24 h, then nuclear proteins were isolated and analyzed for 
nuclear IRF1, 2, 3, and 7 expression by Western blot. 
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4.7.3  Region -75 to -39 binds SP1 and SP3 constitutively and Rel p65-p50 
heterodimers following activation with TNF-α and IFN-γ 
The region -75 to -39 contains tandem NF-kB elements with overlapping SP1 binding sites. 
EMSA analysis using oligonucleotide probes for -75 to -56 and -55 to -39 resulted in a series 
of complexes when nuclear extracts from non-stimulated cells were used. One additional 
prominent band was seen following TNF-α/IFN-γ stimulation. Each complex was specifically 
competed with an excess of cold -75 to -56 and -55 to -39 probes, respectively. Competition 
studies showed that the upper and lower bands could be competed with a consensus 
oligonucleotide for SP1, but not with NF-kB consensus or mutant oligonucleotides. The TNF-
α/IFN-γ inducible complex found on both the -75 to -56 and -55 to -39 probes was competed 
with NF-kB, but not with mutant or SP1 consensus oligonucleotides. Factor specific antibody 
reagents demonstrated that the various complexes could be shifted or blocked with antibody 
reagents directed against Rel p50, Rel p65, SP1 and SP3 (Figure 4.23 A and B). The results 
show that the TNF-α/IFN-γ inducible complex on -75 to -56 and -55 to -39 is formed by Rel 
p65/p50 heterodimers. The faster migrating complex was completely shifted/blocked using 
anti-SP3 antibody and slower migrating upper band by antibody specific for SP1 (Figure 4.23 
A and B).  
Activation of the NF-kB pathway is a hallmark of TNF-α stimulation [164, 165]. Serum starved 
HIMC were stimulated with TNF-α and IFN-γ (for 0, 5, 15, 30, 45 and 60 min). The cells were 
then lysed and evaluated for activation of the NF-kB pathway by immunoblotting using 
reagents directed against the native and phosphorylated forms of IKKα, IKKβ and IkBα. 
(Figure 4.23 C). Nuclear translocation of SP1, p65 and p50 were evaluated by Western blot 
using nuclear extracts. While SP1 was constitutively present in the nuclear fraction, p65 and 
p50 were present after TNF-stimulation (Figure 4.23 D). 
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Figure 4.23   SP1/SP3 constitutively bind to the –75 to –56 region, TNF-α and IFN-γ stimulation 
induces Rel p65/p50 nuclear translocation and binding to the –75 to –39 CCL5 promoter region  
(A) and (B) EMSA competition/supershift experiment with -75 to -58 and -56 to -39 as probe and 
nuclear extracts from serum starved, unstimulated or TNF-α and IFN-γ stimulated HIMC; 50 ng of 
unlabeled -75 to -58, 56 to -39 oligonucleotide or 40 ng of consensus (SP1 and NF-kB) or mutant 
competitors were added to the binding reactions prior to incubation with probe. For supershift 1-2 µg of 
antibodies were added to the binding reactions prior to incubation with probe. (C and D) Serum 
starved HIMC were stimulated with TNF-α and IFN-γ for 0-60 min (0, 5, 15, 30, 45 and 60 min) for 
cellular protein isolation or 24 h for nuclear protein isolation, then cellular and nuclear proteins were 
isolated and analyzed for the activation of NF-kB and nuclear SP1, p50 and p65 by western blotting. 
   83
Results 
4.7.4   Knock-down by siRNA of p50, p65, IRF-1 and SP1 reduces CCL5 gene 
expression 
To verify involvement of p50, p65, IRF1 and SP1 in TNF-α/IFN-γ induction of CCL5 in HIMC 
in vivo, siRNA knock down experiments were performed. RT-PCR was first used to confirm 
knock down of the individual factors (Figure 4.24 A). RT-PCR and ELISA analyzes 
determined expression of CCL5 after treatment. Targeting p50, p65, IRF1 and SP1 
transcripts using siRNA reduced expression of CCL5 (Figure 4.24 B and C).   
 
Figure 4.24   siRNA knock down of SP1, IRF1, p50 and p65 reduces CCL5 expression (A) siRNA 
was used to knock down specific transcription factors in the HIMC. (B) Serum starved HIMC were 
transfected with control and transcription factors specific siRNA for 48 h. The transfected cells were 
stimulated with TNF-α and IFN-γ for 24 h. After 24 h the cells were lysed, RNA was isolated, reverse 
transcribed and analyzed for CCL5 mRNA expression. (C) In parallel, cell supernatants were collected 
and analyzed for secreted CCL5. (Error bars represent standard deviation) 
4.8   JNK MAPK/AP1, IFN-γ/IRF and NF-kB/Rel pathways converge 
independently on the CCL5 promoter 
Site directed mutagenesis of AP1/CREB in the CCL5 promoter showed only 50-60% loss of 
TNF-α and IFN-γ inducible promoter activity whereas JNK MAP kinase inhibition was found 
to reduce more than 90% the TNFα and IFN-γ induced CCL5 expression suggesting a 
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possible cross talk between JNK MAP kinase, NF-kB and IFN-γ/JAK/STAT-IRF pathways. To 
study the potential cross talk between JNK MAP kinase NF-kB and IFN-γ/JAK/STAT-IRF 
pathways, serum starved HIMC were pretreated with JNK inhibitor, DMSO control or left 
untreated for 1 h followed by TNFα and IFN-γ. After 24 h total RNA was isolated followed by 
reverse transcription to analyze IRF1 expression and nuclear proteins were isolated to 
analyze rel p50 and p65 proteins. As shown in (Figure 4.25 A, B and C), JNK inhibition did 
not show any effect on the TNF-α and IFN-γ induced IRF1 expression, or on p50 and p65 
nuclear translocation. Thus, in this context, the effects of JNK blockade may act at other 
levels of the regulatory networks mediating CCL5 expression.    
           
 
Figure 4.25   TNF-α and IFN-γ activated pathways (JNK/AP1, NF-kB/p50/p65 and IFN-γ/IRF1) act 
independently of each other. (A) Serum starved HIMC were stimulated with TNF-α or IFN-γ alone or 
in combination. After 24 h the cells were analyzed for IRF1 mRNA expression. (B) HIMC were 
pretreated with JNK inhibitors (25 µM) or DMSO Control 1 h before TNF-α/IFN-γ stimulation or left 
unstimulated, after 24 h the cells were lysed and total RNA was isolated, reverse transcribed and 
analyzed for IRF1 mRNA level. (C) Serum starved HIMC were pretreated with MAP kinase inhibitors 
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(JNK inhibitors: 25 µM, ERK inhibitor: 50 µM, p38 inhibitor: 20 µM and DMSO Control) 1 h before TNF-
α/IFN-γ stimulation for 24 h or left unstimulated (-), then nuclear proteins were isolated and analyzed 
for the activation of NF-kB and nuclear p50 and p65 by western blotting. For statistical analysis, the 
ANOVA/Tukey’s multiple comparison non-parametric test was applied to analyze the differences 
between the individual samples. Significant differences are denoted by an asterisk. * denotes a 
statistically significant difference with a p value < 0.05, ** denote a statistically significant difference 
with a p value < 0.01, *** denote a statistically significant difference with a p value < 0.0001 and n.s 
represents no significant difference. (Error bars represent standard deviation) 
4.8.1   An autocrine TNF-α loop seems to contribute to the regulation of CCL5 
TNF-α can function in an autocrine or paracrine manner in specific biologic settings [166-
170]. We then sought to determine if an autocrine TNF-α loop may play a role in the 
regulation of CCL5 expression in mesangial cells TNF-α stimulation was found to lead to 
increased TNF-α mRNA expression, and treatment of HIMC with TNF-α and IFN-γ resulted in 
a more than additive increase in TNF-α mRNA expression (Figure 4.26 A). This suggested 
an interlinked regulation of TNF-α and CCL5.  
To better characterize the TNF-α biology in this system, the expression of TNFR1 and 
TNFR2 mRNA were determined. Both receptors were induced at the mRNA level by 
stimulation with IFN-γ, and an additive effect of the IFN-γ induced TNFR2 expression was 
observed with TNF-α stimulation (Figure 4.26 B and C). The IFN-γ induced expression of 
TNFR may in part explain the additive effect of IFN-γ on TNF-α mediated p50/p65 nuclear 
translocation. While TNF-α was found to be similarly regulated to CCL5 by the JNK pathway 
(Figure 4.26 D), TNFR1 and TNFR2 were unaffected by JNK inhibition (Figure 4.26 E and F) 
but could be included in the context of an autocrine pathway.  
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Figure 4.26   JNK dependent TNF-α autocrine loop may play a role in CCL5 expression. (A), (B) 
and (C) Serum starved HIMC were stimulated with TNF-α or IFN-γ alone and in combination or left 
unstimulated (control). After 24 h the cells were lysed for the RNA isolation to analyze the TNF-α, 
TNFR1 and TNFR2 mRNA expression. (D), (E) and (F) Serum starved HIMC were either pretreated 
with JNK inhibitor (25 µM) or DMSO (control) 1 h before TNF-α/IFN-γ stimulation or left unstimulated 
(Unst) for 24 h, After 24 h the cells were lysed for the RNA isolation to analyzed the TNF-α, TNFR1 
and TNFR2 mRNA expression. For statistical analysis, the ANOVA/Tukey’s multiple comparison non-
parametric test was applied to analyze the differences between the individual samples. Significant 
differences are denoted by an asterisk. * denotes a statistically significant difference with a p value < 
0.05, ** denote a statistically significant difference with a p value < 0.01, *** denote a statistically 
significant difference with a p value < 0.0001 and n.s represents no significant difference. (Error bars 
represent standard deviation) 
The results of these experiments demonstrate that while JNK signaling is required for the 
induction of CCL5 in mesangial cells, unlike NK cells, it does not go over activation of SP1, 
instead, it acts directly on Jun D, and through indirect mechanisms, on a network of genes 
that help focus the downstream response to the activating signals.  
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4.9  Promoter modelling and transcriptomic profiling identifies 
genes co-regulated with CCL5 in the context of glomerular 
inflammation 
In the next phase of this thesis, the data generated on mesangial cell regulation of CCL5 was 
used to help identify and characterize the broader regulatory network activated in the context 
of mesangial cell activation. To this end, promoter modelling and transcriptomic profiling of 
an exemplary mesangial based disease was used to identify genes potentially co-regulated 
with CCL5 in this tissue context.  
The hypothesis of functional context states that hierarchical features within promoters can 
mediate signal and tissue specific regulation and promote the co-regulation of genes [39, 
144]. The promoters of co-regulated genes often contain a similar organisation of 
transcription factor binding elements [4, 39, 62, 144]. This organisation of elements forms the 
basis for the in-silico based identification of potential coregulated genes [4, 39, 144].  
Theoretically such co-regulated genes are controlled through a common set of pathways. 
This hypothesis was examined using the functionally derived mesangial cell data for CCL5 
transcription. 
In mesangial cells, the JNK MAP kinase pathway was found to regulate CCL5 expression 
through downstream transcription factors AP1 (Fra 1/Jun D). IgA nephropathy is a glomerular 
disease characterized by ongoing mesangial inflammation. CCL5 has been proposed to play 
a role in this disease. We hypothesized that the information obtained from the functional 
dissection of CCL5 promoter using conventional molecular analysis in vitro, could be used to 
help identify de-novo co-expressed and co-regulated inflammatory genes regulated in the 
same functional context using transcriptomic data from glomerular samples taken from 
microdissected IgA nephropathy patient samples [144]. The goal was to provide general 
information about the regulatory pathways controlling the expression of proinflammatory 
genes co-regulated with CCL5 in this tissue context, and through this, expand our 
understanding of how networks of promoters are organized and interlinked with extracellular 
signals, as well as to identify potential targets for therapeutic intervention. 
The general approach applied to identify co-regulated genes with CCL5 in the context of 
glomerular inflammation is outlined in Figure 4.27.  
  Results 
 
Figure 4.27   Overview of the general methodology used to identify potential co-regulated 
inflammatory genes in the context of glomerular inflammation using promoter modelling and 
microarray data.  
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The experimentally verified transcription factor binding elements required for CCL5 promoter 
regulation in mesangial cells were modelled using FasM (see Materials and Methods) (Figure  
4.28 A and B).  
 
Figure 4.28   Design of the FastM computer model. (A) Regions -203 to -186 (AP1/CREB), -137 to -
119 (IRF), -70 to -58 (NF-kB/SP1), -56 to -39 (NF-kB) and the TATA box are represented by 
transcription factor weight matrix parameters obtained from a MatInspector analysis of the CCL5 
promoter sequence. The core similarity regions are boxed and the core and matrix similarity scores 
(CS, MS) state how close the CCL5 promoter sequence matches the weight matrix (perfect match: CS 
= 1, MS =1). (B) The promoter organisation identified in the model. Matrix and distance parameters for 
the elements describing AP1/CREB (-203 to -186), IRF (-137 to -119), NF-kB/SP1 (-70 to -58), NF-kB 
(-56 to -39) and the TATA box in the FastM model (printed in italics as they are representations of the 
experimentally verified elements that are functional in the CCL5 promoter). Limited flexibility was 
introduced for the distances between the elements based upon [39, 144] and unpublished results, 
Fessele et al.) and strand orientation was not restricted. 
 
The promoter model of CCL5 determined in activated mesangial cells was used to search 
(using ModelInspector) the human sections of the Genomatix Promoter Database (56,376 
human promoter sequences) for promoters that contain a similar organisation of transcription 
factor binding elements. Matches to the models were restricted to those occurring within 
annotated gene promoters to facilitate valuation. Modelinspector found 246 annotated 
promoters having 100% model match.  
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Mesangial cell activation and damage is a central feature of IgA-nephropathy. To test 
whether genes identified by the comparative promoter analysis may show similar expression 
characteristics in the context of IgA-nephropathy, mRNA was isolated from microdissected 
glomeruli taken from biopsies patients with IgA-nephropathy (n=27) and control kidneys (pre-
transplant allografts; n=6) and analyzed by Affymetrix microarray (see Materials and 
Methods). Of the 246 promoters identified by ModelInspector, probe sets for 80 of the 
respective genes were present on the Affymetrix array (HG-U133A) (Table 4.3).  
  Results 
 Table 4.3   Of the 246 promoters identified by ModelInspector, probe sets for 80 of the 
genes were present on the Affymetrix array (HG – U133A) 
 
        
Of these, 30 genes were found to be significantly up-regulated in IgA nephropathy as 
compared to control glomeruli. Cluster analysis revealed that the genes were similarly 
expressed when analyzed in an unbiased setting (Probe sets for 13,282 genes on the chip 
were clustered using Euclidean distance as metric and single linkage for aggregating 
clusters) (Figure 4.29).  
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Figure 4.29   Close proximity of the upregulated genes in the cluster of Affymetrix chip for all 
13,282 genes. The microarray data from all patients (IgA nephropathy and LD-living donor) for all 
probe sets above cut-off (13,282) were clustered, as described in the material and methods and 
searched for upregulated genes. The resulting cluster is shown on the left. In the middle and right part 
of the figure, the red arrows point to the positions of the 30 upregulated promoter candidate in the 
clustering (middle) and an enlarged part of the clustering (right). Each red arrow is denoted with the 
respective gene symbol.  
 
The 30 regulated genes were then analyzed by Gene Ontology (GO) categories through 
Bibiliosphere/DAVID analysis (Materials and Methods). The genes were subgrouped into the 
following GO categories: immune response, cell proliferation, and cell adhesion. In this 
setting, CCL5 was subgrouped into the immune response category along with DDX58 (RIG-
I), CD86 and IL-32 (Table 4.4).  
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Table 4.4   Match in IgA nephropathy array data and over – representation by GO 
categories of upregulated genes in IgA nephropathy array data 
 
 
 
The expression and regulatory characteristics of RIG-I, CD86 and IL-32 were then compared 
to CCL5 in mesangial cells. As shown in (Figure 4.30 A, B and C), RIG-I and IL-32 mRNA 
are similarly upregulated in mesangial cells in response to stimulation with TNF-α and IFN-γ. 
As was found for CCL5, blockade of the JNK MAP kinase selectively inhibited the induced 
expression of RIG-I and IL-32 (Figure 4.30 D, E and F). No expression of CD86 was 
observed in the HIMC line used. 
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Figure 4.30   IL-32 and RIG-I are coregulated with CCL5. (A), (B) and (C) Serum starved HIMC 
were stimulated with TNF-α (25 ng/ml), IFN-γ (10 ng/ml) alone and in combination or left unstimulated 
(control) for 24 h. After 24 h post-stimulation the cells were used for RNA isolation and reverse 
transcription to analyze CCL5, IL32 and RIG-I mRNA expression level. (D), (E) and (F) Serum starved 
cells were pretreated with MAP kinase inhibitors (JNK inhibitor: 25 µM, ERK inhibitor: 50 µM, p38 
inhibitor: 20 µM and DMSO (Control)) for 1 h followed by stimulated with TNF-α (25 ng/ml) and IFN-γ 
(10 ng/ml) in combination or left unstimulated for 24 h. 24 h post-stimulation the cells were used for 
RNA isolation and reverse transcription to analyze CCL5, IL-32 and RIG-I mRNA expression level. For 
statistical analysis, the ANOVA/Tukey’s multiple comparison non-parametric test was applied to 
analyze the differences between the individual samples. Significant differences are denoted by an 
asterisk. * denotes a statistically significant difference with a p value < 0.05, ** denote a statistically 
significant difference with a p value < 0.01, *** denote a statistically significant difference with a p 
value < 0.0001 and n.s represents no significant difference. (Error bars represent standard deviation) 
Co-regulation of identified genes IL32, RIG-I and CCL5 was also supported by siRNA knock 
down experiments. siRNA nock down experiments clearly showed the requirements of p50, 
p65, IRF1 and SP1 for the TNF-α/IFN-γ induced CCL5 expression. The requirement of these 
factors for the induction of co-regulated genes IL-32 and RIG-I were then verified by RT-
PCR. Targeting p50, p52, p65 and IRF1 using siRNA reduced both IL-32 (20, 60 and 60% 
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respectively) and RIG-I (30, 60 and 50 % respectively) expression, while no effect of SP1 
siRNA knock down was observed (Figure 4.31 A and B). 
 
Figure 4.31   TNF-α and IFN-γ induced IL32 and RIG-I need similar transcription factors to CCL5 
induction in the similar context. (A) and (B) Serum starved HIMC were transfected with control and 
transcription factors specific siRNA for 48 h. The transfected cells were then stimulated with TNF-α 
and IFN-γ for 24 h. After 24 h the cells were lysed, RNA was isolated, reverse transcribed and 
analyzed for RIG-I and IL32 mRNA expression. (Error bars represent standard deviation) 
The glomerular expression of RIG-I and IL-32 in the context of IgA-nephropathy was then 
verified by immunohistochemistry using biopsy samples from IgA nephropathy patients As 
shown in (Figure 4.32 A and B), RIG-I and IL-32 protein are highly expression by resident 
glomerular cells during IgA nephropathy.      
                
Figure 4.32   IL-32 and RIG-I proteins are upregulated in the glomeruli of patients with IgA 
nephropathy. Human biopsy samples from patients with IgA nephropathy were examined for the 
expression of IL-32 and RIG-I protein. (A) Demonstrates expression of IL-32 and (B) RIG-I by resident 
cells within the glomerulus. 
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5   Discussion 
CCL5 is a chemokine which can be produced by immune cells such as activated T cells, 
macrophage, neutrophils and natural killer cells, and non immune cells such as fibroblasts, 
epithelial, endothelial, and mesangial cells [39, 42-44, 46, 63, 65, 67, 71, 140, 171, 172]. 
CCL5 is often upregulated in the context of tissue stress but it is also constitutively 
expressed by some cells (e.g. megakaryocytes, and as the shown here by NK cells) [28, 63] 
and is upregulated by other cells in response to specific stimuli (such as the renal mesangial 
cells used here). While only one, rather short promoter region appears to drive CCL5 
expression in all of these diverse tissue settings. Importantly, the molecular mechanisms 
(e.g. the specific series of transcription factors) involved in the upregulation of CCL5 
expression can vary significantly between the various tissues that express the gene [4]. 
Thus, the CCL5 gene represents an excellent example of the flexibility and selectivity that 
underlies the tissue/signal-specific regulation of gene expression.  
The transcriptional control for human CCL5 appears to be mediated through five short 
regulatory regions [4, 39, 62]. The mechanisms underlying CCL5 transcription in T cells, 
macrophage, neutrophils, fibroblast, epithelial and endothelial cells have been previously 
described [39, 42-44, 46, 64-67, 70, 71, 73, 173, 174]. One goal of this thesis was to add to 
our general understanding of the flexibility of this regulation by determining the control of 
CCL5 regulation in natural killer and renal mesangial cells.   
As a further issue, the potential role of mitogen-activated protein kinase (MAPK) pathways in 
the control of CCL5 in both tissue settings was evaluated. The MAP kinases are known to 
regulate diverse processes including aspects of inflammation, and can be activated by an 
array of stimuli. The MAPKs phosphorylate proteins, such as transcription factors, and can 
moderate gene expression [74, 76, 98, 99, 175].  
MAP kinase pathways have been studied in the context of NK cell effector function. It was 
thus proposed that MAPKs may also play a role in the regulation of CCL5 in NK cells. Study 
of the role of MAP kinase pathways in CCL5 regulation would be helpful to better understand 
the role of CCL5 in NK cell biology. 
The induction of CCL5 transcription by resident tissue cells such as astrocytes, fibroblasts, or 
endothelial cells can be seen following stimulation with proinflammatory stimuli. As 
discussed, different stimuli can uniquely induce the expression of CCL5 in the different cell 
types. For example, astrocytes upregulate CCL5 in response to IL-1β activation, while 
endothelial cells upregulate the gene in response to TNF-α [46]. The basic features of the 
promoter responsible for this regulation have been characterized, Unlike these cells types, in 
renal mesangial cells, a dual stimulation by TNF-α and IFN-γ was required to optimally 
induce CCL5 expression [45].    
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MAP kinase pathways are known to play a role in the progression of renal diseases including 
glomerulonephritis Blockade of the JNK MAP kinase has been shown to reduce proteinuria 
and glomerular lesions in glomerulonephritis disease models [130-134]. 
5.1  JNK MAP kinase pathway regulates CCL5 through SP1 in 
natural killer cells 
Using primary human NK cells isolated from peripheral blood, we observed that CCL5, 
perforin and granzyme B are all constitutively expressed in NK cells. CCL5 is sequestered in 
vesicles distinct from those containing the cytotoxins. The MAP kinase (ERK, JNK and p38) 
and PI-3K pathways are known to be involved in triggering the polarization and secretion of 
cytolytic granules in NK cells [110, 111, 117, 158]. However, here we show that of these 
pathways, only the JNK MAP kinase appears to plays a role in the regulation of steady-state 
CCL5 mRNA levels in NK cells. Inhibition of the JNK pathway resulted in a decrease in 
constitutive CCL5 promoter activity as well as mRNA and protein levels, whereas no effect of 
JNK inhibition was observed on perforin or granzyme B. The phosphorylated state of JNK 
was not altered over time or by serum deprivation, suggesting that activation of JNK is 
intrinsic and spontaneous in these cells. Primary NK cells where found to exhibit active 
JNK2, while the NK cell line YT was found to show constitutive activation of JNK1/2.  
The constitutive activation of JNK2 in freshly isolated NK cells was effectively linked to the 
constitutive transcription of CCL5 seen, while levels of perforin and granzyme B were stable 
and independent of transcription and translation in the time frame tested. Our results in 
concert with previous reports suggest that JNK isoforms (JNK1/2) play a central role in the 
regulation of NK cell function [110, 111]. It has previously been shown that NK cell receptors 
activate ERK2 and JNK1 pathways, which in turn trigger microtubule organizing centre and 
granule polarization and cytotoxicity [110, 111]. In this thesis we show that JNK2 is also 
involved in the constitutive control of CCL5 transcription. As polarization and NK receptor 
activation were not specifically addressed here, we can not attest to the potential role of the 
ERK2 and JNK1 pathways in CCL5 protein release. However, it is interesting to note that the 
YT NK cell line, which shows active JNK1/2, also shows constitutive secretion of the CCL5 
protein. 
The cis-acting promoter elements and the respective binding factors required for the JNK 
mediated constitutive CCL5 promoter activity in NK cells were identified and characterized. 
Five to 3´ deletion analysis of the CCL5 promoter revealed a very compact region from 
nucleotide -83 to nucleotide +58 providing basal promoter activity. Based on the experiments 
performed here, we cannot rule out that additional upstream or downstream signals may also 
contribute to the control of CCL5 transcription.   
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The results found for NK cells are in contrast to what has been described for T cells. In CTL, 
the transcription factor KLF13 binds to the -70 to -58 region of CCL5 and in concert with a 
series of additional transcription factors helps direct the transcription of CCL5 during the 
functional maturation of CD8 T cells [69]. Constitutive transcription of CCL5 by NK cells was 
found to involve the same promoter -70 to -58 region. The CCL5 promoter contains two NF-
kB and SP1/KLF13 binding sites shown to be functional in T cells. Transient transfection of 
site directed individual mutants of SP1, p65 (in the -70 to –58) promoter regions, or complete 
mutation of the -70 to -58 and -55 to -42 demonstrated the importance of SP1 binding site in 
the -70 to - 58 promoter region for constitutive CCL5 promoter activity in YT cells. EMSA 
supershift experiments verified SP1 binding to the -70 to - 58 promoter region while 
chromatin immunoprecipitation (ChiP) demonstrated in vivo binding of SP1 to the CCL5 
promoter proximal to the TATA box.  
SP1 is a ubiquitously expressed transcription factor that binds GC-rich cis elements. Western 
blotting and JNK inhibition demonstrated that constitutive JNK signalling is required for SP1 
expression in NK cells. JNK pathway activation has been shown to play a role in the stability 
of transcription factors which may also be the basis for the effect of JNK inhibition on SP1 
expression seen here. Posttranslational modifications of SP1 have been implicated in the 
regulation of SP1 activity. For example, glycosylation, sumoylation and phosphorylation 
regulate SP1 stability in a proteasome-dependent manner [176-180].  
The results reported here deal only with the molecular mechanisms controlling the 
constitutive expression of CCL5 by NK cells. However, NK cells are also clearly activated by 
various factors and receptors. In subsequent experiments, we examined the effect of IL-2 
stimulation and activation via the phorbol ester PMA and ionomycin (mimicking NK receptor 
activation) [158] on CCL5 mRNA expression. Interestingly, while IL-2 did increase mRNA 
expression of both perforin and granzyme B, it did not influence CCL5 mRNA levels. The 
moderate increase in steady-state mRNA level seen after combined stimulation with PMA 
and ionomycin was suppressed by JNK inhibition suggesting that some aspects of CCL5 
mRNA regulation during NK cell activation may also act through the JNK pathway. An 
additional level of complexity occurs when considering the molecular pathways controlling 
the release of CCL5 protein upon NK cell activation. In this case, it appears that pathways 
other than the JNK pathway identified control release of the protein. This is suggested by the 
results that show that PKC inhibition strongly blocks the release of protein in the context of 
NK activation, while JNK blockade does not have an effect. New protein synthesis was found 
to be required for the PMA/Ionomycin induced CCL5 release. This was demonstrated by use 
of cycloheximide which completely blocked induced CCL5 release. The requirement of PKC 
pathways, as well as new protein synthesis for the PMA/Ionomycin induced CCL5 release 
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suggests that translational control of CCL5 in NK cells may be mediated through PKC 
pathways.  
5.2  JNK MAP kinase pathway regulates CCL5 and co-regulated 
genes in glomerular mesangial cells through AP1 
Mesangial cells are important players in the manifestation of glomerular nephritis 
(inflammation of the glomerulus). A series of pathways were identified that together 
orchestrate the upregulation of CCL5 in response to TNF-α and IFN-γ stimulation in 
mesangial cells. Signaling mediated through JNK, IFN-γ and NF-kB related pathways were 
found to independently converge on the CCL5 promoter where constitutive (SP1 and AP1), 
and induced transcription factors (IRF1, p50, p65 and AP1) dictate the transcriptional 
response. In this regard, the transcriptional regulation seen in mesangial cells differ to a 
degree from that described in other cells [39-41, 46, 63, 65, 67, 70, 71, 173, 174, 181]. 
In this instance, the JNK MAP kinase pathway activated by TNF-α was found to contribute to 
CCL5 transcription through phosphorylation of Jun D, a member of AP1 family of 
transcription factors. While blockade of JNK MAP kinase specifically inhibited Jun D 
phosphorylation and CCL5 expression, JNK pathway regulation of Jun D phosphorylation 
does not appear to explain the complete effect of the pathway on CCL5 upregulation. 
Promoter-reporter activity showed only a 50-60% reduction after mutation of the AP1 
element in the CCL5 promoter, while JNK blockade inhibited CCL5 expression by more than 
90%. This suggests the involvement of additional regulatory features mediated through the 
JNK pathway. A potential involvement of JNK signaling in the regulation of IRF1 and NF-kB 
at some level cannot be excluded. While TNF-α has been shown to induce an upregulation of 
IRF1 in some settings and to activate the NF-κB pathway through JNK MAP kinase activity 
[161, 182-185], in this study JNK blockade did not inhibit IRF1 expression or influence the 
nuclear translocation of p50/p65. Thus, in mesangial cells the effects of JNK blockade 
appear to act at other levels to influence CCL5 expression. 
5.3  Promoter modelling of the CCL5 promoter in mesangial cells 
can be used to help identify a network of genes linked to IgA 
nephropathy 
At this stage, a set of regulatory pathways controlling CCL5 transcription in activated 
mesangial cells had been defined. This then led to the question if the molecular data could 
be expanded in a systems biology-like approach to identify a larger network of genes linked 
to inflammatory glomerular disease.  
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The hypothesis of functional context states that hierarchical features within promoters can 
mediate signal and tissue specific regulation and promote the co-regulation of genes. We 
have previously shown that this data can be used to identify factors de novo that are similarly 
controlled [4, 39, 144], and through this, better characterize the regulatory networks 
underlying pathophysiologic processes. The regulatory elements identified in the context of 
TNF-α/IFN-γ induction of CCL5 by mesangial cells were modelled using the FasM program 
and used for a bioinformatics-based search for other pro-inflammatory genes expressed in 
the same functional context – that is, mesangial cells in an ongoing inflammatory process 
(IgA nephropathy).  
A human promoter database (56,376 promoter sequences) was searched using 
ModelInspector (Genomatix), it found 246 promoters with the same general structure of 
transcription factor binding sites. In parallel, transcriptomic profiling of gene expression in 
microdissected glomeruli from patients with active glomerular disease linked to mesangial 
cell activation (IgA nephropathy) was performed. Thirty genes were found to overlap between 
the promoter model search results and the transcriptomic data derived from the IgA-
nephropathy samples. In keeping with the hypothesis of functional context, sub-grouping of 
the 30 genes by gene ontology (DAVID) showed four genes linked to the proinflammatory 
category (CCL5, CD86, RIG-I and IL-32). Of these, RIG-I and IL-32 were found to be 
similarly regulated in the mesangial cell line in response to TNF-α/IFN-γ, while CD86 was not 
expressed by cell line. Interestingly, CD86 was previously shown to be expressed in the 
glomerulus in IgA patients. The lack of expression of CD86 in the HIMC line could represent 
a tissue culture artifact.  
The potential co-regulation of CCL5, RIG-I and IL-32 was supported by their close proximity 
in nonbiased clustering of all 13,282 genes upregulated on the Affymetrix chip. The knock 
down of p50, p65 and IRF1 showed reduced TNF-α/IFN-γ induced RIG-I and IL32 expression 
in HIMC also support the co-regulation of CCL5, RIG-I and IL32. The increased ex vivo co-
expression of RIG-I and IL-32 was supported by immunohistochemical data showing 
glomerular upregulation in IgA nephropathy. 
 
TNF-α can function in an autocrine or paracrine manner in specific biologic settings [166-
170]. Further analysis showed that an autocrine TNF-α loop appears to help regulate CCL5 
expression in mesangial cells. TNF-α stimulation lead to increased TNF-α mRNA expression, 
and treatment of HIMC with TNF-α and IFN-γ resulted in a more than additive increase in 
TNF-α mRNA expression. This suggests an interlinked regulation of TNF-α, IL-32, CCL5 and 
RIG-I in this biologic context.  
To better characterize the TNF-α biology in this system, the expression of TNFR1 and 
TNFR2 mRNA was determined. Both receptors were induced at the mRNA level by 
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stimulation with IFN-γ, and an additive effect of the IFN-γ induced TNFR2 expression was 
observed with TNF-α stimulation. The IFN-γ induced expression of TNFR may explain in part 
the additive effect of IFN-γ on TNF-α mediated p50/p65 nuclear translocation.  
IL-32 and RIG-I have been previously shown to be functionally related independent of their 
connection with CCL5. The RIG-I gene encodes a protein containing RNA helicase-DEAD 
box protein motifs and a caspase recruitment domain (CARD). RIG-I is involved in viral 
double-stranded (ds) RNA recognition and in the regulation of the immune response. RIG-I 
has been shown to help regulate a series of inflammatory genes including; CXCL10, 
CXCL11, COX2, TNF-α and CCL5 [186-197].  
IL-32, a recently discovered pro-inflammatory cytokine, induces various proinflammatory 
cytokines including: TNF-α, IL-1β, IL-6 and some chemokines. In addition, its expression 
correlates with the severity of various chronic inflammatory diseases. IL-32 is thought to be 
intricately linked to the biology of TNF-α and to contribute to the exacerbation of TNF-α 
related inflammatory diseases [198-205]. The expression of IL-32 and TNF-α in response to 
TNF-α/IFN-γ stimulation may act in a positive autocrine loop linking the control of TNF-α and 
IL-32 production in mesangial cells.  
In keeping with the idea that conserved transcriptional mechanisms help orchestrate sets of 
genes expressed in the same functional context, a blockade of JNK MAP kinase was found 
to reduce the induced RIG-I and IL-32 expression in HIMC by 75 and 60% respectively. 
 
Collectively, findings of this thesis demonstrate that JNK, a MAP kinase pathway, 
differentially regulate CCL5 in human natural killer and glomerular mesangial cells using two 
different mechanisms (as shown in Figure 5.1). Importantly, this study also demonstrates that 
it is possible to use experimentally determined data representing the regulatory signature of 
an exemplary gene to identify co-regulated genes, and through this, gene networks in 
specific biologic settings. This analysis can provide information about common pathways that 
represent potential targets for therapeutic intervention. These results further demonstrate 
that in addition its role in regulating macrophage derived cytokines and chemokines, JNK/Jun 
D pathway also plays a crucial role in the control of resident tissue mesangial cell derived 
cytokines and chemokines in the context of IgA nephropathy. 
 
 
 
 
 
 
 
Discussion 
 
   103
 
 
     
Fi
gu
re
 5
.1
  
 S
ch
em
at
ic
 r
ep
re
se
nt
at
io
n 
sh
ow
in
g 
th
e 
di
ffe
re
nt
ia
l 
re
gu
la
tio
n 
of
 C
C
L5
 g
en
e 
tr
an
sc
rip
tio
n 
by
 J
N
K
 M
A
P 
ki
na
se
 
pa
th
w
ay
 in
 h
um
an
 n
at
ur
al
 k
ill
er
 a
nd
 g
lo
m
er
ul
ar
 m
es
an
gi
al
 c
el
ls
 
 
  104 
References 
   105
6   REFERENCES 
1. Murphy, P.M., et al., International union of pharmacology. XXII. Nomenclature 
for chemokine receptors. Pharmacol Rev, 2000. 52(1): p. 145-76. 
2. Schall, T.J., et al., A human T cell-specific molecule is a member of a new 
gene family. J Immunol, 1988. 141(3): p. 1018-25. 
3. Taub, D.D., Chemokine-leukocyte interactions. The voodoo that they do so 
well. Cytokine Growth Factor Rev, 1996. 7(4): p. 355-76. 
4. Werner, T., et al., Computer modeling of promoter organisation as a tool to 
study transcriptional coregulation. Faseb J, 2003. 17(10): p. 1228-37. 
5. Laing, K.J. and C.J. Secombes, Chemokines. Dev Comp Immunol, 2004. 
28(5): p. 443-60. 
6. Moser, B., et al., Chemokines: multiple levels of leukocyte migration control. 
Trends Immunol, 2004. 25(2): p. 75-84. 
7. Broxmeyer, H.E., Chemokines in hematopoiesis. Curr Opin Hematol, 2008. 
15(1): p. 49-58. 
8. Strieter, R.M., et al., CXC chemokines in angiogenesis. Cytokine Growth 
Factor Rev, 2005. 16(6): p. 593-609. 
9. Taub, D.D., Cytokine, growth factor, and chemokine ligand database. Curr 
Protoc Immunol, 2004. Chapter 6: p. Unit 6 29. 
10. Simon, S.I. and C.E. Green, Molecular mechanics and dynamics of leukocyte 
recruitment during inflammation. Annu Rev Biomed Eng, 2005. 7: p. 151-85. 
11. Kim, C.H., Chemokine-chemokine receptor network in immune cell trafficking. 
Curr Drug Targets Immune Endocr Metabol Disord, 2004. 4(4): p. 343-61. 
12. Conti, P., R.C. Barbacane, and M. Reale, Chemokines in inflammatory states. 
Allergy Asthma Proc, 1999. 20(4): p. 205-8. 
13. Mathew, A., et al., Cutting edge: Th2 cell trafficking into the allergic lung is 
dependent on chemoattractant receptor signaling. J Immunol, 2002. 169(2): p. 
651-5. 
14. Hersh, E.M. and G.P. Bodey, Leukocytic mechanisms in inflammation. Annu 
Rev Med, 1970. 21: p. 105-32. 
15. Feghali, C.A. and T.M. Wright, Cytokines in acute and chronic inflammation. 
Front Biosci, 1997. 2: p. d12-26. 
16. Viola, A. and A.D. Luster, Chemokines and their receptors: drug targets in 
immunity and inflammation. Annu Rev Pharmacol Toxicol, 2008. 48: p. 171-
97. 
17. Luster, A.D., Chemokines--chemotactic cytokines that mediate inflammation. 
N Engl J Med, 1998. 338(7): p. 436-45. 
18. Rossi, D. and A. Zlotnik, The biology of chemokines and their receptors. Annu 
Rev Immunol, 2000. 18: p. 217-42. 
19. Kuna, P., [Cytokines in allergic inflammation]. Pol Merkur Lekarski, 2003. 
14(84): p. 497-9. 
20. Johnson, Z., et al., Chemokine inhibition--why, when, where, which and how? 
Biochem Soc Trans, 2004. 32(Pt 2): p. 366-77. 
21. Kuna, P., et al., Characterization of the human basophil response to cytokines, 
growth factors, and histamine releasing factors of the intercrine/chemokine 
family. J Immunol, 1993. 150(5): p. 1932-43. 
22. Kapp, A., et al., The chemokine RANTES is more than a chemoattractant: 
characterization of its effect on human eosinophil oxidative metabolism and 
References 
 106 
morphology in comparison with IL-5 and GM-CSF. J Invest Dermatol, 1994. 
102(6): p. 906-14. 
23. Taub, D.D., et al., Beta chemokines costimulate lymphocyte cytolysis, 
proliferation, and lymphokine production. J Leukoc Biol, 1996. 59(1): p. 81-9. 
24. Taub, D.D., et al., Chemokines and T lymphocyte activation: I. Beta 
chemokines costimulate human T lymphocyte activation in vitro. J Immunol, 
1996. 156(6): p. 2095-2103. 
25. Taub, D.D., et al., Alpha and beta chemokines induce NK cell migration and 
enhance NK-mediated cytolysis. J Immunol, 1995. 155(8): p. 3877-88. 
26. Nieto, M., et al., Roles of chemokines and receptor polarization in NK-target 
cell interactions. J Immunol, 1998. 161(7): p. 3330-9. 
27. Robinson, E., et al., Chemokine expression in rheumatoid arthritis (RA): 
evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta 
production by synovial T cells. Clin Exp Immunol, 1995. 101(3): p. 398-407. 
28. Takeuchi, K., et al., Chemokine production by human megakaryocytes derived 
from CD34-positive cord blood cells. Cytokine, 1999. 11(6): p. 424-34. 
29. Nelson, P.J. and A.M. Krensky, Chemokines, chemokine receptors, and 
allograft rejection. Immunity, 2001. 14(4): p. 377-86. 
30. Yamamoto, T., Chemokines and chemokine receptors in scleroderma. Int Arch 
Allergy Immunol, 2006. 140(4): p. 345-56. 
31. Moore, K.J., et al., Gene transfer of RANTES elicits autoimmune renal injury in 
MRL-Fas(1pr) mice. Kidney Int, 1998. 53(6): p. 1631-41. 
32. Schall, T.J., Biology of the RANTES/SIS cytokine family. Cytokine, 1991. 3(3): 
p. 165-83. 
33. Snowden, N., et al., RANTES role in rheumatoid arthritis. Lancet, 1994. 
343(8896): p. 547-8. 
34. Krensky, A.M. and Y.T. Ahn, Mechanisms of disease: regulation of RANTES 
(CCL5) in renal disease. Nat Clin Pract Nephrol, 2007. 3(3): p. 164-70. 
35. Pattison, J., et al., RANTES chemokine expression in cell-mediated transplant 
rejection of the kidney. Lancet, 1994. 343(8891): p. 209-11. 
36. Pattison, J.M., et al., RANTES chemokine expression in transplant-associated 
accelerated atherosclerosis. J Heart Lung Transplant, 1996. 15(12): p. 1194-9. 
37. Segerer, S. and P.J. Nelson, Chemokines in renal diseases. 
ScientificWorldJournal, 2005. 5: p. 835-44. 
38. Distler, O., et al., Expression of RANTES in biopsies of skin and upper 
gastrointestinal tract from patients with systemic sclerosis. Rheumatol Int, 
1999. 19(1-2): p. 39-46. 
39. Fessele, S., et al., Molecular and in silico characterization of a promoter 
module and C/EBP element that mediate LPS-induced RANTES/CCL5 
expression in monocytic cells. Faseb J, 2001. 15(3): p. 577-9. 
40. Boehlk, S., et al., ATF and Jun transcription factors, acting through an 
Ets/CRE promoter module, mediate lipopolysaccharide inducibility of the 
chemokine RANTES in monocytic Mono Mac 6 cells. Eur J Immunol, 2000. 
30(4): p. 1102-12. 
41. Nelson, P.J., et al., Genomic organisation and transcriptional regulation of the 
RANTES chemokine gene. J Immunol, 1993. 151(5): p. 2601-12. 
42. Ortiz, B.D., A.M. Krensky, and P.J. Nelson, Kinetics of transcription factors 
regulating the RANTES chemokine gene reveal a developmental switch in 
nuclear events during T-lymphocyte maturation. Mol Cell Biol, 1996. 16(1): p. 
202-10. 
References 
   107
43. Liu, J. and X. Ma, Interferon regulatory factor 8 regulates RANTES gene 
transcription in cooperation with interferon regulatory factor-1, NF-kappaB, and 
PU.1. J Biol Chem, 2006. 281(28): p. 19188-95. 
44. Liu, J., X. Guan, and X. Ma, Interferon regulatory factor 1 is an essential and 
direct transcriptional activator for interferon {gamma}-induced RANTES/CCl5 
expression in macrophages. J Biol Chem, 2005. 280(26): p. 24347-55. 
45. Banas, B., et al., Chemokine and chemokine receptor expression in a novel 
human mesangial cell line. J Am Soc Nephrol, 1999. 10(11): p. 2314-22. 
46. Miyamoto, N.G., et al., Interleukin-1beta induction of the chemokine RANTES 
promoter in the human astrocytoma line CH235 requires both constitutive and 
inducible transcription factors. J Neuroimmunol, 2000. 105(1): p. 78-90. 
47. Maghazachi, A.A., A. Al-Aoukaty, and T.J. Schall, CC chemokines induce the 
generation of killer cells from CD56+ cells. Eur J Immunol, 1996. 26(2): p. 315-
9. 
48. Skelton, N.J., et al., Proton NMR assignments and solution conformation of 
RANTES, a chemokine of the C-C type. Biochemistry, 1995. 34(16): p. 5329-
42. 
49. Miller, M.D. and M.S. Krangel, Biology and biochemistry of the chemokines: a 
family of chemotactic and inflammatory cytokines. Crit Rev Immunol, 1992. 
12(1-2): p. 17-46. 
50. Bacon, K.B., et al., Activation of dual T cell signaling pathways by the 
chemokine RANTES. Science, 1995. 269(5231): p. 1727-30. 
51. Rathanaswami, P., et al., Expression of the cytokine RANTES in human 
rheumatoid synovial fibroblasts. Differential regulation of RANTES and 
interleukin-8 genes by inflammatory cytokines. J Biol Chem, 1993. 268(8): p. 
5834-9. 
52. von Luettichau, I., et al., RANTES chemokine expression in diseased and 
normal human tissues. Cytokine, 1996. 8(1): p. 89-98. 
53. Hadida, F., et al., Cutting edge: RANTES regulates Fas ligand expression and 
killing by HIV-specific CD8 cytotoxic T cells. J Immunol, 1999. 163(3): p. 1105-
9. 
54. Hadida, F., et al., HIV-specific T cell cytotoxicity mediated by RANTES via the 
chemokine receptor CCR3. J Exp Med, 1998. 188(3): p. 609-14. 
55. Bacon, K.B., et al., RANTES induces tyrosine kinase activity of stably 
complexed p125FAK and ZAP-70 in human T cells. J Exp Med, 1996. 184(3): 
p. 873-82. 
56. Kuna, P., et al., RANTES, a monocyte and T lymphocyte chemotactic cytokine 
releases histamine from human basophils. J Immunol, 1992. 149(2): p. 636-
42. 
57. Appay, V. and S.L. Rowland-Jones, RANTES: a versatile and controversial 
chemokine. Trends Immunol, 2001. 22(2): p. 83-7. 
58. Cocchi, F., et al., Identification of RANTES, MIP-1 alpha, and MIP-1 beta as 
the major HIV-suppressive factors produced by CD8+ T cells. Science, 1995. 
270(5243): p. 1811-5. 
59. Baggiolini, M. and C.A. Dahinden, CC chemokines in allergic inflammation. 
Immunol Today, 1994. 15(3): p. 127-33. 
60. Devergne, O., et al., Production of the RANTES chemokine in delayed-type 
hypersensitivity reactions: involvement of macrophages and endothelial cells. 
J Exp Med, 1994. 179(5): p. 1689-94. 
61. Schlondorff, D., et al., Chemokines and renal disease. Kidney Int, 1997. 51(3): 
p. 610-21. 
References 
 108 
62. Fessele, S., et al., Regulatory context is a crucial part of gene function. Trends 
Genet, 2002. 18(2): p. 60-3. 
63. Kumar, D., J. Hosse, C. von toerne, E. Noessner and P.J. Nelson, JNK MAP 
kinase pathway regulates constitutive transcription of CCL5 by human natural 
killer cells through SP1. J. of Immunol., 2009. 182(2): p. 1011-20. 
64. Adams, J., et al., 13-cis retinoic acid inhibits development and progression of 
chronic allograft nephropathy. Am J Pathol, 2005. 167(1): p. 285-98. 
65. Cho, M.L., et al., Transforming growth factor beta 1(TGF-beta1) down-
regulates TNFalpha-induced RANTES production in rheumatoid synovial 
fibroblasts through NF-kappaB-mediated transcriptional repression. Immunol 
Lett, 2006. 105(2): p. 159-66. 
66. Blaber, R., et al., Selective regulation of ICAM-1 and RANTES gene 
expression after ICAM-1 ligation on human renal fibroblasts. J Am Soc 
Nephrol, 2003. 14(1): p. 116-27. 
67. Casola, A., et al., Regulation of RANTES promoter activation in alveolar 
epithelial cells after cytokine stimulation. Am J Physiol Lung Cell Mol Physiol, 
2002. 283(6): p. L1280-90. 
68. Nelson, P.J., J.M. Pattison, and A.M. Krensky, Gene expression of RANTES. 
Methods Enzymol, 1997. 287: p. 148-62. 
69. Ortiz, B.D., P.J. Nelson, and A.M. Krensky, Switching gears during T-cell 
maturation: RANTES and late transcription. Immunol Today, 1997. 18(10): p. 
468-71. 
70. Ahn, Y.T., et al., Dynamic interplay of transcriptional machinery and chromatin 
regulates "late" expression of the chemokine RANTES in T lymphocytes. Mol 
Cell Biol, 2007. 27(1): p. 253-66. 
71. Nikolcheva, T., et al., A translational rheostat for RFLAT-1 regulates RANTES 
expression in T lymphocytes. J Clin Invest, 2002. 110(1): p. 119-26. 
72. Nakamichi, K., et al., Suppressive effect of simvastatin on interferon-beta-
induced expression of CC chemokine ligand 5 in microglia. Neurosci Lett, 
2006. 407(3): p. 205-10. 
73. Huang, B., et al., Interaction of PRP4 with Kruppel-like factor 13 regulates 
CCL5 transcription. J Immunol, 2007. 178(11): p. 7081-7. 
74. Lawrence, M.C., et al., The roles of MAPKs in disease. Cell Res, 2008. 18(4): 
p. 436-42. 
75. Gaestel, M., Specificity of signaling from MAPKs to MAPKAPKs: kinases' 
tango nuevo. Front Biosci, 2008. 13: p. 6050-9. 
76. Dong, C., R.J. Davis, and R.A. Flavell, MAP kinases in the immune response. 
Annu Rev Immunol, 2002. 20: p. 55-72. 
77. Han, J. and J.D. Molkentin, Regulation of MEF2 by p38 MAPK and its 
implication in cardiomyocyte biology. Trends Cardiovasc Med, 2000. 10(1): p. 
19-22. 
78. Han, J., et al., Activation of the transcription factor MEF2C by the MAP kinase 
p38 in inflammation. Nature, 1997. 386(6622): p. 296-9. 
79. Di Giacomo, V., et al., Regulation of CREB activation by P38 mitogen 
activated protein kinase during human primary erythroblast differentiation. Int J 
Immunopathol Pharmacol, 2009. 22(3): p. 679-88. 
80. Markou, T., M. Hadzopoulou-Cladaras, and A. Lazou, Phenylephrine induces 
activation of CREB in adult rat cardiac myocytes through MSK1 and PKA 
signaling pathways. J Mol Cell Cardiol, 2004. 37(5): p. 1001-11. 
81. Gee, K., et al., Intracellular HIV-Tat expression induces IL-10 synthesis by the 
CREB-1 transcription factor through Ser133 phosphorylation and its regulation 
References 
   109
by the ERK1/2 MAPK in human monocytic cells. J Biol Chem, 2006. 281(42): 
p. 31647-58. 
82. Kaiser, M., et al., MSK regulate TCR-induced CREB phosphorylation but not 
immediate early gene transcription. Eur J Immunol, 2007. 37(9): p. 2583-95. 
83. Chung, K.C., et al., Raf and fibroblast growth factor phosphorylate Elk1 and 
activate the serum response element of the immediate early gene pip92 by 
mitogen-activated protein kinase-independent as well as -dependent signaling 
pathways. Mol Cell Biol, 1998. 18(4): p. 2272-81. 
84. Vanhoutte, P., et al., Glutamate induces phosphorylation of Elk-1 and CREB, 
along with c-fos activation, via an extracellular signal-regulated kinase-
dependent pathway in brain slices. Mol Cell Biol, 1999. 19(1): p. 136-46. 
85. Shi, J. and P.K. Vogt, Posttranslational regulation of Myc by promyelocytic 
leukemia zinc finger protein. Int J Cancer, 2009. 125(7): p. 1558-65. 
86. Shamsasenjan, K., et al., IL-6-induced activation of MYC is responsible for the 
down-regulation of CD33 expression in CD33+ myeloma cells. Int J Hematol, 
2009. 89(3): p. 310-8. 
87. So, E.Y., et al., Ras/Erk pathway positively regulates Jak1/STAT6 activity and 
IL-4 gene expression in Jurkat T cells. Mol Immunol, 2007. 44(13): p. 3416-26. 
88. Vanhatupa, S., et al., MAPK-induced Ser727 phosphorylation promotes 
SUMOylation of STAT1. Biochem J, 2008. 409(1): p. 179-85. 
89. Park, Y., et al., SOCS1 induced by NDRG2 expression negatively regulates 
STAT3 activation in breast cancer cells. Biochem Biophys Res Commun, 
2007. 363(2): p. 361-7. 
90. Tsatsanis, C., C. Patriotis, and P.N. Tsichlis, Tpl-2 induces IL-2 expression in 
T-cell lines by triggering multiple signaling pathways that activate NFAT and 
NF-kappaB. Oncogene, 1998. 17(20): p. 2609-18. 
91. Ortega-Perez, I., et al., c-Jun N-terminal kinase (JNK) positively regulates 
NFATc2 transactivation through phosphorylation within the N-terminal 
regulatory domain. J Biol Chem, 2005. 280(21): p. 20867-78. 
92. Leung-Theung-Long, S., et al., Impaired NFAT transcriptional activity in 
antigen-stimulated CD8 T cells linked to defective phosphorylation of NFAT 
transactivation domain. J Immunol, 2009. 182(11): p. 6807-14. 
93. Wang, X., et al., Phosphorylation of HSF1 by MAPK-activated protein kinase 2 
on serine 121, inhibits transcriptional activity and promotes HSP90 binding. J 
Biol Chem, 2006. 281(2): p. 782-91. 
94. Li, J.C. and A.S. Lau, A role for mitogen-activated protein kinase and Ets-1 in 
the induction of interleukin-10 transcription by human immunodeficiency virus-
1 Tat. Immunology, 2007. 121(3): p. 337-48. 
95. Liu, S., et al., ERK-dependent signaling pathway and transcriptional factor Ets-
1 regulate matrix metalloproteinase-9 production in transforming growth factor-
beta1 stimulated glomerular podocytes. Cell Physiol Biochem, 2005. 16(4-6): 
p. 207-16. 
96. Pomerance, M., et al., CCAAT/enhancer-binding protein-homologous protein 
expression and transcriptional activity are regulated by 3',5'-cyclic adenosine 
monophosphate in thyroid cells. Mol Endocrinol, 2003. 17(11): p. 2283-94. 
97. Karin, M., Z. Liu, and E. Zandi, AP-1 function and regulation. Curr Opin Cell 
Biol, 1997. 9(2): p. 240-6. 
98. Avruch, J., MAP kinase pathways: the first twenty years. Biochim Biophys 
Acta, 2007. 1773(8): p. 1150-60. 
References 
 110 
99. Whitmarsh, A.J. and R.J. Davis, Transcription factor AP-1 regulation by 
mitogen-activated protein kinase signal transduction pathways. J Mol Med, 
1996. 74(10): p. 589-607. 
100. Rincon, M. and G. Pedraza-Alva, JNK and p38 MAP kinases in CD4+ and 
CD8+ T cells. Immunol Rev, 2003. 192: p. 131-42. 
101. Farag, S.S., et al., Natural killer cell receptors: new biology and insights into 
the graft-versus-leukemia effect. Blood, 2002. 100(6): p. 1935-47. 
102. Long, E.O., Regulation of immune responses by inhibitory receptors. Adv Exp 
Med Biol, 1998. 452: p. 19-28. 
103. Kelley, J., L. Walter, and J. Trowsdale, Comparative genomics of natural killer 
cell receptor gene clusters. PLoS Genet, 2005. 1(2): p. 129-39. 
104. Natarajan, K., et al., Structure and function of natural killer cell receptors: 
multiple molecular solutions to self, nonself discrimination. Annu Rev Immunol, 
2002. 20: p. 853-85. 
105. Vely, F. and E. Vivier, Conservation of structural features reveals the 
existence of a large family of inhibitory cell surface receptors and 
noninhibitory/activatory counterparts. J Immunol, 1997. 159(5): p. 2075-7. 
106. Stebbins, C.C., et al., Vav1 dephosphorylation by the tyrosine phosphatase 
SHP-1 as a mechanism for inhibition of cellular cytotoxicity. Mol Cell Biol, 
2003. 23(17): p. 6291-9. 
107. Lanier, L.L., On guard--activating NK cell receptors. Nat Immunol, 2001. 2(1): 
p. 23-7. 
108. Vivier, E., J.A. Nunes, and F. Vely, Natural killer cell signaling pathways. 
Science, 2004. 306(5701): p. 1517-9. 
109. Yokoyama, W.M., Natural killer cell immune responses. Immunol Res, 2005. 
32(1-3): p. 317-25. 
110. Chen, X., et al., Many NK cell receptors activate ERK2 and JNK1 to trigger 
microtubule organizing center and granule polarization and cytotoxicity. Proc 
Natl Acad Sci U S A, 2007. 104(15): p. 6329-34. 
111. Chen, X., et al., CD28-stimulated ERK2 phosphorylation is required for 
polarization of the microtubule organizing center and granules in YTS NK 
cells. Proc Natl Acad Sci U S A, 2006. 103(27): p. 10346-51. 
112. Upshaw, J.L., et al., NKG2D-mediated signaling requires a DAP10-bound 
Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural 
killer cells. Nat Immunol, 2006. 7(5): p. 524-32. 
113. Vely, F. and E. Vivier, Natural killer cell receptor signaling pathway. Sci STKE, 
2005. 2005(292): p. cm6. 
114. Giurisato, E., et al., Phosphatidylinositol 3-kinase activation is required to form 
the NKG2D immunological synapse. Mol Cell Biol, 2007. 27(24): p. 8583-99. 
115. Cella, M., et al., Differential requirements for Vav proteins in DAP10- and 
ITAM-mediated NK cell cytotoxicity. J Exp Med, 2004. 200(6): p. 817-23. 
116. Colucci, F., J.P. Di Santo, and P.J. Leibson, Natural killer cell activation in 
mice and men: different triggers for similar weapons? Nat Immunol, 2002. 
3(9): p. 807-13. 
117. Jiang, K., et al., Pivotal role of phosphoinositide-3 kinase in regulation of 
cytotoxicity in natural killer cells. Nat Immunol, 2000. 1(5): p. 419-25. 
118. Tangye, S.G., et al., 2B4-mediated activation of human natural killer cells. Mol 
Immunol, 2000. 37(9): p. 493-501. 
119. Graham, D.B., et al., Vav1 controls DAP10-mediated natural cytotoxicity by 
regulating actin and microtubule dynamics. J Immunol, 2006. 177(4): p. 2349-
55. 
References 
   111
120. Billadeau, D.D., et al., NKG2D-DAP10 triggers human NK cell-mediated killing 
via a Syk-independent regulatory pathway. Nat Immunol, 2003. 4(6): p. 557-
64. 
121. Huntington, N.D., et al., A requirement for CD45 distinguishes Ly49D-
mediated cytokine and chemokine production from killing in primary natural 
killer cells. J Exp Med, 2005. 201(9): p. 1421-33. 
122. Russo, G.E., A. Morgia, and M. Cavallini, [Glomerulonephritis]. Clin Ter, 2007. 
158(6): p. 495-6. 
123. Couser, W.G., Pathogenesis of glomerulonephritis: from chickens to humans. 
Nephron Physiol, 2009. 112(1): p. p17-23. 
124. Rougier, J.P. and P. Ronco, [Pathogenesis of immune glomerulonephritis]. 
Rev Prat, 2003. 53(18): p. 1998-2004. 
125. Segerer, S. and D. Schlondorff, Role of chemokines for the localization of 
leukocyte subsets in the kidney. Semin Nephrol, 2007. 27(3): p. 260-74. 
126. Anders, H.J., V. Vielhauer, and D. Schlondorff, Chemokines and chemokine 
receptors are involved in the resolution or progression of renal disease. Kidney 
Int, 2003. 63(2): p. 401-15. 
127. Segerer, S., P.J. Nelson, and D. Schlondorff, Chemokines, chemokine 
receptors, and renal disease: from basic science to pathophysiologic and 
therapeutic studies. J Am Soc Nephrol, 2000. 11(1): p. 152-76. 
128. Zernecke, A., et al., Combinatorial model of chemokine involvement in 
glomerular monocyte recruitment: role of CXC chemokine receptor 2 in 
infiltration during nephrotoxic nephritis. J Immunol, 2001. 166(9): p. 5755-62. 
129. Lloyd, C.M., et al., RANTES and monocyte chemoattractant protein-1 (MCP-1) 
play an important role in the inflammatory phase of crescentic nephritis, but 
only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp 
Med, 1997. 185(7): p. 1371-80. 
130. Flanc, R.S., et al., A pathogenic role for JNK signaling in experimental anti-
GBM glomerulonephritis. Kidney Int, 2007. 72(6): p. 698-708. 
131. Ikezumi, Y., et al., Macrophage-mediated renal injury is dependent on 
signaling via the JNK pathway. J Am Soc Nephrol, 2004. 15(7): p. 1775-84. 
132. Sakurai, H. and T. Sugita, c-Jun N-terminal kinase-mediated AP-1 activation in 
experimental glomerulonephritis in rats. Biochem Mol Biol Int, 1998. 45(4): p. 
831-9. 
133. Budisavljevic, M.N., et al., Oxidative stress in the pathogenesis of 
experimental mesangial proliferative glomerulonephritis. Am J Physiol Renal 
Physiol, 2003. 285(6): p. F1138-48. 
134. Behmoaras, J., et al., Jund is a determinant of macrophage activation and is 
associated with glomerulonephritis susceptibility. Nat Genet, 2008. 40(5): p. 
553-9. 
135. Tsuge, T. and Y. Tomino, [Molecular mechanisms in renal disease]. Nippon 
Rinsho, 2006. 64 Suppl 2: p. 341-4. 
136. Davison, A.M., et al., The role of the mesangial cell in proliferative 
glomerulonephritis. J Clin Pathol, 1973. 26(3): p. 198-208. 
137. Luo, Y., et al., Chemokine amplification in mesangial cells. J Immunol, 1999. 
163(7): p. 3985-92. 
138. Daha, M.R., Mechanisms of mesangial injury in glomerular diseases. J 
Nephrol, 2000. 13 Suppl 3: p. S89-95. 
139. Makino, H., [Glomerular extracellular matrix in glomerulosclerosis by molecular 
biology]. Nippon Rinsho, 1992. 50(12): p. 3038-45. 
References 
 112 
140. Satriano, J.A., et al., Regulation of RANTES and ICAM-1 expression in murine 
mesangial cells. J Am Soc Nephrol, 1997. 8(4): p. 596-603. 
141. Kawamura, T., [Mechanisms implicated in the progression of IgA 
nephropathy]. Nippon Jinzo Gakkai Shi, 2008. 50(4): p. 461-7. 
142. Lim, C.S., et al., Th1/Th2 predominance and proinflammatory cytokines 
determine the clinicopathological severity of IgA nephropathy. Nephrol Dial 
Transplant, 2001. 16(2): p. 269-75. 
143. Wagrowska-Danilewicz, M., M. Danilewicz, and O. Stasikowska, CC 
chemokines and chemokine receptors in IgA nephropathy (IgAN) and in non-
IgA mesangial proliferative glomerulonephritis (MesProGN). the 
immunohistochemical comparative study. Pol J Pathol, 2005. 56(3): p. 121-6. 
144. Cohen, C.D., et al., Comparative promoter analysis allows de novo 
identification of specialized cell junction-associated proteins. Proc Natl Acad 
Sci U S A, 2006. 103(15): p. 5682-7. 
145. Irizarry, R.A., et al., Exploration, normalization, and summaries of high density 
oligonucleotide array probe level data. Biostatistics, 2003. 4(2): p. 249-64. 
146. Tusher, V.G., R. Tibshirani, and G. Chu, Significance analysis of microarrays 
applied to the ionizing radiation response. Proc Natl Acad Sci U S A, 2001. 
98(9): p. 5116-21. 
147. Li, C. and W.H. Wong, Model-based analysis of oligonucleotide arrays: 
expression index computation and outlier detection. Proc Natl Acad Sci U S A, 
2001. 98(1): p. 31-6. 
148. Kumar, D., et al., JNK MAPK pathway regulates constitutive transcription of 
CCL5 by human NK cells through SP1. J Immunol, 2009. 182(2): p. 1011-20. 
149. Grund, E.M. and R.C. Muise-Helmericks, Cost efficient and effective gene 
transfer into the human natural killer cell line, NK92. J Immunol Methods, 
2005. 296(1-2): p. 31-6. 
150. Segerer, S., et al., Expression of the chemokine receptor CXCR1 in human 
glomerular diseases. Kidney Int, 2006. 69(10): p. 1765-73. 
151. Green, L.M., et al., Cytotoxic lymphokines produced by cloned human 
cytotoxic T lymphocytes. I. Cytotoxins produced by antigen-specific and 
natural killer-like CTL are dissimilar to classical lymphotoxins. J Immunol, 
1985. 135(6): p. 4034-43. 
152. Swanson, B.J., et al., RANTES production by memory phenotype T cells is 
controlled by a posttranscriptional, TCR-dependent process. Immunity, 2002. 
17(5): p. 605-15. 
153. Marcais, A., et al., Maintenance of CCL5 mRNA stores by post-effector and 
memory CD8 T cells is dependent on transcription and is coupled to increased 
mRNA stability. Eur J Immunol, 2006. 36(10): p. 2745-54. 
154. Aluoch, A.O., S.O. Odman-Ghazi, and M.M. Whalen, Pattern of MAP kinases 
p44/42 and JNK activation by non-lethal doses of tributyltin in human natural 
killer cells. Arch Toxicol, 2007. 81(4): p. 271-7. 
155. Trotta, R., et al., Differential role of p38 and c-Jun N-terminal kinase 1 
mitogen-activated protein kinases in NK cell cytotoxicity. J Immunol, 2000. 
165(4): p. 1782-9. 
156. Liang, S., et al., Differential roles of constitutively activated ERK1/2 and NF-
kappa B in cytotoxicity and proliferation by human NK cell lines. Int 
Immunopharmacol, 2005. 5(5): p. 839-48. 
157. Fasciano, S., A. Kaufman, and R.C. Patel, Expression of PACT is regulated by 
Sp1 transcription factor. Gene, 2007. 388(1-2): p. 74-82. 
References 
   113
158. Bonnema, J.D., et al., Fc receptor stimulation of phosphatidylinositol 3-kinase 
in natural killer cells is associated with protein kinase C-independent granule 
release and cell-mediated cytotoxicity. J Exp Med, 1994. 180(4): p. 1427-35. 
159. Davis, R.J., Signal Transduction by the JNK Group of MAP Kinases. Cell, 
2000. 103(2): p. 239-252. 
160. Gallo, A., et al., Menin uncouples Elk-1, JunD and c-Jun phosphorylation from 
MAP kinase activation. Oncogene, 2002. 21(42): p. 6434-45. 
161. Pine, R., Convergence of TNFalpha and IFNgamma signalling pathways 
through synergistic induction of IRF-1/ISGF-2 is mediated by a composite 
GAS/kappaB promoter element. Nucleic Acids Res, 1997. 25(21): p. 4346-54. 
162. Miscia, S., et al., Tumor Necrosis Factor {alpha} (TNF-{alpha}) Activates 
Jak1/Stat3-Stat5B Signaling through TNFR-1 in Human B Cells. Cell Growth 
Differ, 2002. 13(1): p. 13-18. 
163. Guo, D., et al., Induction of Jak/STAT Signaling by Activation of the Type 1 
TNF Receptor. J Immunol, 1998. 160(6): p. 2742-2750. 
164. Ting, A.Y. and D. Endy, SIGNAL TRANSDUCTION: Decoding NF-kB 
Signaling. Science, 2002. 298(5596): p. 1189-1190. 
165. Verstrepen, L., et al., TLR-4, IL-1R and TNF-R signaling to NF-kappaB: 
variations on a common theme. Cell Mol Life Sci, 2008. 
166. Kuno, R., et al., Autocrine activation of microglia by tumor necrosis factor-
alpha. J Neuroimmunol, 2005. 162(1-2): p. 89-96. 
167. Qin, Y., et al., TNF-alpha as an autocrine mediator and its role in the activation 
of Schwann cells. Neurochem Res, 2008. 33(6): p. 1077-84. 
168. Coward, W.R., et al., NF-kappa B and TNF-alpha: a positive autocrine loop in 
human lung mast cells? J Immunol, 2002. 169(9): p. 5287-93. 
169. Yarilina, A., et al., TNF activates an IRF1-dependent autocrine loop leading to 
sustained expression of chemokines and STAT1-dependent type I interferon-
response genes. Nat Immunol, 2008. 9(4): p. 378-87. 
170. Xaus, J., et al., LPS induces apoptosis in macrophages mostly through the 
autocrine production of TNF-alpha. Blood, 2000. 95(12): p. 3823-31. 
171. Li, Q.Q., et al., Induction of RANTES chemokine expression in human 
astrocytic cells is dependent upon activation of NF-kappaB transcription factor. 
Int J Mol Med, 2001. 7(5): p. 527-33. 
172. Kudo, T., et al., Regulation of RANTES promoter activation in gastric epithelial 
cells infected with Helicobacter pylori. Infect Immun, 2005. 73(11): p. 7602-12. 
173. Kim, M.O., et al., Regulation of RANTES/CCL5 expression in human 
astrocytes by interleukin-1 and interferon-beta. J Neurochem, 2004. 90(2): p. 
297-308. 
174. Nelson, P.J., et al., Identification of a novel regulatory region critical for 
expression of the RANTES chemokine in activated T lymphocytes. J Immunol, 
1996. 157(3): p. 1139-48. 
175. Karin, M., The regulation of AP-1 activity by mitogen-activated protein kinases. 
Philos Trans R Soc Lond B Biol Sci, 1996. 351(1336): p. 127-34. 
176. Han, I. and J.E. Kudlow, Reduced O glycosylation of Sp1 is associated with 
increased proteasome susceptibility. Mol Cell Biol, 1997. 17(5): p. 2550-8. 
177. Spengler, M.L. and M.G. Brattain, Sumoylation inhibits cleavage of Sp1 N-
terminal negative regulatory domain and inhibits Sp1-dependent transcription. 
J Biol Chem, 2006. 281(9): p. 5567-74. 
178. Wang, Y.T., et al., Sumoylation of specificity protein 1 augments its 
degradation by changing the localization and increasing the specificity protein 
1 proteolytic process. J Mol Biol, 2008. 380(5): p. 869-85. 
References 
 114 
179. Chuang, J.Y., et al., Phosphorylation by c-Jun NH2-terminal kinase 1 
regulates the stability of transcription factor Sp1 during mitosis. Mol Biol Cell, 
2008. 19(3): p. 1139-51. 
180. Su, K., et al., Human Sug1/p45 is involved in the proteasome-dependent 
degradation of Sp1. Biochem J, 2000. 348 Pt 2: p. 281-9. 
181. Krohn, R., et al., Y-box binding protein-1 controls CC chemokine ligand-5 
(CCL5) expression in smooth muscle cells and contributes to neointima 
formation in atherosclerosis-prone mice. Circulation, 2007. 116(16): p. 1812-
20. 
182. Yarilina, A., et al., TNF activates an IRF1-dependent autocrine loop leading to 
sustained expression of chemokines and STAT1-dependent type I interferon-
response genes. 2008. 9(4): p. 378-387. 
183. Wullaert, A., K. Heyninck, and R. Beyaert, Mechanisms of crosstalk between 
TNF-induced NF-kappaB and JNK activation in hepatocytes. Biochem 
Pharmacol, 2006. 72(9): p. 1090-101. 
184. Nakano, H., et al., Reactive oxygen species mediate crosstalk between NF-
kappaB and JNK. Cell Death Differ, 2006. 13(5): p. 730-7. 
185. Bubici, C., et al., NF-kappaB and JNK: an intricate affair. Cell Cycle, 2004. 
3(12): p. 1524-9. 
186. Yoshida, H., et al., Retinoic acid-inducible gene-I mediates RANTES/CCL5 
expression in U373MG human astrocytoma cells stimulated with double-
stranded RNA. Neurosci Res, 2007. 58(2): p. 199-206. 
187. Yuzawa, E., et al., Retinoic acid-inducible gene-I is induced by interferon-
gamma and regulates CXCL11 expression in HeLa cells. Life Sci, 2008. 
82(11-12): p. 670-5. 
188. Hirata, Y., et al., Activation of Innate Immune Defense Mechanisms by 
Signaling through RIG-I/IPS-1 in Intestinal Epithelial Cells. J Immunol, 2007. 
179(8): p. 5425-5432. 
189. Cui, X.F., et al., Retinoic acid-inducible gene-I is induced by interferon-gamma 
and regulates the expression of interferon-gamma stimulated gene 15 in MCF-
7 cells. Biochem Cell Biol, 2004. 82(3): p. 401-5. 
190. Wornle, M., et al., Novel role of toll-like receptor 3, RIG-I and MDA5 in poly 
(I:C) RNA-induced mesothelial inflammation. Mol Cell Biochem, 2009. 322(1-
2): p. 193-206. 
191. Hagele, H., et al., Double-stranded RNA activates type I interferon secretion in 
glomerular endothelial cells via retinoic acid-inducible gene (RIG)-1. Nephrol 
Dial Transplant, 2009. 24(11): p. 3312-8. 
192. Onomoto, K., M. Yoneyama, and T. Fujita, Regulation of antiviral innate 
immune responses by RIG-I family of RNA helicases. Curr Top Microbiol 
Immunol, 2007. 316: p. 193-205. 
193. Wang, J., et al., Retinoic Acid-Inducible Gene-I Mediates Late Phase Induction 
of TNF-{alpha} by Lipopolysaccharide. J Immunol, 2008. 180(12): p. 8011-
8019. 
194. Datta, P.K. and E.A. Lianos, Retinoic acids inhibit inducible nitric oxide 
synthase expression in mesangial cells. 1999. 56(2): p. 486-493. 
195. Imaizumi, T., et al., Retinoic acid-inducible gene-I is induced in endothelial 
cells by LPS and regulates expression of COX-2. Biochem Biophys Res 
Commun, 2002. 292(1): p. 274-9. 
196. Imaizumi, T., et al., Involvement of retinoic acid-inducible gene-I in 
inflammation of rheumatoid fibroblast-like synoviocytes. Clin Exp Immunol, 
2008. 
References 
   115
197. Kitamura, H., et al., Cytokine modulation of retinoic acid-inducible gene-I (RIG-
I) expression in human epidermal keratinocytes. J Dermatol Sci, 2007. 45(2): 
p. 127-34. 
198. Joosten, L.A., et al., IL-32, a proinflammatory cytokine in rheumatoid arthritis. 
Proc Natl Acad Sci U S A, 2006. 103(9): p. 3298-303. 
199. Kim, S.H., et al., Interleukin-32: a cytokine and inducer of TNFalpha. Immunity, 
2005. 22(1): p. 131-42. 
200. Marcondes, A.M., et al., Dysregulation of IL-32 in myelodysplastic syndrome 
and chronic myelomonocytic leukemia modulates apoptosis and impairs NK 
function. Proceedings of the National Academy of Sciences, 2008. 105(8): p. 
2865-2870. 
201. Shoda, H., et al., Interactions between IL-32 and tumor necrosis factor alpha 
contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res 
Ther, 2006. 8(6): p. R166. 
202. Conti, P., P. Youinou, and T.C. Theoharides, Modulation of autoimmunity by 
the latest interleukins (with special emphasis on IL-32). Autoimmun Rev, 2007. 
6(3): p. 131-7. 
203. Calabrese, F., et al., IL-32, a novel proinflammatory cytokine in chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med, 2008. 178(9): p. 
894-901. 
204. Nold-Petry, C.A., et al., IL-32-dependent effects of IL-1beta on endothelial cell 
functions. Proc Natl Acad Sci U S A, 2009. 106(10): p. 3883-8. 
205. Mun, S.H., et al., Tumor necrosis factor alpha-induced interleukin-32 is 
positively regulated via the Syk/protein kinase Cdelta/JNK pathway in 
rheumatoid synovial fibroblasts. Arthritis Rheum, 2009. 60(3): p. 678-85. 
 
 
 
 
 
 

Abbreviations and symbols 
   117
7   ABBREVIATIONS AND SYMBOLS 
ATF      Activating transcription factor 
APC      Allophycocyanin 
AP1      Activator Protein-1 
bp      Base pair 
BSA      Bovine serum albumin 
CCR     β-chemokine receptor 
CD     Cluster of differentiation 
cDNA      complementry Deoxyribonucleic Acid 
CXCR      α-chemokine receptor  
DMSO     Dimethyl Sulphoxide 
DNA      Deoxyribo Nuleic Acid 
DTT      Dithiothreitol 
EDTA      Ethylene Diamine Tetra Acetic Acid 
ELISA      Enzyme Linked Immunosorbent Assay 
ERK     Extracellular signal-regulated kinases 
FACS      Fluorescence-activated cell sorting 
hrs      hours 
HS      Human serum 
IL      Interleukin 
Ig      Immunglobulin 
IRF     Interferon regulatory factor 
IFN                                                Interferon 
IKK      IkappaB kinase 
JNK     c-Jun N-terminal kinases 
kb      Kilo base 
kDa      Kilo dalton 
MAPK     Mitogen-activated protein kinases 
MHC     Major Histocompatibility Complex 
MEM      Modifiziertes Eagle-Medium 
mins      min 
mRNA     messenger-RNA 
mg      milligram 
ml      millilitre 
µg      microgram 
µl      microlitre 
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µM      micromolar 
NF-kB   NF-kB (nuclear factor kappa-light-chain-enhancer of 
activated B cells)  
nt      nucleotide 
OD      Optical Density 
PI3K     Phosphoinositide 3-kinases 
PCR      Polymerase Chain Reaction 
PVDF      Polyvinylidene Fluoride 
PBS      Phosphate buffered saline 
PE      Phycoerythrin 
RNA      Ribonucleic Acid 
RIG-I      Retinoic acid inducible gene- I 
rpm      revolutions per min 
RPMI      Roswell Park Memorial Institute 
RT-PCR     Reverse Transcription-Polymerase Chain Reaction 
SDS      Sodium Dodecyl Sulphate 
SDS-PAGE     Sodium Dodecyl Sulphate Polyacrylamide Gel 
SP1      Specificity Protein 1 
STAT      Signal Transducer and Activator of Transcription 
Strep      Streptomycin 
TCR      T cell receptor  
TNF     Tumor Necrosis Factor 
TNFR     TNF Receptor 
Taq      Thermus aquaticus 
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